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A B S T R A C T
Background
Tobacco smoking in pregnancy remains one of the few preventable factors associated with complications in pregnancy, low birthweight,
preterm birth and has serious long-term health implications for women and babies. Smoking in pregnancy is decreasing in high-income
countries and increasing in low- to middle-income countries and is strongly associated with poverty, low educational attainment, poor
social support and psychological illness.
Objectives
To assess the effects of smoking cessation interventions during pregnancy on smoking behaviour and perinatal health outcomes.
Search strategy
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (June 2008), the Cochrane Tobacco Addiction Group’s
Trials Register (June 2008), EMBASE, PsycLIT, and CINAHL (all from January 2003 to June 2008). We contacted trial authors to
locate additional unpublished data.
Selection criteria
Randomised controlled trials where smoking cessation during pregnancy was a primary aim of the intervention.
Data collection and analysis
Trials were identified and data extracted by one person and checked by a second. Subgroup analysis was conducted to assess the effect
of risk of trial bias, intensity of the intervention and main intervention strategy used.
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Main results
Seventy-two trials are included. Fifty-six randomised controlled trials (over 20,000 pregnant women) and nine cluster-randomised trials
(over 5000 pregnant women) provided data on smoking cessation outcomes.
There was a significant reduction in smoking in late pregnancy following interventions (risk ratio (RR) 0.94, 95% confidence interval
(CI) 0.93 to 0.96), an absolute difference of six in 100 women who stopped smoking during pregnancy. However, there is significant
heterogeneity in the combined data (I2 > 60%). In the trials with the lowest risk of bias, the interventions had less effect (RR 0.97,
95% CI 0.94 to 0.99), and lower heterogeneity (I2 = 36%). Eight trials of smoking relapse prevention (over 1000 women) showed no
statistically significant reduction in relapse.
Smoking cessation interventions reduced low birthweight (RR 0.83, 95% CI 0.73 to 0.95) and preterm birth (RR 0.86, 95% CI 0.74
to 0.98), and there was a 53.91g (95% CI 10.44 g to 95.38 g) increase in mean birthweight. There were no statistically significant
differences in neonatal intensive care unit admissions, very low birthweight, stillbirths, perinatal or neonatal mortality but these analyses
had very limited power.
Authors’ conclusions
Smoking cessation interventions in pregnancy reduce the proportion of women who continue to smoke in late pregnancy, and reduce
low birthweight and preterm birth. Smoking cessation interventions in pregnancy need to be implemented in all maternity care settings.
Given the difficulty many pregnant women addicted to tobacco have quitting during pregnancy, population-based measures to reduce
smoking and social inequalities should be supported.
P L A I N L A N G U A G E S U M M A R Y
Interventions to help women to stop smoking in pregnancy
Smoking during pregnancy increases the risk of the mother having complications during pregnancy and the baby being born too small
(with low birthweight) and too early (prematurely, before 37 weeks). Low birthweight has been associated with coronary heart disease,
type 2 diabetes, and being overweight in adulthood. Tobacco smoking also has serious long-term health risks for both the women
and their babies. Tobacco smoking during pregnancy is relatively common, although the trend is toward becoming less frequent in
high-income countries and more so in low to middle-income countries. Many mothers find it hard to stop or reduce smoking during
pregnancy even knowing the benefits of doing so as the nicotine in tobacco is very addictive. Smoking in pregnancy is also strongly
associated with poverty, low levels of education, poor social support, depression and psychological illness.
The interventions offered to promote smoking cessation in pregnancy are generally given individually and include cognitive behaviour
and motivational interviewing; offering incentives; interventions based on stages of change; giving feedback to the mothers on fetal
health status or nicotine by-products measurements; nicotine replacement therapy, bupropion or other medications. The review of
trials found a total of 72 controlled trials involving over 25,000 women. These were conducted from 1975 to 2008 and nearly all were
in high-income countries. Interventions were effective in helping women to stop smoking during pregnancy (overall by approximately
6%). The most effective intervention appeared to be providing incentives, which helped around 24% of women to quit smoking during
pregnancy. The smoking cessation interventions reduced the number of babies with low birthweight and preterm births, confirming
that smoking cessation can reduce the adverse effects of smoking on newborn infants.
Women in the control groups of most trials received information about the risks of smoking in pregnancy and were advised to quit as
part of usual care. The intensity of both that information and the interventions has increased over time.
B A C K G R O U N D
Description of the condition
Risks associated with smoking in pregnancy
Tobacco smoking during pregnancy is the most important poten-
tially preventable cause of a range of adverse pregnancy outcomes,
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including placental abruption, miscarriage, preterm birth (less
than 37 weeks’ gestation) and low birthweight (less than 2500 g)
(Hammoud 2005; Salihu 2007; US DHHS 2004). Nicotine and
other harmful compounds in cigarettes restrict the supply of oxy-
gen and other essential nutrients, retarding fetal growth (Crawford
2008) and neuro-development (Herrman 2008). Preterm birth is
the leading cause of neonatal mortality (Hammoud 2005; Kramer
1987) and morbidity, with up to half of all paediatric neuro-devel-
opmental problems ascribed to preterm birth (Green 2005). Low
birthweight is a surrogate measure of the harmful impact of to-
bacco smoking on fetal development and there is growing evidence
of the association between low birthweight and adult morbidities,
including coronary heart disease, type 2 diabetes, and adiposity (
Gluckman 2008).
Tobaccco smoking also has many long-term health impacts for
women and their children, and is a major risk factor for six of the
eight leading causes of death globally (WHO 2008a).
Tobacco addiction is caused by the nicotine in tobacco which pro-
duces a cascade of actions, including release of “pleasure enhanc-
ing” dopamine, which strengthens associations of positive feelings
with smoking behaviour and appears to be involved in all addictive
behaviours (Schmidt 2004).
Epidemiology of smoking in pregnancy
Tobacco smoking is associated with low socioeconomic status and
has been cited as one of the principal causes of health inequality
between rich and poor (Wanless 2004). In high-income countries,
such as the United States (US), Denmark and Sweden, the preva-
lence of smoking in pregnancy has declined from 20% to 35% in
the 1980s to 12% to 25% in 2001 (Cnattingius 2004; USDHHS
2004). However, the decline has not been consistent across all
sectors of society, with lower rates of decline across the lower so-
cioeconomic sector (US DHHS 2004). There are marked socioe-
conomic differences between women who continue to smoke in
pregnancy and those who do not. Women who continue to smoke
in pregnancy generally have a low income, have high parity, are
without a partner, have low levels of social support, receive pub-
licly funded maternity care, have limited education and are more
likely to feel criticised by society (Ebert 2007; Frost 1994; Graham
1977; Graham 1996; Tappin 1996; US DHHS 2004). There is a
significantly higher prevalence of smoking in pregnancy in several
indigenous and ethnic minority groups, which is in accord with
their social and material deprivation (Chan 2001; Hunt 2003;
Kaplan 1997; US DHHS 2004; Wiemann 1994). Despite the
high prevalence, there is a paucity of evidence-based literature into
interventions to reduce antenatal smoking in indigenous groups (
Gilligan 2007). In some migrant groups, cultural differences may
cut across this social gradient.Womenwho aremigrants or refugees
to theUnitedKingdom,NorthernEurope,North America or Aus-
tralia who originate from South East Asia retain a lower preva-
lence of smoking, despite major social disadvantage (Bush 2003;
Potter 1996; Small 2000). In the US, African American, Hispanic,
and Pacific-Islander women have a lower prevalence of smoking in
pregnancy than white women (Andreski 1995; Wiemann 1994;
US DHHS 2004).
The global tobacco smoking epidemic is shifting from high-
income countries to low- and middle-income countries, where
the prevalence of tobacco smoking among women is increasing
(rather than decreasing) and is expected to rise to 20% by 2025
(Richmond 2003; Samet 2001). The World Health Organizaton
have identified this rise of tobacco use in young females in low-
income, high population countries as one of the most ominous
developments of the tobacco epidemic (WHO 2008a). There is
marked variation in prevalence of smoking in pregnancy. For ex-
ample, in Poland the prevalence is estimated at 30% (Polanska
2004), while the prevalence in countries such as the Democratic
Republic of Congo is still very low (Richmond 2003). However,
given the aggressive nature of tobacco marketing there is concern
that prevalence will increase with economic development (WHO
2008a), with subsequent health impacts on countries with already
high disease burdens and limited resources to provide health care,
particularly neonatal care (Cnattingius 2004).
In addition to the socioeconomic factors associated with contin-
ued smoking, there is a growing understanding of psychologi-
cal associations, especially depression and stress (Aveyard 2007;
Blalock 2005; Crittenden, 2007).Depressedwomen are up to four
times more likely to smoke during pregnancy than non depressed
women (Blalock 2005). There is limited information available
about the effects of smoking and interventions in pregnant women
with psychological symptoms, as they are often excluded from tri-
als (Blalock 2005). Two reviews in the general population (Stead
2006a; Tsoi 2008), and several included trials in this review report
stress and depression outcomes in randomised controlled trials of
smoking in pregnancy (Aveyard 2007; Blalock 2005; Crittenden,
2007).
A higher proportion of women stop smoking during pregnancy
than at other times in their lives. Up to 45% of women who
smoke before pregnancy “spontaneously quit” or stop before their
first antenatal visit (Quinn 1991; Woodby 1999), a quit rate sub-
stantially higher than reported in the general population (Ershoff
1999; McBride 2003). ’Spontaneous quitters’ usually smoke less,
are more likely to have stopped smoking before, to have a non-
smoking partner, to have more support and encouragement at
home for quitting, be less seriously addicted, or to have stronger be-
liefs about the dangers of smoking (Baric 1976; Cinciripini 2000;
Ryan 1980). But only a third of these quitters remain abstinent af-
ter one year (CDCP 2002). McBride 2003 hypothesises that preg-
nancy may be a “teachable moment” for smoking cessation, de-
scribing an increased perception of risk and personal outcomes in
pregnancy which prompts strong affective or emotional responses,
and redefines a woman’s self-concept or social role, especially when
failure to comply with a social role results in social stigmatisation.
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Description of the intervention
The range of interventions offered to promote smoking cessation
in pregnancy are primarily individual strategies which currently
include:
• provision of advice and counselling, using various tools
(written and electronic resources and telephone support) and
theoretical basis’, such as cognitive behavioural therapy and
motivational interviewing;
• advice and counselling based on assessment of the women’s
’stage of change’;
• feedback of fetal health status or measurement of by-
products of tobacco smoking to the mother;
• provision of pharmacological agents, such as nicotine
replacement therapy and bupropion;
• social support and encouragement, including the use of
rewards for cessation;
• other interventions such as hypnosis.
At the time of this publication there were over 50 Cochrane re-
views assessing the effectiveness of smoking cessation interven-
tions in the general population. These include reviews on popu-
lation wide measures (smoking bans, mass media) organisational
interventions (workplace and school-based interventions), com-
munity interventions (including family-based programmes, group
behaviour interventions), individual strategies (aversive smok-
ing, acupuncture, hypnotherapy, self-help, exercise, individual be-
havioural counselling, motivational interviewing, stage based in-
terventions, competitions and incentives, telephone counselling,
mobile-phone based interventions (protocol only), nursing and
physician advice, enhancing partner support), pharmacotherapies
(antidepressants, anxiolytics, nicotine replacement therapy, cloni-
dine, mecamylamine, nicobrevin, nicotine agonists, opioid ago-
nists, silver acetate and nicotine vaccines) and relapse prevention.
There are also other reviews assessing effectiveness of interventions
in specific population groups (people with schizophrenia (protocol
only), depression (protocol only), cardiovascular and pulmonary
disease, and hospitalised patients), see Appendix 1.
O B J E C T I V E S
The review evaluated the effect of interventions designed to pro-
mote smoking cessation in pregnant women. We tried to address
the following questions.
• Are interventions designed to promote smoking cessation in
pregnancy effective in assisting pregnant women to quit?
• Do smoking cessation interventions in pregnancy have an
impact on health outcomes for the mother and baby?
• What is the differential effectiveness between types of
intervention strategies?
• Is there a difference in effectiveness dependent on the
intensity of the intervention?
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised and quasi-randomised controlled trials where the
primary aim of the study was smoking cessation in pregnancy were
considered.Trials which combine strategies for smoking cessation
with other interventions in pregnancy were considered for the re-
view for smoking cessation and reduction outcomes but not for
outcome measures such as birthweight, preterm birth, breastfeed-
ing and perinatal mortality which might be attributable to other
components of an intervention package.
Cluster randomisation
There are good reasons for considering random allocation of mid-
wives, clinics, health educators, hospitals, general practitioners, or
antenatal classes to intervention or comparison group, rather than
random allocation of pregnant women. Itmay be difficult for those
providing pregnancy care to treat women differentially according
to the intervention or usual care protocol, and not to introduce
co-interventions in one or other group. As women within a cluster
will be more like one another, and less like the women in another
cluster, outcomes were adjusted for intracluster correlation for the
data to be included in this review.
Types of participants
1. Women who are pregnant, in any care setting.
2. Women seeking a pre-pregnancy consultation.
3. Health professionals in trials of strategies to change
knowledge, attitudes and behaviour with respect to smoking
cessation.
Types of interventions
1. Cognitive behaviour therapy, educational and motivational
interviewing strategies (using a range of media). These
educational interventions were grouped separately from stage-
based interventions as they were offered to all women in the
intervention group.
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2. Interventions based on stages of change (using a range of
media). These interventions were grouped separately from other
educational strategies as they involve assessment of “readiness” to
change and exposure to the intervention may be more selective.
3. Feedback of fetal health status or measurement of by-
products of tobacco smoking to the mother.
4. Provision of rewards and incentives for smoking cessation.
5. Provision of pharmacotherapies (nicotine replacement
therapy, bupropion or other pharmacological agents).
6. Other strategies, including hypnosis.
Types of outcome measures
1. Smoking cessation (continued smoking in late pregnancy,
self-reported and validated).
2. Smoking reduction from the first antenatal visit to late
pregnancy, self-reported and validated.
3. Smoking cessation in the puerperium, self-reported and
validated.
4. Birthweight (mean birthweight, proportion less than 2500
g, less than 1500 g).
5. Gestation at birth (proportion less than 37 weeks, less than
32 weeks, less than 30 weeks).
6. Perinatal mortality (stillbirths, neonatal deaths, all perinatal
deaths).
7. Mode of birth.
8. Proportion of women initiating breastfeeding; breastfeeding
at three and six months after birth.
9. Measures of anxiety, depression and maternal health status
in late pregnancy and after birth.
10. Participants’ views of the interventions, both women and
intervention providers.
11. Measures of family functioning in late pregnancy and
postpartum.
12. Measures of knowledge, attitudes and behaviour of health
professionals (obstetricians, midwives and family physicians)
with respect to facilitating smoking cessation in pregnancy.
To complement what is known from research literature about
smoking in pregnancy, direct contributions to this review were
sought from women who smoked before or during pregnancy in
1999. Women were identified through community networks, and
their views emphasised the need to focus attention on potential
adverse effects of smoking cessation programmes; in particular,
the consequent guilt, anxiety and additional stress experienced by
those who continue to smoke, especially through ’high risk’ preg-
nancies, and the detrimental effect on their relationships with their
family and maternity care providers.
Search methods for identification of studies
This is the fourth update of this review and the methods for pre-
vious searches are described in other published versions of this
review (Lumley 1995a; Lumley 1999; Lumley 2004).
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s Tri-
als Register by contacting the Trials Search Co-ordinator (June
2008).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. quarterly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. handsearches of 30 journals and the proceedings of major
conferences;
4. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL and MEDLINE,
the list of handsearched journals and conference proceedings, and
the list of journals reviewed via the current awareness service can
be found in the ‘Specialized Register’ section within the edito-
rial information about the Cochrane Pregnancy and Childbirth
Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
In addition, we searched theCochrane TobaccoAddictionGroup’s
Trials Register (June 2008) and a qualified librarian searched EM-
BASE, PsycLIT, and CINAHL (January 2003 to June 2008) using
the search strategy detailed in Appendix 2.
Searching other resources
We also checked cited studies while reviewing the trial reports and
contacted trial authors to locate additional unpublished data
We did not apply any language restrictions.
Data collection and analysis
Data extraction and management
Data from included studies was independently extracted from the
published reports by two review authors without blinding as to
journal, author, or research group. For each trial the following
aspects were documented.
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Methods
• Country of origin and year of trial.
• Brief description of trial methodology.
• Risk of bias assessment.
Participants
• Description of participants/study population, including
pre-pregnancy cigarettes per day.
• Inclusion and exclusion criteria.
• Participation rate of eligible study population.
• Timing within pregnancy of recruitment and outcome
measurement.
Interventions
• A description of the intervention(s) and the control.
• Intervention provider.
• Main intervention strategy (as described in ’types of
interventions’).
• Intensity rating of intervention and controls.
1 to 2 = low intensity (1: provision of leaflet, posters or self-help
materials available, 2: ++advice to quit and written or verbal in-
formation on risks);
3 = medium intensity (2 + self-help materials on strategies for
quitting);
4 = high intensity (3 + other forms of support, such as personal
contacts, reminders, incentives, pharmacological agents).
Outcomes
• Outcome measures including smoking cessation and
reduction, birthweight, mode of birth, perinatal outcomes,
breastfeeding, gestation, psychological measures.
• Withdrawals.
Notes
• Process evaluation of the intervention(s).
• Women’s and provider views
Assessment of risk of bias in included studies
We assessed the methodological quality of the included studies as
recommended in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2008). The ’quality assessment’ from pre-
vious reviews has been replaced with the ’risk of bias’ assessment.
(1) Sequence generation (checking for possible selection
bias)
We have described for each included study the methods used to
generate the allocation sequence, and have assessed the methods
as:
• adequate (any truly random process, e.g. random number
table; computer random number generator);
• inadequate (any non random process, e.g. odd or even date
of birth; hospital or clinic record number); or
• unclear.
(2) Allocation concealment (checking for possible selection
bias)
We have described for each included study the method used to
conceal the allocation sequence in sufficient detail to determine
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We have assessed the methods as:
• adequate (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• inadequate (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear.
(3) Blinding (checking for possible performance bias)
We have described for each included study the methods used, if
any, to blind study participants and personnel from knowledge
of which intervention a participant received. With educational
interventions (such as those assessed in this review) it is often not
possible to blind women or their care-givers to group allocation.
It is possible for outcome assessors to be blind to group allocation
and we have noted where there was partial blinding.
We have assessed the methods as:
• adequate, inadequate or unclear.
(4) Incomplete outcome data (checking for possible attrition
bias through withdrawals, dropouts, protocol deviations)
We have described for each included study and for each outcome
or class of outcomes the completeness of data including attrition
and exclusions from the analysis. We have noted whether attri-
tion and exclusions were reported, the numbers included in the
analysis at each stage (compared with the total randomised par-
ticipants), reasons for attrition or exclusion where reported, and
whether missing data were balanced across groups. Where suffi-
cient information has been reported or has been supplied by the
trial authors, we have re-included missing data in the analyses.
We have indicated where an intention-to-treat (or available case)
analysis was carried out for the smoking cessation outcome.
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(5) Selective reporting bias
We have described for each included study how the possibility of
selective outcome reporting bias was examined by us and what we
found.
We assessed the methods as:
• adequate (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• inadequate (where not all the study’s pre-specified outcomes
have been reported; one or more reported primary outcomes were
not pre-specified; outcomes of interest are reported incompletely
and so cannot be used; study fails to include results of a key
outcome that would have been expected to have been reported);
• unclear.
(6) Detection bias
We have described for each included study whether the outcome
of smoking cessation was biochemically validated or assessed by
self-report only, as there is evidence that there may be substantial
misclassification by self-report.
Overall risk of bias
Wemade explicit judgements about whether studies were at high,
moderate or low risk of bias, according to the criteria given in the
Handbook (Higgins 2008). With reference to (1) to (6) above, we
assessed the likelymagnitude and direction of the bias andwhether
we considered it likely to impact on the findings.
Measures of treatment effect
Dichotomous data
All data were entered into review manager software (RevMan
2008) for analysis. For dichotomous data, we have presented re-
sults as summary risk ratio with 95% confidence intervals.
Continuous data
For continuous data, we have used themean difference if outcomes
have been measured in the same way between trials. We used the
standardised mean difference to combine trials that measured the
same outcome, using different methods.
We used the statistical methods described in the Handbook (
Higgins 2008).
Adjustment for clustering was conducted using a reported intra-
cluster correlation (ICC) if available, and if not, a range of ICCs
(from 0.003 to 0.20) was assumed and a sensitivity analysis con-
ducted as recommended byMerlo 2005. A conservative ICC value
of 0.10 was used for the primary analysis and the cluster trials were
included by adjusting the sample sizes and numbers of events.
In all pooled analyses, we examined levels of heterogeneity (
Cochran 1954). We used the I² statistic to quantify heterogene-
ity among the trials in each analysis (Higgins 2008). We explored
heterogeneity by pre-specified secondary analysis.
Subgroup analysis and investigation of heterogeneity
Unit of randomisation (individual versus cluster
randomisation)
The main analyses (comparison tables) combine data from all tri-
als to produce an overall treatment effect, subgrouped into trials
where the individual woman was randomised and cluster trials
where the service or provider was randomised. These were sub-
grouped separately as it is possible there is a difference in the de-
gree of exposure the participants have to the intervention, with
cluster trials more closely resembling implementation trials, with
potentially less scrutiny on the intervention for each woman.
There is likely to be significant heterogeneity between trials and
that by pooling results the combined treatment effect is likely
to be biased towards interventions with the most data (cognitive
behavioural therapy (CBT) based interventions). We considered
carrying out separate comparisons for different types of interven-
tions (e.g. where the main strategy was motivational interview-
ing as opposed to rewards). However, trials frequently used more
than one approach (e.g. nicotine replacement therapy and CBT)
and there were many other variables to consider: the intensity of
interventions, the high risk of bias in some trials and the unit of
randomisation. Therefore, we explored the impact of risk of bias
and heterogeneity through undertaking analyses for the following
subgroups.
Risk of bias
In the context of this review, the factors which were assessed as
posing the greatest risk of bias weremisclassification by self-report,
lack of treating trial “drop outs” as continuing smokers, followed
by the adequacy randomisation. Very few trials reported alloca-
tion concealment methods clearly, so this was not included in the
criteria for this update of the review.
1. Trials with the lowest risk of bias:
• trials with biochemical validation of smoking status;
• have complete outcome data addressed (intention-to-treat),
as attrition is a major problem with trials;
• are adequately randomised.
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2. Trials with moderate risk of bias
• biochemical validation of smoking status only.
3. Trials with the highest risk of bias
• no biochemical validation, as misclassification of smoking
status by self-report one of the most significant risks of bias (
Donovan 1977; Kendrick 1995).
Main intervention strategy
(as described under ’types of interventions’). While many trials
incorporated several interventions (described in detail in the char-
acteristics of included studies), the authors have made an assess-
ment of the primary strategy. As this is the only smoking review
which collates data on perinatal outcomes, subgroup analysis was
conducted on smoking cessation outcomes and birthweight (as it
had the largest volume of data) subgrouped by main intervention
strategy.
Intensity of the intervention
(as described under ’data extraction/intervention’) subgrouped by
low, medium, high.
Other aspects of intervention quality, including women’s and
provider’s views, and whether trials were well implemented are
presented in the results.
To assess any differences between subgroups we examined forest
plots for overlap of confidence intervals; non-overlapping confi-
dence intervals indicating a significant difference in treatment ef-
fect between subgroups.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
Results of the search
Eight-hundred and seventy-eight papers related to pregnancy and
smoking published between 2003 and 2007 were identified in the
most recent search conducted in September 2007. An Ovid auto
alert conducted up until 1 April 2008 identified a further 20 pa-
pers. The abstracts of these papers were reviewed (C Chamberlain
(CC)) and 35 papers co-reviewed (CC and J Lumley) for consid-
eration for inclusion in the review. Eleven new randomised con-
trolled trials from 2003 to 2008, which included 4 new cluster
RCTs, were identified and added to this update of the review.
The results of previous searches are described in previous publica-
tions of this review (Lumley 1999; Lumley 2004).
Included studies
Outcomes reported
A total of 72 trials, conducted between 1975 and 2008 and com-
prising over 25,000 women, provided outcome data for this re-
view. Fifty-six randomised and quasi-randomised controlled trials
and nine cluster-randomised trials reported the principal outcome
measure of continued smoking in late pregnancy (21,258women).
The women included in this analysis were assessed as “smokers”
at recruitment. The criteria used to assess a woman as a “smoker”
varies significantly between trials, and is detailed for each study in
the characteristics of included studies.
Eight trials reported continued cessation at end of pregnancy sep-
arately for women who had quit spontaneously before the inter-
vention (relapse prevention), three of which were separate trials
not included in the primary outcome trial reports. The women in-
cluded in this analysis are not included in the analysis of continued
smoking in women who were assessed as smokers at recruitment.
Twenty-one trials reported mean birthweight (15,119 women),
four of which were new trials not included in the primary outcome
trial reports.
Sixteen trials reported rates of low birthweight babies (< 2500 g)
and four reported rates of very low birthweight babies (< 1500 g).
Other trials reporting birth outcomes included: perinatal deaths
(3), preterm births (14), stillbirths (6), neonatal deaths (3), neona-
tal intensive care unit (NICU) admissions (4).
Twenty-four trials reported various measures of smoking reduc-
tion in late pregnancy, including self-reported reduction (8), self-
reported reduction >50% (3), biochemically validated reduction
(4). Three trials recorded both self-reported and biochemically
validated reduction; in these cases we have included only the val-
idated data in the analysis. Other measures of reduced smoking
included mean biochemical cotinine or thiocyanate (4), or mean
cigarettes per day (10).
Twenty-two trials reported continued cessation in the postpartum
period.
Thirteen trials discussed participant views of the intervention, and
sixteen trials discussed provider views of the intervention.
Nine trials assessed a range of psychological health measures. Two
trials reported mode of birth, two trials reported breastfeeding
initiation in women and four reported NICU admissions.
No trials measured any effect of smoking cessation on family func-
tioning or the well-being of other family members.
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Other outcome measures which were measured, but not included
in this review were fetal growth (1), fetal length (1), maternal
weight gain (1), mean gestation (1), shifts in stages of change, and
descriptions of all adverse outcomes (1).
Trial countries
Almost all trials were conducted in high-income countries. This
includes theUSA (39), theUnitedKingdom (14), theNetherlands
(7), Australia (6), New Zealand (2), and Canada (2).
Only two trials have been conducted in middle-income countries.
Belizan 1995 conducted a trial in four Latin American countries
(Argentina, Brazil, Cuba and Mexico). Polanska 2004 conducted
a cluster-randomised trial in the Lodz district of Poland. Nei-
ther trial had biochemically validated smoking outcomes and have
therefore, been assessed as being at high risk of bias in this review.
Participants
Participants were generally healthy pregnant women and the usual
setting was a hospital or community antenatal clinic. Many trials
reported interventions aimed at specific socio-demographic sub-
populations.
Interventions
Women in the control arms in 55 of the 72 trials received informa-
tion about the risks of smoking in pregnancy and were advised to
quit as part of ’usual care’ (controls/low intensity). Interventions
ranged from low intensity or usual care (3), medium intensity with
provision of materials or support for developing strategies for quit-
ting (18) or high intensity with other forms of support including
follow up and reminders, home visits, personal contacts, incen-
tives or provision of pharmacological therapy (45). As would be
expected, the median intensity of interventions and controls has
increased over time (Figure 1).
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Figure 1.
Many interventions were multimodal, but the main interven-
tion strategies identified were based on cognitive behavioural ther-
apy (31), stages of change (11), feedback (4), incentives (4), phar-
macological therapy (5) and other miscellaneous strategies (11),
such as hypnosis.
Two dissemination trials were identified, carried out in Australia
(Campbell 2006; Lowe 2002). Data for Campbell 2006 are in-
cluded under cluster-randomised trials.
Excluded studies
Forty-nine studies were excluded from the review, for the following
reasons:
• outcome data were not reported in format or detail to
enable inclusion in analysis;
• design not adequately randomised (e.g. cohort studies, pre-
post design, quasi experimental designs with matched controls);
• primary population was not pregnant women (e.g.
postpartum interventions, intervention for partners, non-
pregnant women).
Risk of bias in included studies
Allocation
The method of randomisation was rarely described in sufficient
detail to permit assessment of whether the allocation was con-
cealed at the time of trial entry. For example, a common state-
ment was that “a computer-generated list of random numbers was
used”. Quasi-randomisation was not uncommon even in large tri-
als. Where pregnancy caregivers were involved in the provision
of the intervention or its reinforcement - something expected by
many commentators to enhance the effectiveness of the interven-
tion - allocation to intervention or comparison group could not
be concealed and the possibility of co-interventions could not be
excluded.
Blinding
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Very few trials had any blinding of participants or providers, largely
due to pragmatic issues associated with administering an edu-
cational intervention. We have noted in the Characteristics of
included studies tables where there was blinding of outcome as-
sessors.
Incomplete outcome data
Withdrawals
Withdrawals from the trials were common. When women were
recruited at their first antenatal visit some participants had a mis-
carriage or a termination of pregnancy before the timewhen smok-
ing behaviour was reassessed. Others moved out of the area or
changed to another provider of care. The latter was a common
cause of attrition in those trials carried out among populations
characterised by severe poverty and the receipt of special needs
benefits such as Medicaid, or WIC (food program for women, in-
fants and children) clinics. In studies where there was longer-term
follow up, attrition was sometimes high; approximately half of the
included studies had high levels of missing data (> 20%) for some
outcomes. Where possible, women lost to attrition were included
in this analysis as continuing smokers. Attrition is potentially a
serious risk of bias in these studies. Levels of attrition for each
study, and information about any intention-to-treat analysis has
been provided in the ’Risk of bias tables’.
Exclusions
Two groups of women that were often excluded from outcome
measurement were those who had a perinatal death or a preterm
infant. This means that important outcomes linked in observa-
tional studies to smoking exposure were not ascertained. Assessing
smoking at 20 to 28 weeks instead of at 36 to 38 weeks would
reduce the need to exclude women with particularly adverse out-
comes, since their smoking status in mid-pregnancy would have
been ascertained before preterm birth or a perinatal death had oc-
curred.
Selective reporting
It was not clear in many trials the extent of outcome data which
were collected and therefore, difficult to assess whether the out-
comes have been selectively reported.
Other potential sources of bias
Detection bias from misclassification by self-report
The unreliability of self-report as a measure of smoking status in
healthcare settings, especially in maternity care, was noted even in
the first pregnancy trial (Donovan 1977), though not found by
others in the 1980s (Fox 1989). Findings in other trials (Kendrick
1995;Mullen 1991; Petersen 1992;Walsh 1997) show substantial
misclassification by self-report with up to a quarter or a third of
women who describe themselves as non-smokers having levels of
salivary or urine cotinine (a metabolite of nicotine) incompatible
with that self-description. There may also be differential misclas-
sification between intervention and control groups, though no in-
vestigations have published this effect. This finding means that
trials which do not validate smoking status are likely to have sub-
stantial measurement errors, andmay be biased if women receiving
the intervention are more likely to misreport their smoking status
than those in the control group. These trials have been classified as
“high risk of bias” in this review. Later trials more often relied on a
definition of smoking cessation requiring biochemical validation.
Change in ’usual care’
In many cases the comparison/control group was described as re-
ceiving ’usual care’ without specifying further what constituted
usual practice (at a particular time and in a particular setting) with
respect to advice and assistance. It can be seen from Figure 1 that
current ’usual care’ may be a more substantial intervention than
the defined intervention in some of the earliest trials (for example,
MacArthur 1987).
Intervention exposure
Smoking cessation interventions implemented during pregnancy
differ substantially in their intensity, their duration, and the peo-
ple involved in their implementation. Process evaluation of the
intervention occurred in only some trials and in some of these the
implementation was less than ideal (Hajek 2001; Kendrick 1995;
MacArthur 1987).
The timing of the final antenatal assessment of smoking status
varied considerably between trials between the second and third
trimester. This may affect the amount of time the participants
were exposed to the intervention (if it involved ongoing support),
as well as the number of those lost to follow up and measurement
of perinatal outcomes.
A summary of risk of bias assessments in the included trials are set
out in Figure 2 and Figure 3.
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Figure 2. Risk of bias summary: review authors’ judgments about each risk of bias item for each included
study.
12Interventions for promoting smoking cessation during pregnancy (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. Risk of bias graph: review authors’ judgments about each risk of bias item presented as
percentages across all included studies.
Effects of interventions
1. Smoking cessation outcomes
Pooled data from 65 trials revealed a significant reduction in
continued smoking in late pregnancy in the intervention groups
(pooled risk ratio (RR) 0.94, 95% confidence interval (CI) 0.93
to 0.96). This equates to an absolute difference in the proportion
continuing to smoke of 6%. In trials where the unit of randomi-
sation was individual women, intervention RR for smoking ces-
sation was 0.94, (95% CI 0.92 to 0.96) and in cluster trials where
the unit of randomisation was a clinician or service, the interven-
tion RR was 0.97, (95% CI 0.94 to 1.00); these results showed
no evidence of a difference in treatment effect between types of
randomisation.The heterogeneity amongst both individually and
cluster-randomised trials was high (I2 > 60%) and results should
be interpreted with caution.
Cluster trials
Nine cluster-randomised trials were included as a subgroup of the
combined comparison table of all trials. No studies reported indi-
vidual cluster data to enable calculation of clustering effect using
generic inverse variance method. Three trials reported the clus-
tering effect (Kendrick 1995; Lawrence 2003; Moore 2002) and
these figures were used in the tables.One trial reported cluster vari-
ance which was used to derive the intracluster correlation (ICC) (
Merlo 2005). One trial reported the design effect (McLeod 2004)
which was used in the outcome tables. Five trials had no cluster-
ing effect reported (Campbell 2006; Hajek 2001; Manfredi 1999;
Pbert 2004; Polanska 2004). A sensitivity analysis was conducted
for these trials, using four ICC effects: of 0.003, 0.05, 0.1 and 0.2,
as recommended by Merlo 2005. There was minimal difference
in effect (RR 0.94, 95% CI 0.91 to 0.99 when calculated using
ICC of 0.003, to RR 0.98, 95% CI 0.95 to 1.01 when calculating
using ICC of 0.2). Therefore, a conservative median ICC of 0.1
has been used in this review, which provides a pooled RR 0.97,
95% CI 0.94 to1.00 for randomised cluster trials.
Subgroup analysis (risk of bias)
Trials with the ’lowest risk of bias’ had an intervention effect cor-
responding to a RR of 0.97 (95% CI 0.94 to 0.99) with a decrease
in heterogeneity (I2 = 36%), which was the lowest of any of the
sensitivity analyses conducted. Trials with the highest risk of bias
(no biochemical validation) showed an RR of 0.91 (95% CI 0.87
to 0.95).Trials with ’moderate risk of bias’ showed an effect of RR
0.94 (95% CI 0.92 to 0.97); these results showed no evidence
of a significant difference in treatment effect between trials with
differences in the assessed risk of bias.
Subgroup analysis (intervention intensity)
The 45 trials assessed as ’high intensity’ (provision of strategies
and continued support to quit) demonstrated an intervention RR
0.94, (95% CI 0.92 to 0.96), while the three trials assessed as ’low
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intensity’ (provision of written or verbal advice to quit, or both)
demonstrated an intervention RR of 0.95 (95% CI 0.93 to 0.96);
these results showed no evidence of a significant difference in treat-
ment effect according to the assessed intensity of the intervention.
All these groups showed significant heterogeneity.
Subgroup analysis (main intervention strategy)
When trials were subgrouped by intervention strategies, only one
group (those including an incentive component) showed a sig-
nificantly larger effect (RR 0.76, 95% CI 0.71 to 0.81). Their
results were consistent but comprised only four trials. The CBT
group, showed a similar pooled effect to that of the whole group
(RR 0.95, 95% CI 0.93 to 0.97) compared with pooled data from
all trials, which is what would be expected as it was the largest
(31 trials). The five trials of nicotine replacement therapy were
as effective as the CBT group (RR 0.95, 95% CI 0.92 to 0.98),
though there is still no clear evidence of safety in terms of perinatal
outcomes (discussed below). The intervention RR for the eleven
trials using ’stages of change’ theory was RR 0.99, (95% CI 0.97
to 1.00), which is not significantly different from CBT or NRT.
The four trials using feedback were not significantly effective (RR
0.92, 95% CI 0.84 to 1.02).
Even when different interventions were separated into subgroups
heterogeneity for subgroups remained relatively high, particularly
for the large group of trials using CBT as the main intervention
strategy (I2 = 55%).
2. Relapse prevention
Eight trials (more than 1000 women) included a specific inter-
vention for smoking relapse prevention among women who had
stopped smoking by the first antenatal visit. The women in this
analysis were not included in the analysis of women counted as
smokers. In these, the pooled risk ratio indicated that fewerwomen
receiving the intervention relapsed to smoking in late pregnancy
but the effect did not reach statistical significance (RR 0.91, 95%
CI 0.75 to 1.10).
3. Smoking reduction
There was limited evidence that women in intervention groups
reduced smoking in late pregnancy, but the evidence was weak and
not consistent. Pooled data from studies collecting self-reported
information on reduced smoking (where womenwere asked if they
had cut down at all in smoking) showed significant evidence of
a difference between intervention and control groups (RR 1.52,
95% CI 1.29 to 1.78). However, studies where women reported
that they had cut down their smoking by more that half showed
no significant differences between intervention and control groups
(RR 1.23, 95% CI 0.91 to 1.67). Where reductions were bio-
chemically validated there was no significant evidence of reduced
smoking in the intervention group (RR 1.27, 95% CI 0.84 to
1.91). (Where studies recorded both self-reported and biochem-
ically validated data we have included only the validated data in
the analysis). There was no significant difference in self-reported
mean cigarettes per day, and the skewed distribution of the data
suggests there is a lack of precision with these self-reported esti-
mates (the mean and standard deviations are very similar).
4. Continued smoking cessation in the postnatal
period
Ten individually randomised trials and five cluster trials examined
continued smoking cessation at between one to five months post-
partum. The time of data collection varied in different studies
and the results included both self-reported and validated smoking
cessation outcomes. Overall, there was a statistically significant
difference between intervention and control groups for continued
smoking cessation in the early postpartum period (RR 1.65, 95%
CI 1.22 to 2.24). However, there was no evidence of difference
between groups in smoking cessation rates at longer-term follow
up (RR 1.39, 95% CI 0.82 to 2.38). Eight trials (all individually
randomised) reported smoking cessation at between six and 12
months postpartum (again there was variation between trials in
terms of when data was collected and in how this outcome was
measured).
5. Perinatal outcomes
The 21 trials with information on perinatal outcomes revealed a
reduction in low birthweight (RR 0.83, 95% CI 0.73 to 0.95), a
reduction in preterm birth (RR 0.86, 95% CI 0.74 to 0.98), and
an increase in mean birthweight of 39.26 g (95% CI 15.77 g to
62.74 g) in the treatment group. There was adequate power to
detect differences for these outcomes (n = > 10 000).
Trials using CBT and incentives as the main intervention strat-
egy demonstrated statistically significant improvements in mean
birthweight.
There were no significant differences in very low birthweight, still-
births, neonatal deaths, NICU admissions or total perinatal mor-
tality. The subset of trials in which those outcomes were assessed
had a very low power to detect clinically important differences in
these outcomes (n = < 5000). A number of trials excluded women
who had a perinatal death or a preterm birth from the study pop-
ulation.
A follow up of MacArthur’s trial which had reduced smoking and
increased birthweight assessed subsequent child growth and de-
velopment at nine to 10 years (MacArthur 1987). Neither height
nor weight, nor intelligence quotient (IQ) or a screening test for
’soft’ neurological signs identified any differences between the in-
tervention and control groups (insufficient data for tabulation).
Two trials measured mode of delivery (Tappin 2005; Thornton
1997) and showed no significant difference in outcome by inter-
vention group.
14Interventions for promoting smoking cessation during pregnancy (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Two trials measured breastfeeding initiation (McLeod 2004;
Panjari 1999) and showed no significant difference in iniation or
duration of breastfeeding in control or intervention arms.
Other perinatal outcome measures reported in trials included ad-
verse perinatal outcomes (Pollak 2007); fetal growth (Heil 2008);
fetal length (MacArthur 1987); maternal weight gain (Rush 1992)
and shifts in stages of change (Solomon 1996 and Solomon 2000).
6. Psychosocial effects
Thirteen trials included women’s views of intervention and 16 in-
cluded midwives’ views of the intervention. Some studies asked
about women’s views of the intervention (DeVries 2006; Hajek
2001; Thornton 1997), sometimes focussing specifically on the
use of intervention materials (Ershoff 1999; Hotham 2005;
Strecher 2000; Valbo 1994; Wisborg 2000) or providers’ activites
(Tappin 2000; Thornton 1997), and whether they thought the
intervention was helpful for giving up smoking (Cinciripini 2000;
Cope 2003; Ershoff 1999; Hajek 2001; Rigotti 2006; Valbo 1994;
Walsh 1997). There were few direct comparisons. Women offered
personal contact and a manual considered the personal contact
the most important element; the two together were more effective
than the usual care of information provision at the time of rou-
tine ultrasound examination (Valbo 1994). Similarly, women of-
fered motivational interviewing for relapse prevention were more
likely to be satisfied than those offered a booklet, although the
motivational interviewing was no more effective (Ershoff 1999).
Cinciripini 2000 found that women appreciated printed materials
much less if they were also offered a video, although the video
combined with printed materials was no more effective than the
printed materials alone. As mentioned above, subgroup analyses
of trials showed no statistically significant difference between the
effects of more and less intense interventions.
In a trial of cessation advice and feedback from a point-of-care
urine test for the products of nicotine, women were asked to sub-
jectively evaluate the influence of the smoking test on changes in
their behaviour. A majority thought the test was a good idea and
had helped them to appreciate more about their smoking (Cope
2003).
Case study reports associated with a trial of NRT reported partic-
ipants’ views suggesting significant resistance of women to using
NRT in pregnancy. Only 25% of women in the treatment group
(n = 5) complied with the treatment protocol (Hotham 2005).
A recurrent theme in the trials reporting providers’ views was their
concern about the time taken by the intervention. 65% of mid-
wives asked to use a carbon monoxide monitor and provide ’stage
of change’ based advice considered that this could not be achieved
in the time available (Hajek 2001). Midwives reported time pres-
sures for counselling in other trials (Lowe 1998a; Lowe 1998b).
The use of existing staff to deliver the new interventions and to col-
lect data seemed to affect the study negatively especially given the
time needed to process questionnaires and urine samples. This led
to less than full implementation and variable motivation to pro-
mote smoking cessation counselling among staff (Kendrick 1995).
Nine studies reported baseline psychological well-being though
not all of them reported findings post-intervention (Belizan 1995;
Ershoff 1999). The findings suggest there are significant psycho-
logical symptoms amongst pregnant women who smoke. More
than50%of pregnantwomenwho smokedhad current or previous
psychological symptoms, and approximately 20% reported ma-
jor depression based on CES-D scale assessments (Blalock 2005;
Dornelas 2006).
Consultation with health promotion specialists identified con-
cerns about adverse effects of quitting, or increased guilt over con-
tinued smoking, on women’s psychological well-being and capac-
ity to cope with adverse circumstance, with flow-on effects to the
women’s families (Oliver 1997). Women who smoke report that
smoking helps them to deal with stress and quitting may require
expenditure of emotional energy which they may not have whilst
meeting the demands of a young family (Ebert 2007). Pregnant
women are vulnerable to social pressures to confirm to the image
of ’good mother’ (Ebert 2007) and report feeling judged by others.
Despite these concerns, five trials have demonstrated that smoking
cessation interventions in pregnancy do not increase stress and psy-
chological symptoms for women (Aveyard 2007; Lawrence 2003;
Manfredi 1999; Panjari 1999; Rigotti 2006; Solomon 2006).
Bullock 1995 reported that women in the intervention group had
significant decreases in stress and depression scores, and an im-
provement in self-esteem scores.
Crittenden, 2007 analysed theManfredi 1999 data and found that
smoking outcomes are negatively mediated by stress in low SES
women.
7. Other outcomes measures
Heil 2008 reported significant increases in fetal growth measures
including birthweight, fetal femur length and fetal abdominal cir-
cumference, but no significant difference in lean thigh area, head
circumference or biparietal diameter, between control and inter-
vention groups.
MacArthur 1987 reported a small difference inmean infant length
at birth, but no difference in head circumference.
Only one trial (Rush 1992)measuredmaternal weight gain during
pregnancy (despite this being identified as a major area of concern
for women) which showed a non significant difference of 0.04
kg/week increase in the intervention group.
D I S C U S S I O N
Summary of main results
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There is approximately 6% difference in the combined effect of in-
terventions to promote smoking cessation in pregnancy. However,
heterogeneity remained high, even following subgroup analyses of
intervention strategy and intensity (I2 > 55%). Subgroup analyses
of trials at low risk of bias had the largest effect on reducing the
heterogeneity, but some heterogeneity remained (I2 = 36%). The
treatment effect in those trials at low risk of bias was more modest,
but still demonstrated an absolute difference of 3% of women in
the intervention group who quit smoking during pregnancy (risk
ratio 0.97, 95% confidence interval (CI) 0.94 to 0.99).
Public health impact of the interventions
Reducing smoking in pregnancy reduces the population at-
tributable risk of preterm birth and low birthweight (Hammoud
2005; Kramer 1987). It is this that makes a focus on interventions
to promote smoking cessation in pregnancy an important public
health issue, as there are significant impacts on the immediate and
long-term health of newborn babies.
The close to 15% reductions in preterm birth and low birth-
weight in the intervention arm of smoking cessation trials confirm
that smoking cessation can reverse the adverse effects of smoking
on perinatal outcomes. If all women in the intervention groups
stopped smoking and none of those in the control groups did, the
expected mean birthweight difference would have been about 200
g. The weighted difference in mean birthweight in these trials was
53 g. The expected mean difference from the extent of smoking
cessation alone would have been about 12 g. This suggests that
smoking reduction is also happening to a greater extent in the in-
tervention than the comparison groups, in line with self-reported
changes. Windsor 1993 has proposed using a halving of the co-
tinine level from trial entry as a measure of smoking reduction,
and in 1999 promoted the use of biochemical measurement as a
new behavioural indicator of ’harm reduction’ (Windsor 1999),
though this finding was not supported by Secker-Walker’s subse-
quent (Secker-Walker 2002a) analysis of infant birthweight in re-
lation to maternal cotinine from a different trial. The latter makes
the point that for a heavy smoker a halving of the cotinine level
may still represent a level of tobacco consumption hazardous to the
fetus. Secondary analysis of data from the trial of Kendrick 1995
suggests that reduction in smoking to fewer than eight cigarettes a
day is necessary to avoid reduction in infant birthweight (England
2001).
The impacts of smoking cessation on birthweight alone provide
rapid and significant “returns on investment” from smoking ces-
sation interventions in pregnancy. Miller 2003 2001 estimated
birth and first year costs for both mothers and infants attributed to
smoking were $1142 to $1358 per smoking woman. Infant costs
are approximately 10 times maternal costs and account for 90% of
costs in the first year. Low birthweight produces the highest eco-
nomic burden as it is the most common adverse outcome (Miller
2001). In contrast with that finding, the quality of diet in preg-
nancy (in high-income countries) has not been shown to affect
the mean birthweight of infants over 32 weeks’ gestation (Rogers
1998). Adams 1998, Melvin 2000, and Ayadi 2006 estimated the
additional costs of maternal conditions attributed to smoking in
pregnancy (preterm prelabour rupture of membranes (PPROM),
ectopic pregnancy, placenta praevia, placental abruption, sponta-
neous abortion, and taking into account a protective effect against
pre-eclampsia) at a total of $135 to $167 million per annum in
the US, based on 1993 US healthcare cost and dollar estimates.
As well as being a critical public health intervention for the baby’s
immediate health, pregnancy and motherhood is a major mile-
stone in a women’s lifecourse. The quit rate for smoking during
pregnancy is up to eight times that of the general population.
There are significant lifelong benefits for children growing up in
a smoke-free environment, and smoking is the major preventable
cause of premature mortality for the mother.
Psychosocial considerations
Smoking has been identified as a major preventable cause of the
health and life expectancy inequalities experienced by women who
suffer psychosocial disadvantage, including psychological illness,
low educational attainment, young early motherhood, lack of so-
cial support, and limited employment (Graham 2006). While the
importance of reducing smoking in all women is clear, the reduc-
tion in smoking has not been as effective in women experiencing
psychosocial disadvantage. Graham 2009 suggests that some of
the reasons that individual behavioural interventions may not as
effective may be that:
• they are unable to change the environmental factors that
increase the risk of smoking;
• they may have the effect of being judgemental and alienate
women;
• they are unable to change generational patterns.
Therefore, there is a need to gain greater insight into the experi-
ences and vulnerabilities of women who continue to smoke dur-
ing pregnancy and develop sensitive effective interventions which
support women and reduce vulnerability, without increasing risks.
Despite these concerns, the evidence from the included trials in
this review suggests that there are no negative psychological im-
pacts from behavioural interventions and that the psychological
impact may be positive, with responses from women feeling that
“somebody cared”.
Implementation and process issues identified
The first trials of anti-smoking interventions during pregnancy
were published more than 30 years ago (Baric 1977; Donovan
1977). The first trial to demonstrate the reversibility of the birth-
weight reduction associated with smoking by an intensive inter-
vention during pregnancy was published in 1984 (Sexton 1984).
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TheUS,UK andAustralia have developed guidelines recommend-
ing all pregnant women receive interventions to promote smoking
cessation in pregnancy (Aveyard 2007).These guidelines generally
incorporate a number of interventions, and are currently based on
the “5 A’s”, which involves:
• asking all pregnant women if they smoke;
• advising all pregnant women who smoke about the risks of
smoking in pregnancy and emphasising the benefits of quitting;
• assisting all pregnant women who smoke to quit, using a
range of interventions;
• assessing the pregnant women’s readiness to change and
setting a quit date;
• asking and assisting again at each subsequent encounter.
However, despite evidence of effectiveness of interventions in preg-
nancy and development of guidelines, widespread implementa-
tion of smoking cessation interventions in pregnancy in clinical
settings remain the exception (DeVries 2006; Lowe 2002;McLeod
2004; Windsor 2000b) rather than the norm (Abatemarco 2007;
Lumley 2002; McDermott 2006; NICS 2003). Walsh 1997 ar-
gues that evaluation of any preventive intervention should include
monitoring as to whether it has been implemented as planned,
and if not, why not?
Data from the two dissemination trials demonstrate challenges
to implementation in routine practice. Campbell 2006 showed
uptake of the intervention, but not at levels sufficient to have a
significant impact on smoking outcomes in women. Lowe 2002
found a significantly higher program implementation rate when
using an intervention based on Rogers’ ’Diffusion of Innovation’
theory (43% compared with only 9% implementation in the con-
trol group after one year), but there were no data on the im-
pact on smoking outcomes. Five of the six cluster trials imple-
mented in routine care by midwives reported difficulties with im-
plementation (DeVries 2006; Dunkley 1997; Hajek 2001; Lowe
1998b; Moore 2002). Some of the issues which arose included:
variable perceptions of smoking cessation as part of the midwives
role (DeVries 2006), midwives stating they were too busy and
did not have enough time to complete the intervention (Dunkley
1997; Hajek 2001), difficulty recruiting midwives to the study (
Lawrence 2003), women unable to recall intervention from amid-
wife (Moore 2002), and lack of acceptability of resources (Lowe
1998a). Three of the four physician implemented trials also re-
ported implementation problems (MacArthur 1987; Valbo 1994;
Walsh 1997). Three US cluster trials using routine staff to de-
liver the intervention reported similar challenges (Kendrick 1995;
Manfredi 1999;Wisborg 2000). In comparison, smaller trials may
benefit from greater enthusiasm of local champions. An analysis of
health promotion trials has concluded that where the providers are
also the researchers (more likely in single centre studies thanmulti-
centre studies) they appear to be better providers for influencing
behavioural outcomes and about the same as other providers for
other outcome domains (Oliver 2008). The larger, multicentre
trials may therefore be a more accurate representation of imple-
menting policy than smaller, single centre.
There are numerous papers which confirm that the major barriers
to implementation of evidence based interventions include:
• lack of time, with many competing pressures on clinicians
time (Haines 1998; Leviton 2003), also reported by providers in
studies included in this review (Hajek 2001; Lowe 1998a; Lowe
1998b);
• staff attitudes and perceptions of interventions, with
pessimism over interventions (McLellan 2000), a focus on the
90% failure rate rather than the 10% success rate (Moore 2002),
and peer pressure playing an important role (Grol 1999);
• perceived lack of skills and training (DeVries 2006);
• organisational and administrative barriers (Strand 2003);
• lack of high-quality programs which are acceptable to
women and care providers (Cabana 1999; Haynes 1998).
Offering additional group sessions for smoking cessation, even
in otherwise successful trials (O’Connor 1992; Sexton 1984;
Windsor 1985) was a very poorly accepted intervention, but ap-
peared to be accepted better in Northern Europe (Hegaard 2003;
Valbo 1991).
Effectiveness of interventions
Nicotine replacement therapy (NRT) during pregnancy
NRT in this review does not appear to have a significant advantage
over other types of interventions in terms of smoking cessation
in subgroup analysis, but there has been no direct comparison of
NRT outcomes with any other strategy. There are still concerns
about the safety of prescribing a neurotoxicant in pregnancy, and
the possibility of adverse effects of nicotine on the fetus, through
alterations in uterine, placental or blood flow or directly on the
brain (Slotkin 2008).
The safety of NRT in terms of effect on fetal development and
birth outcomes remains unclear in pooled data from this review.
Only three of the five NRT trials recorded birth outcomes (
Hegaard 2003; Pollak 2007; Wisborg 2000). One trial (Pollak
2007) suspended study enrolment due to a recommendation by
the Data and Safety Monitoring Board following a statistically
significant increase in serious adverse events between study arms
(30% in intervention group and 17% in control group: risk dif-
ference = 0.13, 95% CI 0.00 to 0.26 P = 0.007). The adverse
events are individually listed in the trial report and include pre-
eclampsia, placental abnormality, preterm birth, small for gesta-
tional age, neonatal intensive care unit admissions and fetal loss.
A large Danish cohort study identified a slight increase in rates of
congenital malformations in used nicotine substitutes over women
who smoked (Morales-Suarez-Varela 2006).
The pooled birth outcome data from these trials are not significant
(birthweight increase 33.96 g, 95% CI -125.5 to 193.43), low
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birthweight babies odds ratio (OR) 0.95, 95%CI0.42 to 2.42, and
preterm birth OR 0.97, 95% CI 0.61 to 1.53. However, the only
trial measuring non-significant positive birth outcomes (Wisborg
2000) reported only 17% compliance in the intervention group.
The other two trials (Hegaard 2003; Pollak 2007) which had high
compliance rates (approximately 80%) reported non significant
negative trends in birthweight and low birthweight babies.
Most NRT trials in pregnancy to date have used mainly nico-
tine patches with continuous use formulations (over 80%). Pollak
2007 used continuous and intermittent dose formulations, but
did not report outcomes by type of formulation. Two small (phys-
iological) randomised trials have compared the effects of nicotine
gum (Oncken 1996) or transdermal nicotine (Oncken 1997) with
maternal smoking in relation to blood concentrations of nicotine
and cotinine and to maternal-fetal haemodynamics.
Dempsey 2001 recommend doses of prescribed nicotine in preg-
nancy should be similar to a smoking dose, and that intermittent
forms of NRT (gum, spray, inhaler) are preferred to continuous
use formulations as the total dose of nicotine will be less. In some
countries, though not in all, nicotine gum and nicotine patches
may not be sold without a prescription and in others there are
packet warnings against their use in pregnancy, though the ap-
propriateness of this has been debated (Benowitz 1991; Hughes
1993).
Other challenges for NRT trials have included apparent reluctance
amongst pregnant women to use NRT (Hotham 2005; Rigotti
2008; Wisborg 2000), and for doctors to prescribe NRT (Vogt
2006). Some trials reported other adverse effects, including low
rates of skin irritation and headaches (Hotham 2005; Wisborg
2000), which were given as reasons why women chose to discon-
tinue with the treatment.
Ther has been one randomised controlled trial of Bupropion in
pregnancy (Miller 2003), which did not demonstrate a significant
difference in smoking cessation.This study is included in “ongoing
studies” in this review as the available trial report had insufficient
details for inclusion. Cohort studies suggest that it may be safe to
use in pregnancy (Chan 2005).
As there are still too few trials to assure safe use in pregnancy, and
animal studies suggest nicotine may be toxic to the developing
central nervous system, Dempsey 2001 recommend registries of
women using NRT be established to gather more outcome data.
Other associated factors
There was no significant difference in rates of smoking initiation
or duration in the intervention arms of the two trials measuring
breastfeeding outcomes in this review. However, smoking is asso-
ciated with low rates of breastfeeding initiation, and reduced du-
ration (Horta 1997; Sayers 1995), an association which persists
in some, but not all studies, after adjustment for social and repro-
ductive factors. This is likely to be due to motivational rather than
physiological causes (Donath 2004).
There is a growing interest in interventions to increase smoking
cessation among the partners of pregnant women, with the ad-
ditional aim of facilitating cessation by the women themselves (
Gage 2007; Stanton 2004). In some cases this reflects cultural and
demographic patterns of smoking, where smoking rates are still
highest amongst men. A review by Park 2004 evaluates the effect
of interventions to promote partner support on smoking cessa-
tion.
Overall completeness and applicability of
evidence
There was limited data for some types of interventions and for
some types of outcomes. The review includes a relatively large
number of studies focusing on educational and counselling inter-
ventions but relatively few focusing on other approaches, such as
the use of nicotine patches and rewarding women for giving up
smoking. Relatively few of the included trials provided informa-
tion on perinatal outcomes other than birthweight, and there was
very little evidence on the effect of interventions on maternal psy-
chosocial outcomes such as anxiety.
Many of the studies did not provide information on the number of
women who were eligible for inclusion or were approached to take
part in trials, but who were not randomised. This information is
useful to interpret the findings; if only a small proportion of those
approached take part in a trial the results may only be applicable
to a self-selected part of the smoking population. The high levels
of attrition in many of these studies also limits the applicability
of findings, those women lost to follow up may be different in a
number of ways from those providing complete data.
Most of the included studies were carried out in western Europe
andNorth America and it is not clear that the results are applicable
in other contexts.The transfer of an intervention from one setting
to another may reduce its effectiveness if elements are changed or
aspects of the materials are culturally inappropriate. Examples in
these trials are the performance of the Windsor self-help manual.
This was developed and shown to be effective in Birmingham,
Alabama (Windsor 1985; Windsor 1993). However, when it was
used in Baltimore with peer counsellors who received minimal
training (Gielen 1997), instead of trained health educators, the
effectiveness was much lower. In addition, aspects of the interven-
tion recommended in the same manual were shown to have very
poor acceptability in Brisbane (Australia) and a very low level of
effectiveness (Lowe 1998a).
Quality of the evidence
The studies included in the review were of mixed quality and we
would emphasise the need to consider the risk of bias tables when
interpreting results. For educational and counselling interventions
blinding of participants, clinical staff and outcome assessors was
18Interventions for promoting smoking cessation during pregnancy (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
frequently not feasible and rarely attempted. This is likely to be a
source of bias. Levels of attrition were generally high, particularly
for outcomes where information was collected by postal question-
naire months after the initial intervention; high levels of attrition
may mean that it is difficult to interpret results. We have also
mentioned problems associated with detection bias when smoking
outcomes relied on maternal self-report.
There is a very high level of heterogeneity amongst the trial re-
sults (I2 generally greater than 60%), hence we urge caution when
interpreting the combined effect of the interventions. Subgroup
analysis of trials at low risk of bias had the greatest effect on re-
ducing heterogeneity, though this was still high at 36%.
In addition, at a more general level, there are some criticisms in
the literature of smoking cessation programs, including failure to
consider the following.
• Relevant health promotion theory and knowledge (
Solomon 1996; Stotts 1996). However, there have been some
recent studies which have investigated the applicability of
theories to smoking cessation in pregnancy (Riemsma 2003;
Slade 2006).
• Views of women (Ebert 2007; Gilligan 2007; Jayaweera
2006; McDermott 2006) or caregivers (McLeod 2003; Vogt
2006) or inadequate implementation and little or no process
evaluation (Herbert 2005; Windsor 1998). However, there has
been some discussion of women’s preferences for cessation
support in recent years (Coleman 2004; Ussher 2004).
• Weight concerns, with women being asked both to control
weight gain and relinquish an addictive drug with weight
suppressing effects; yet there is limited research into strategies to
help women address this dilemma. There is some evidence
women are more likely to smoke to control their weight, and
female body image is extensively targeted by tobacco marketing
campaigns (CDCP 2002; Levine 2006; Pomerleau 2000). A
recent review by Shraim 2006 has assessed the impact of
interventions to prevent weight gain after smoking cessation.
• Women’s fears that smoking reduction will, by increasing
fetal size, increase the probability of a difficult labour or an
operative delivery have been taken into account very rarely (
Sexton 1984) in the design and implementation of smoking
cessation programs. A small cohort study in the US found that
smoking cessation was associated with protection against lower
birthweight through mechanisms other than increased maternal
weight gain or different weight gain patterns (Groff 1997). One
study modelled increases in birthweight (from 2450 g to 2550 g)
in Guatemala and found an increased risk of caesarean section
due to obstruction by eight in every 1000 cases, but this was
outweighed by a reduction in risk of caesarean section due to
fetal distress by 34 per 1000 cases (Merchant 2001).
Potential biases in the review process
Impact of population based interventions over time
Population-based campaigns to encourage smoking reduction and
smoking cessation during pregnancy are now widespread in high-
income countries (Campion 1994; Eriksson 1996). Tappin 2005
reported a modest reduction in smoking in the intervention arm,
and notes that the inability of the study to replicate the results of
this reviewmay be due to the fact that women continuing to smoke
in pregnancy in later studies, despite widespread population based
campaigns, may be more seriously addicted, and have lower self-
efficacy to quit.
Misclassification of smoking by self-report
A very high proportion of pregnant women describe themselves as
having “cut down” but given the problems of self-report described
previously, important questions about the effectiveness of inter-
ventions in facilitating smoking reduction remain unanswered at
present: only biochemically validated smoking cessation can be
regarded as a reliable outcome measure.
The sensitivity of screening and disclosure of smoking status can
be improved by adjusting the question format, from yes or no to
multiple options including “I used to smoke”, and “I have cut
down” (Mullen 1991).
Agreements and disagreements with other
studies or reviews
Stages of change
The data from Solomon 1996 suggest that the transtheoretical
model of stages of change in readiness to stop smoking (pre-con-
templation, contemplation, preparation and action) may not ap-
ply in pregnancy, and that stage changes in early pregnancy are
not sustained. Pooled analyses showed no evidence for a signifi-
cant effect with stages of change based interventions, compared
with interventions based on other theories. A systematic review of
smoking cessation also concluded that stage-based interventions
are no more effective in general than interventions which do not
tailor the intervention according to the stage of change (Riemsma
2003).
NRT
NRT in pregnant women does not appear to be as effective as is
reported in the general population.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
As smoking cessation programs have been shown to increase smok-
ing cessation, reduce preterm birth and low birthweight, and in-
crease mean birthweight, smoking cessation programs need to be
implemented in all maternity care settings. Attention to smoking
behaviour together with support for smoking cessation and relapse
prevention needs to be as routine a part of antenatal care as the
measurement of blood pressure. Local piloting of programs shown
elsewhere to be effective would be a good place to begin .The use
of the NNT (number needed to treat) as a counter to views that
smoking cessation interventions do not work in pregnancy, may
be a useful strategy.
Given the clear difficulties which most women still smoking at the
first antenatal visit have in stopping smoking, midwives, general
practitioners, and obstetricians need to support population-wide
strategies for smoking control in the whole community to reduce
the initiation of smoking by young people: action to prevent sales
of tobacco products to young people, prohibition of smoking in
all public places, increases in tobacco taxation, workplace smoking
cessation programs and bans on tobacco sponsorship of prestigious
sporting and cultural events as outlined in the WHOMPOWER
package (WHO 2008a).
In order to avoid ’victim-blaming’, or the perception of ’victim-
blaming’, and compounding issues of social disadvantage closely
associated with smoking, attention needs to be given to the con-
sumer concerns and to supporting these population based mea-
sures which are non-discriminatory.
Given the strong association between social inequality and con-
tinued smoking by pregnant women, and bearing in mind that
smoking is the major preventable cause of inequalities in life ex-
pectancy, strategies in the wider community to reduce social in-
equalities, as recommended in the Closing the Gap in a generation:
Health Equity through Action on the Social Determinants of Health
(WHO 2008b).
Implications for research
Future trials need to include the following elements.
• A description of the intervention in sufficient detail for its
replication even if the detail requires a separate paper.
• Process data as evidence of implementation.
• A relapse prevention component for those who have
stopped smoking before the first antenatal visit.
• Biochemical validation of non-smoking status.
• The collection of perinatal outcome data on birthweight,
preterm birth and perinatal deaths, particularly for nicotine
replacement therapy trials.
• Collection of outcome data on breastfeeding, operative
delivery, maternal psychological well-being, and the perceived
impact of the intervention on family functioning.
• In order to assess the effect of clustering and include
cluster-randomised trials in meta-analysis, the impact factor or
intracluster correlation needs to be reported.
The strong results from trials using incentive strategies is encour-
aging, but as yet the trials are small scale and there are no trials in
routine practice or discussion papers of the policy implications of
implementing such an intervention at population level.
There are two aspects of smoking cessation interventions in which
there are mixedmessages. These are likely to detract from the over-
all effectiveness of programs, since simple and explicit messages
are a key aspect of effective health promotion.
• Is there a place for including smoking reduction as one of
the goals, in line with ’harm minimisation’ strategies for other
harmful substances and practices?Research in this area, including
better measures of tobacco exposure is necessary.
• Facilitating smoking cessation in pregnancy is worthwhile
to improve pregnancy and infant outcomes and reduce maternal
complications of pregnancy. Some programs promote stopping
smoking in pregnancy primarily as a strategy for stopping
smoking altogether, that is as a strategy for reducing cancer and
chronic diseases in later life. An unambiguous recommendation
that stopping smoking in pregnancy is an important and
worthwhile goal for the fetus is necessary.
As smoking rates have decreased in the general population in
high-income countries, it is becoming increasingly recognised that
smoking has become more closely correlated with entrenched
social disadvantage and psychological co-morbidity. Studies are
needed which refine interventions to address the specific needs of
these subpopulations, without compounding problems of social
alienation and lack of self-efficacy. There is currently very lim-
ited applied research into interventions in indigenous (Gilligan
2007) and ethnic minority populations, whose unique perspec-
tives would need to be incorporated into a culturally appropriate
intervention. Population wide interventions have not been effec-
tive in reducing smoking rates amongst many indigenous and eth-
nic minority groups, and the appropriateness of messages needs
careful review. Given the shifting demographics and burden of
diseases from tobacco smoking from high- to low- and middle-
income countries, more research is needed to develop strategies
which are culturally appropriate for these settings. The authors
of this review are frequently asked whether there is evidence of
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differential effectiveness of interventions by social, economic or
demographic factors, particularly poverty or lack of support. If
there is adequate reporting of subgroup analysis in trials, we will
attempt to apply an “equity lens” (Murray 2005) to trials in the
next update to answer these important questions.
In the next update we will attempt to definemeasures of “interven-
tion quality”, such as whether the interventions have considered
or addressed the views of women and/or providers, and whether
they were well implemented. To assess these issues, trials will need
to report:
• a developmental phase for the intervention materials and
methods to be carried out with women similar to those who will
be exposed to the intervention, taking full account of women’s
concerns (negative impact on the woman herself and therefore
on her family of stopping smoking because of its role in stress
management and coping, perceived advantages of smaller babies
such as shorter labours and less likelihood of operative delivery,
the good outcomes of previous pregnancies despite smoking, or
the good health of babies born to other women who smoke), and
assessing the cultural appropriateness of material developed
elsewhere;
• full involvement of staff who will be involved in any aspects
of the intervention to ensure, in a similar way, that their concerns
have been addressed, and to increase their understanding, active
participation and support;
• a process evaluation identifying the extent of
implementation in terms of its reach and the satisfaction of
clients/consumers and staff;
• any theories which are used to inform the development of
the intervention.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Albrecht 1998
Methods A randomised pilot study including two different interventions and UC provided to
“pregnant teens” recruited through local prenatal clinics and public schools in Pittsburgh,
USA. The hypothesis was that an intervention including peer support would be more
effective than the intervention alone. The aim was to develop an effective intervention
which could be implemented by clinics and schools.
Participants Inclusion criteria were: 12 to 20 years of age; 4 to 28 weeks’ gestation; reported smoking
at least 1 cigarette a day; single; no previous live birth; able to read and write English.
Exclusion criteria: pregnancy complications preventing attendance at group sessions or
participation in a home study program.
84 women recruited (not known how many were eligible or approached), 53 African-
American heritage, 31 European-American heritage.
29 randomised to UC, 29 to TFS and 26 to TFSB.
46/84 had outcome data post-intervention. Mean cigarettes/day at first visit: UC = 6.44;
TFS = 5.87; TFSB = 6.81.
Interventions UC 30 minutes individual educational session with project nurse including information
about the risks of smoking to the mother and the fetus and brochures on smoking and
pregnancy.
TFS: cognitive behavioural group model designed specifically for adolescents: 8 modules
to heighten awareness and attention to smoking messages; build and enhance smoking
cessation skills; teach skills for maintenance of smoking control; includes experiential
learning and round robindiscussion.TFSwasmodified to include additional information
on smoking and the fetus, body image changes and overall health. The intervention also
included social activities, immediate rewards and adult modelling.
TFS plus peer support (TFSB) utilised all the components of TFS plus one-to-one
support through a non-smoking peer (buddy) chosen by the young woman. Buddies
were asked to attend all 8 sessions and to be available at other times for reinforcement
of techniques learned and encouragement for continued cessation. Intensity rating: I =
4, C = 3.
Outcomes Smoking cessation at 4-6 weeks’ post baseline, validated by exhaled CO. Reduction in
expired CO.
Modified Fagerstrom Tolerance Questionnaire for adolescents to assess nicotine depen-
dence.
Notes TFS and UC outcomes were combined in this preliminary paper.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as randomly assigned.
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Albrecht 1998 (Continued)
Allocation concealment? Unclear No information.
Blinding?
Women and clinical staff
No Provider and participants unable to be
blinded to educational intervention.
Incomplete outcome data addressed?
All outcomes
No Only 46/84 had complete outcome data
(high attrition rate = 45%), UC = 12
(41%), TFS = 13 (46%), TFSB = 13
(50%). No explanation for attrition. ITT
analysis not mentioned.
Free of selective reporting? Unclear Only smoking outcomes reported.
Free of detection bias? Yes Exhaled CO levels.
Baric 1976
Methods A randomised pilot study of the effect of medical advice on smoking cessation in preg-
nancy, in 2 public antenatal clinics in Bolton and District General Hospital, England.
Participants Women smokers or ex-smokers, at their first antenatal visit, less than 20 weeks’ gestation.
110 women, mostly working-class, mostly long-term and heavy smokers. I: n = 63 C: n
= 47.
Interventions Control group received UC, which was advice at the discretion of the doctor.
Intervention group received one to one counselling from a senior medical student which
involved discussion of the disadvantages of smoking during pregnancy: risk to the fetus;
long-term risks of physical and intellectual impairment and possible reasons for this;
possible effects on the mother’s own health; costs of smoking; special dangers of smok-
ing in late pregnancy; various ways to help someone to stop smoking. Given strong
encouragement to quit and to make a commitment to do so. If this was not agreed then
reduction to less than 5 cigarettes a day.
Half the intervention group were given a diary to record each cigarette smoked and a
gift of a free smoking diary. No theoretical basis of intervention specified. Intervention
intensity I = 3, C = 2.
Outcomes Smoking cessation assessed by self-report in a home interview 11 weeks after baseline
visit. Discusses participants’ views of intervention.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided. Described as
“randomly divided”.
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Baric 1976 (Continued)
Allocation concealment? Unclear No information provided.
Blinding?
Women and clinical staff
No Educational intervention at first antenatal
visit.
Incomplete outcome data addressed?
All outcomes
Unclear There are some missing data in the tables.
It is not clear if there was any overall loss to
follow up or whether missing data relate to
specific outcomes only. 110/142 analysed.
No explanation as to reason for attrition.
No ITT analysis.
Free of selective reporting? Unclear No other outcomes reported.
Free of detection bias? No Smoking outcomes were reported by par-
ticipants. There was no biochemical vali-
dation.
Bauman 1983
Methods Randomised trial of effectiveness of use of exhaled carbon monoxide feedback for pro-
moting smoking cessation in pregnancy, in Guildford County, North Carolina. Trial
over 6 months in 1981. No sample size justification.
Participants Women currently or recently smoking, attending public clinics. No exclusion criteria
details or characteristics of participants in each group. 47% were current smokers, 43%
had completed high school education, 56% were black, 80% classified as having no
pregnancy risks other than smoking. 38% in the first trimester and 46% in the second
trimester of pregnancy. 88 women were included in the analysis for the main outcome.
Interventions Experimental group provided breath specimen inwhich carbonmonoxide wasmeasured,
with feedback of the result, and a 135 word script describing the relationship between
CO and cigarette smoking and the harmful effects of smoking during pregnancy, by
health educator.
Women in the control group were read the script only.
Intervention carried out by regular health educators. Theoretical basis: feedback. Inten-
sity rating I = 2, C = 1.
Outcomes Smoking cessation 6 weeks after intervention confirmed by subsequent CO <= 9 ppm
in breath specimen.
Notes Not clear whether this was a group intervention - in which case there was no adjustment
for clustering.
Risk of bias
Item Authors’ judgement Description
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Bauman 1983 (Continued)
Adequate sequence generation? Yes Random number table.
Allocation concealment? Unclear No information provided.
Blinding?
Women and clinical staff
No Intervention was carried out by UC staff,
no participant blinding.
Incomplete outcome data addressed?
All outcomes
No High rate of attrition (24.8%).The authors
report that those lost to follow up had
similar characteristics in the experimental
and control groups. Analyses included only
those remaining at follow up.
Free of selective reporting? Unclear None apparent.
Free of detection bias? Yes Biochemical validation of reported smok-
ing behaviour for those followed up.
Belizan 1995
Methods Randomised trial of psychosocial support in pregnancy in 4 hospitals in Latin America
(Argentina, Brazil, Cuba, Mexico). January 1989 - March 1991.
Participants High-risk women whose antenatal care began at 15-22 weeks’ gestation, singleton preg-
nancy, 1 or more of the following: prior LBW infant; preterm birth; perinatal/infant
death; < 18 years; body weight <= 50 kg; height <= 150 cm; low family income (local
definitions applied); < 3 years school; crowded household (4 or more persons/bedroom);
smoking; not living with husband or partner. 2235 women recruited 1115 to interven-
tion 1120 to control.
Exclusions: heart or renal failure; diastolic BP > 100 mmHg; history of cervical cerclage;
Rh negative; mental disease or any chronic disease that might interfere with pregnancy.
Interventions Control group received routine antenatal care. Intervention involved flexible use of a
standardised manual, based on site-specific ethnographic studies of needs, fears, expecta-
tions, social support networks, including detailed descriptions of situations likely to oc-
cur during home visits. 4 to 6 home visits of 1 to 2 hours with emphasis on psychosocial
support, education on health habits including better nutrition, reducing smoking alcohol
and other drugs, reducing their physical workload, recognition of alarm signs and symp-
toms, improved access to hospital facilities, reinforcement of health service utilization.
Additional components were a poster, a booklet, hotline to project office, guided tour of
hospital, encouragement of family support and participation. Intervention was provided
by specially trained female social workers or obstetric nurses with previous experience of
childbirth. Theoretical basis: reinforcement of social support networks. Intensity rating:
I = 4, C = 1.
Outcomes Self-reported smoking cessation, no biochemical validation.
Multiple perinatal and maternal health outcome data were collected.
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Belizan 1995 (Continued)
Baseline state anxiety score.
Notes Sample size was planned for the primary trial objective.
Process evaluation showing good implementation is reported.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Centrally prepared, method not stated.
Allocation concealment? Yes Allocation was by opening sealed, opaque
envelopes.
Blinding?
Women and clinical staff
No Home visitors were aware of group allo-
cation. Social support intervention with
home visits.
Incomplete outcome data addressed?
All outcomes
No Nine per cent lost to follow up. No ITT
analysis of drop-outs as continuing smok-
ers.
Free of selective reporting? Unclear None apparent.
Free of detection bias? No No biochemical validation of reported
smoking behaviour.
Bullock 1995
Methods Trial of telephone support for improving outcomes in late pregnancy, in the outpatient
department of a large maternity hospital in New Zealand, or its associated GP practices,
or self-referral, from March to December 1993.
Participants Women with telephone access, who were either single or with an unemployed partner,
were recruited before 20 weeks’ gestation. The eligible population was 221 women of
whom 131 took part (103 OPD, 22 fromGPs, 6 self-referred). 49 were never located, 23
were not interested, 10 refused after explanation, 8 moved away, did not speak English
or had a miscarriage.
Over 50% of women smoked at recruitment.
Interventions Introductory letter, phone call, full discussion of “Healthy Mothers/Healthy Babies”.
Controls: package of publicly available educationalmaterial onhealthy behaviours during
pregnancy.
High intensity intervention: package plus weekly telephone call from trained volunteer
with the aim of providing minimal support until 12 weeks after birth; aim “to be a friend
and a good listener”; to ask about symptoms; signs; alcohol; drugs; smoking and meals
in every call; to encourage attendance at antenatal clinic appointments and to ask about
“feeling stressed”.
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Bullock 1995 (Continued)
Intervention provided by 19 female volunteers, trained for the project with a “case load”
of 2 to 6 women each. Theoretical basis: social support. Intensity rating: I = 4, C = 1.
Outcomes Smoking cessation at 34/40. Anxiety and depression scores at baseline and 34/40. There
were other intervention components which might have influenced these outcomes.
Notes No process evaluation is reported. No sample size justification.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated random assignment
to control or intervention in balanced
blocks of 50.
Allocation concealment? Unclear No information provided.
Blinding?
Women and clinical staff
Yes Caregiver blinded to allocation. Women
not blinded to intervention.
Incomplete outcome data addressed?
All outcomes
Unclear Attrition was relatively low (9 of 131
women were lost to follow up) but there
was a high non-participation rate. Attrition
= 7%. Women lost to follow up were in-
cluded in the analysis as continuing smok-
ers.
Free of selective reporting? Unclear None apparent.
Free of detection bias? No No biochemical validation of reported
smoking behaviour.
Burling 1991
Methods Trial of CO assessment and brief directive feedback, in a large US municipal hospital
antenatal clinic, over an 18 month study period.
Participants All attending women screened for smoking by questionnaire + CO breath measurement
(>= 9 ppm). Pregnant women, currently smoking, at any stage of gestation. Over 50%
were current smokers; 40% of women were Black.
Exclusion criteria were very young age (not specified)or “complications” (not specified)
. 139 women included in the analysis.
Interventions Control group (UC): clinic nurse provided health education, including smoking.
Intervention: UC and a personal letter from the Chief (physician)of the prenatal clinic
within 3 days of the visit, mentioning the CO test, discussing the risks of smoking to
herself and the fetus and urging her to stop plus the American Cancer Society pamphlet
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Burling 1991 (Continued)
(“Why start life under a cloud?”) about the negative effects of smoking and simple guide-
lines for self-directed smoking cessation. Theoretical basis: feedback. Intensity rating: I
= 3, C = 2.
Outcomes CO measurements (biochemical validation)and smoking data were collected at all sub-
sequent visits.
Notes Simple intervention so no process evaluation.
Clinic-wide implementation so no consent sought.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided.
Allocation concealment? Unclear No information provided.
Blinding?
Women and clinical staff
Unclear The authors state that clinic staff were un-
aware of group allocation. Women would
not have been blind to educational inter-
vention.
Incomplete outcome data addressed?
All outcomes
Yes No loss to follow up apparent.
Free of selective reporting? Unclear None apparent.
Free of detection bias? Yes Biochemical validation of reported be-
haviour by exhaled CO.
Campbell 2006
Methods Cluster-randomised trial in Newcastle, New South Wales, Australia.
Participants Women attending 22 public antenatal clinics (unit of randomisation). Exclusion criteria:
under 16 years of age, too sick, non-English speaking, illiterate, attendance was first visit.
194 women included in the analysis.
Interventions Intensive dissemination of programme (Intervention group) included written informa-
tion and feedback about programme benefits to managers, provision of programme re-
sources, offers of visits to explain programme and provide training, sample smoking
cessation policy, regular contacts to offer support, and computerised feedback on activ-
ities. Simple dissemination of programme to clinics (control group) included mail out
of written information on programme benefit and resources. The cessation programme
“Fresh Start for you and your baby”, developed by Windsor, based on CBT, was used.
Intervention intensity: I = 4, C = 4 (same intervention in both groups, only dissemination
method differed).
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Campbell 2006 (Continued)
Outcomes Biochemically validated smoking cessation at end of pregnancy, recall of smoking advice
received.
Participants and provider views of interventions discussed.
Notes Process evaluation showed good implementation in intervention group. No intracluster
correlation or impact factor reported, so sensitivity analysis conducted using four ICCs
and figures adjusting using ICC of 0.1 in outcome tables.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Methodof randomallocationnot specified,
but taken within strata based on clinic size
and baseline smoking rates.
Allocation concealment? Unclear Not specified.
Blinding?
Women and clinical staff
Unclear Educational intervention. Neither women
nor providers would have been blind to the
intervention.
Incomplete outcome data addressed?
All outcomes
No One clinic excluded as did not report final
data and some missing data for post-dis-
semination measures. No ITT of women
dropping out of study. Only women com-
pleting study measures included in analy-
sis.
Free of selective reporting? Yes Smoking status and recall of intervention
reported.
Free of detection bias? Yes Exhaled carbon monoxide >= 9.
Cinciripini 2000
Methods Trial of provision of videotaped vignettes for promoting smoking cessation and relapse
prevention in a community-based university setting, Texas, US.
Participants Volunteers who were willing to quit within 2 weeks, were recruited through local media,
such as newspaper, radio, subscriber letters, community business flyers, waiting room
posters. Exclusion criteria: women smoking < 3 cigarettes per day; < 18 years; > 30 weeks’
pregnant; do not have a working video recorder (approximately 12% Americans); not
depressed. Participants n = 82. Mean cigarettes/day at first visit I = 17.3, C = 14.5. No
significant difference in socioeconomic variables between groups.
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Cinciripini 2000 (Continued)
Interventions The control group received a quit calendar and tip guide.
Intervention group were also mailed a video with 6 x 25-30 minute vignettes covering
a range of topics and strategies from initial quitting to relapse prevention. Theoretical
basis: videos to teach coping skills/ cognitive behavioural techniques. Intensity rating: I
= 3, C = 1.
Outcomes Self-reported smoking abstinence obtained within 2-3 days of quit date, 4-5 weeks after
the quit date and onemonth postpartum. Biochemically validated with salivary cotinine.
Participant evaluation of intervention materials.
Associated references report association of quitting and depressive disorders.
CES-D scores at baseline only.
Notes Authors say women in this study tend to be heavier smokers than described in previous
studies.
Process evaluation showed only 53% of the intervention group viewed 1-3 of the 6
videos. 47% did not view them.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not stated.
Allocation concealment? Unclear Not stated.
Blinding?
Women and clinical staff
No Video mailed to participants. Not clear if
UC givers were aware of group allocation.
Incomplete outcome data addressed?
All outcomes
No Only 61% of participants completed all as-
sessments. All those with missing data were
treated as continuing smokers.
Free of selective reporting? Yes Pre-specified outcomes reported.
Free of detection bias? Yes All reports of abstinence were validated by
measurement of salivary cotinine.
Cope 2003
Methods Randomised controlled trial in 3 large inner city hospital antenatal clinics, Birmingham,
UK.
Participants “Current smokers” (> 10 mg/ml in preliminary urine cotinine result) were enrolled in
study. No exclusion criteria specified. Intervention group = 447 allocated, with 164
current smokers identified. Control group = 298, with 116 current smokers identified.
An average consumption of 11.8 cigarettes per day in intervention group (not reported
in control group). No demographic variables between groups reported.
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Cope 2003 (Continued)
Interventions Control group: urine measured at initial visit, but no feedback given to women about
results. Routine counselling about smoking in pregnancy from doctor or midwife, at 36
weeks’ gestation, women had an interview to explain study, and obtain verbal consent
to participate.
Intervention group: all allocated women seen at initial visit and given brief explanation
of test and asked for consent to participate. After consent, they were asked for sample of
urine, and 6minute test completed in their presence. Results given as number and graphic
illustration. A specific “quit date”, usually within 14 days, set by mutual agreement and
written on result sheet. Women were given printed leaflet on advice of how to quit and
invited for further urine measurement and repeated support at subsequent visits.
Theoretical basis: feedback. Intensity rating: I = 4, C = 2
Outcomes Biochemically validated cessation (urine cotinine) at 36 weeks’ gestation.
Self-reported smoking status and consumption at 36 weeks’ gestation.
Proportion with “significant reduction” (20-80%) in urine cotinine.
Birthweight and length. SD for birthweight not provided, assumption of P = 0.03 used
to calculate SD.
Gestation, type of delivery and Apgar scores (collected but results not reported).
Participants’ views of intervention included.
Notes Process evaluation feedback from participants suggests that the “majority thought the
test was good idea and had helped them to appreciate more about their smoking”. Few
women in the control group recalled receiving advice about smoking in pregnancy.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No Sequence generation based on odd or even
hospital numbers.
Allocation concealment? No Group allocation could be anticipated.
Blinding?
Women and clinical staff
No Neither providers nor women were blind
to the intervention.
Incomplete outcome data addressed?
All outcomes
No One table states that 298 were allocated to
control group, but in the text, it states 409
(which would add up to correct total of
eligible patients in table).However, the text
states that only 280 were current smokers
(I = 164, C = 116).
Of these, only 192 completed the trial, but
the above figures have been used in this
analysis.
Attrition = 55 in intervention group and 33
in control group (included in this analysis
as continuing smokers).
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Cope 2003 (Continued)
Free of selective reporting? Yes
Free of detection bias? Yes Smoking status validated with urine coti-
nine. >10 mg/ml indicates active smoker.
Lower rates of self-reported cessation at
36/40 than biochemically validated (I = 16,
C = 0). Biochemically validated used in this
analysis.
DeVries 2006
Methods Cluster-randomised trial in Maastricht, The Netherlands. Feb-December 1996.
Participants Women using public health services, who smoke more than 1 cigarette per day, literate
in Dutch, and gravidity less than or equal to 4. 80% eligible population approached.
Participation rate 72% (n = 318). Mean cigarettes per day at intake I = 9.1, C = 7.7.
Mean gestation at intake I = 12.4, C = 13.5. (ii) included women from trial (i) and
spontaneous quitters; n = 253 (I) and 303 (C); 80% approached. 72% participation.
Interventions Control group received routine smoking cessation counselling and a folder about smok-
ing cessation in pregnancy, (Both trials i and ii)
Intervention group received routine care plus a minimum of 2 counselling sessions from
their midwife (who received a 3 hour training session on smoking cessation counselling
and a booklet); a video; self-help guide; partner booklet and post-delivery booklet. In-
formation was based on the stages of change model. Intensity rating: I = 4, C = 3.
Outcomes Self-reported quit attempts at 6 weeks’ postpartum, with urine cotinine biochemical
validation in a small proportion of participants (n = 14).
Self-reported partner smoking status.
Detailed assessment of participant and midwifery views of interventions, including an
analysis of psychosocial motives which are thought to be associated with implementation.
Notes Inconsistent information on gravidity criteria. Significant clustering identified atmidwife
level. The reported inter-cluster variance of 0.82 was used to derive ICC for adjusting
reported outcome figures used in analysis. A separate detailed paper published on process
evaluation issues which reports poor implementation in some aspects. Only 16.7% of
women received the post-delivery booklet. No validation of longer-term self-reported
smoking.Only 24.2%of chairs ofmidwifery agreed to approachmidwives in their region
to participate.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No The first 40 practices (118 midwives) were
selected, from4provinces, whichwere then
matched (by location and level of urbanisa-
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DeVries 2006 (Continued)
tion)into 2pairs. Allmidwives in a province
were allocated to either intervention or
control care.
Allocation concealment? Unclear Not reported.
Blinding?
Women and clinical staff
No Neither providers nor women were blinded
for this counselling intervention.
Incomplete outcome data addressed?
All outcomes
Unclear Not clear, figures are not consistent, as well
as loss to follow up there are missing data
for some variables.
When all drop-outs included as smokers 7-
day abstinence I = 19% of 141 and C = 7%
of 177, included in this analysis.
Free of selective reporting? Unclear None apparent.
Free of detection bias? No Biochemical validation for a small sub-sam-
ple only.
Donatelle 2000
Methods Trial of “Significant Other Supporter” (SOS) program, of bolstered social support and
direct financial rewards, for low-income high-risk women in 4 Oregon WIC program
sites, US. Conducted between June 1996 and June 1997.
Participants Women smoking (even a puff in the last 7 days); less than 28 weeks’ gestation; over
15 years of age; literate in English. Participation rate 71%. Mean salivary cotinine at
baseline: I: 45.4 (n = 112);
C: 45.7 (n = 108).
Interventions Control group received verbal and written information on the importance of smoking
cessation, a pregnancy specific smoking cessation self-help kit, and were telephoned
monthly for self-reports on their smoking status.
The intervention group received as for the control group plus were asked to designate
a social supporter (preferably a female non-smoker), and were advised both she and
her supporter would receive an incentive: participants were given $50 voucher for each
month biochemically confirmed as quit. Supporter received $50 voucher in first month
and at 2 months postpartum, and $25 voucher for other months. The intervention was
delivered by trained program staff or research staff. Theoretical basis: rewards and social
support. Intensity rating: I = 4, C = 3.
Outcomes Smoking cessation biochemically validated with salivary cotinine at 34 weeks’ gestation
and 2 months postpartum.
Notes Data in outcome tables is inconsistent.
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Donatelle 2000 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided.
Allocation concealment? Unclear No information provided.
Blinding?
Women and clinical staff
No Neither providers nor women were blinded
for this educational intervention with in-
centives.
Incomplete outcome data addressed?
All outcomes
Unclear High attrition rates I = 32%; C = 51.5%,
but drop-outs included as smokers in this
analysis.Those lost to follow up were con-
sidered to be smokers.
Free of selective reporting? Yes Main outcomes reported.
Free of detection bias? Yes Reported quitting validated by salivary co-
tinine analysis.
Donovan 1977
Methods Randomised trial of advice to stop smoking in pregnancy, provided by a (public health)
doctor, reinforced by the woman’s own GP and other providers involved in shared ante-
natal care, in 3 UK maternity units.
Participants Pregnant women < 35; currently smoking >= 5 cigarettes/day and had been smoking >=
1/day at the onset of pregnancy; < 30 weeks’ gestation at first visit; no prior perinatal
death; not seeking, nor sought termination. Other exclusions: not pregnant; refused
consent; miscarriage or termination of pregnancy; moved to another care provider; twin
pregnancy or birth before 28 weeks. 552 women enrolled in the study.
Interventions Control group received ANC usually provided by the hospital, including any anti-smok-
ing advice which may have been given routinely. Intervention: individualised medical
advice by clinic doctor,
(i) tell the woman the facts about smoking in pregnancy;
(ii) encourage questions about these facts;
(iii) once the woman has agreed to try, discuss how she may best give up;
(iv) follow up the advice at all later contacts. Medical records labelled asking other staff
to reinforce advice.
Theoretical basis - not clear/ stages of change. Intensity rating: I = 3 (advice reinforced
at each clinic visit), C = 2.
Outcomes Self-reported smoking in cigarettes/day at four stages of pregnancy; mean birthweight;
low birthweight; preterm birth (< 36 weeks); perinatal deaths. No data on smoking
cessation.
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Donovan 1977 (Continued)
No biochemical validation of smoking status.
Notes Details of the intervention are in Donovan 1975.
Good discussion of common problems identified when advising women to stop and on
the contextual factors which encourage the continuation of smoking.
Process evaluation of the reinforcement of advice showed little difference between the
groups in recall of advice being given.
Major inconsistency in smoking reports pre and post-birth is a problem in this trial.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Table of random numbers.
Allocation concealment? Unclear Information not provided.
Blinding?
Women and clinical staff
No Notes labelled. Caregivers asked to rein-
force information. Educational interven-
tion.
Incomplete outcome data addressed?
All outcomes
Yes No loss to follow up apparent.
Free of selective reporting? Unclear Smoking cessation rates not reported.
Free of detection bias? No No biochemical validation of reported
smoking behaviour.
Dornelas 2006
Methods Randomised controlled trial conducted inHartford,Connecticut,USA, between January
2001 and December 2002.
Participants Inclusion criteria: pregnant women, over 18 years old, less than 30 weeks’ gestation,
current smokers (recent quitters included in associated relapse prevention paper), no
recent history of abuse or dependence on alcohol or other non-nicotine substance, no
major psychiatric illness, access to a telephone.
105 women enrolled in study (I = 53, C = 52).
Interventions Intervention: one 90 minute psychotherapy session at the clinic, followed by bi-monthly
prenatal telephone calls from the therapist during pregnancy, and monthly calls after
delivery. Therapists were masters-prepared mental health counselors trained in smoking
cessation. The theoretical basis of the intervention was CBT.
Control: all participants also receivedUCaccording to standard smoking cessation guide-
lines, including provision of a booklet, a chart prompt to remind providers to provide
quit messages at each visit, and audit to ensure the advice was documented.
Intensity rating: I = 4, C = 3.
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Dornelas 2006 (Continued)
Outcomes Abstinence for smokers at end of pregnancy, aggregated by week of gestation to enter
study. An associated study reports abstinence rates for recent quitters (relapse prevention)
.
Abstinence at 6 months postpartum.
Cost-effectiveness of “cost per quitter”.
Notes Process evaluation showed 17/53 did not receive the phone calls as planned.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No description of methods of randomisa-
tion.
Allocation concealment? Unclear No description.
Blinding?
Women and clinical staff
No Educational intervention so blinding not
feasible.
Incomplete outcome data addressed?
All outcomes
Unclear Attrition rate = 0% at 36 weeks’ gestation
and 18% at 6 months postpartum.
Free of selective reporting? Yes All outcomes reported.
Free of detection bias? Yes Biochemical validation with expired car-
bon monoxide readings (less than 4 ppm).
Dunkley 1997
Methods Trial of midwifery counselling around the ”stages of change“ model”, in a large UK
maternity service.
Participants 100 women; pregnant and booked for maternity care; < 18 weeks’ gestation; currently
smoking 1 or more cigarettes/day. 13 midwives selected for the intervention group and
13 for the control group.
Interventions Intervention midwives were trained to assess the stages of change and provide a be-
havioural intervention, using the Health Education Authority material “Helping preg-
nant smokers quit: training for health professionals”, 1994. Few details of intervention
provided. Intensity rating: I = 2 . C = not clear (0).
Outcomes Smoking cessation; cigarettes/day; “stage of change” at 11 to 18 weeks vs 37 weeks. No
biochemical validation of smoking status. Care providers’ views discussed.
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Dunkley 1997 (Continued)
Notes 3700 births/year at the hospital, all women who smoked were eligible to take part so it
is not clear why only 100 took part (described as “all 100”).
No process evaluation reported.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not stated.
Allocation concealment? Unclear Described as ’randomly allocated’.
Blinding?
Women and clinical staff
No Different midwives caring for women in
the experimental and control groups.
Incomplete outcome data addressed?
All outcomes
Unclear 94 of 100 women recruited followed up.
No ITT analysis.
Free of selective reporting? Unclear All outcomes reported.
Free of detection bias? No No biochemical validation of reported
smoking status.
Ershoff 1989
Methods Prospective randomised controlled trial in 5 health centres of the same HMO in Los
Angeles, 1985 -87.
Participants English-speaking women < 18 weeks’ gestation; still smoking >= 7 cigarettes a week
(n = 323, 165 + 158, with losses due to termination (7 + 11); miscarriage (12 + 13);
disenrolment or transfer to another HMO (20 + 18); leaving 126 + 116.
Interventions Control group: 2 page pamphlet on hazards of smoking and on the need to quit; 2
minutes discussion with a health educator (within a 45 minutes individual conference)
; advised of free 5 session smoking cessation program available through the HMO.
Coverage in antenatal classes remained unchanged.
Intervention group: as for the control group + first of series of 8 self-help booklets
aimed to increase motivation for quitting; teach behavioural strategies for cessation and
relapse prevention; 3 minutes introduction to these by health educator; asked to make
a commitment to read the first one and list reasons for not smoking; others mailed
weekly. Booklets were pregnancy-specific, multi-ethnic, and at a 9th Grade reading level.
Theoretical basis - aimed to increase motivation and teach behavioural change strategies.
Intensity rating: I = 3, C = 2.
Outcomes Smoking cessation validated with urine cotinine; birthweight; low birthweight; preterm
birth (< 37 weeks); stillbirths.
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Ershoff 1989 (Continued)
Notes Process evaluation showed good implementation.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information
Allocation concealment? No The authors state that women had been
randomised in advance of their visit. It was
not clear how women were recruited to the
study or gave consent for participation.The
health educator turned over a ’preassigned
card’ to randomise women.
Blinding?
Women and clinical staff
No The authors state that the health educator
delivering the intervention was not aware
of group allocation, but materials were pro-
vided to the experimental group at the
clinic visit.
Incomplete outcome data addressed?
All outcomes
Unclear Attrition I = 39/165, C = 44/158 not in-
cluded in analysis (due tomiscarriage, abor-
tion or dis-enrolment from the HMO).
Free of selective reporting? Unclear None apparent.
Free of detection bias? Yes Biochemical validation by urinary cotinine
levels.
Ershoff 1995
Methods Ershoff 1989 trial data of relapse prevention in the women who had spontaneously quit
smoking in early pregnancy.
Participants The pre-pregnancy smokers who had quit spontaneously before the first antenatal con-
tact: 110 + 108, with losses due to termination (5); miscarriage (17) and transfer to
alternative prenatal care (25) leaving 87 + 84.
Interventions See Ershoff 1989 except that the intervention group received the first 4 booklets at
the first interview with booklets 5 to 8 mailed weekly thereafter; control group were
congratulated on quitting and given a tip sheet on “staying quit”. Intensity rating: I = 3,
C = 2.
Outcomes Smoking data validated with urinary cotinine measurement, no perinatal data.
Notes Detailed process evaluation and analysis of factors promoting or inhibiting cessation and
maintenance of non-smoking.
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Ershoff 1995 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No No information.
Allocation concealment? No See Ershoff 1989 above.
Blinding?
Women and clinical staff
No Neither caregiver nor womenwere blinded.
Incomplete outcome data addressed?
All outcomes
No 22% attrition. No ITT analysis.
Free of selective reporting? Unclear None apparent.
Free of detection bias? Yes Biochemical validation by urinary cotinine
levels.
Ershoff 1999
Methods Trial of 3 alternative methods of smoking cessation interventions, in a large group model
managed care organisation in Los Angeles, California, USA.
Participants Smokers were identified at first visit as women who self-report “smoking now”, “smoke
but have cut down since pregnancy”, or “smoke from time to time”. Researchers at-
tempted to phone all women over 18 years and less than 26 weeks’ gestation (n = 931).
150 could not be contacted and 90 refused to be interviewed. 233 were excluded as they
did not speak English (n = 44), smoked less than 7 cigarettes per week pre-pregnancy (n
= 114) or experienced miscarriage (n = 34). 380/458 women (82%) agreed to partici-
pate. 60% white, approximately 50% college educated, with a mean age of 29.4. Mean
cigarette/day at first visit = 6.6.
Interventions 3 interventions, based on stages of change model.
Group 1: received a self-help booklet “living smoke-free”.
Group 2: (n = 120): received the same self-help booklet and had access to a computerised
interactive telephone support system, which provided customised messages from a voice
model.
Group 3: (n = 101): received the same self-help booklet and 4-6 x 10-15 minute tele-
phone counselling sessions by nurse educators trained in motivational interviewing. A
personalised postcard sent to reinforce verbal communication. Intensity rating: I = 4, C
= 1.
Outcomes Smoking cessation in the third trimester “not even a puff in the last 7 days”, biochemi-
cally validated with urine cotinine. Smoking reduction in cigarettes/day. Baseline mental
health index and Cohen’s perceived stress scale.
Number of quit attempts and movement in stages of change.
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Ershoff 1999 (Continued)
Notes Data from group 1 and group 3 only compared in outcome tables. Good process evalu-
ation of each of the methods.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as “random assignment”
Allocation concealment? Unclear No information.
Blinding?
Women and clinical staff
Unclear Authors state that care providers were blind
to group allocation. Educational interven-
tion so blinding women not feasible.
Incomplete outcome data addressed?
All outcomes
Unclear 15% attrition but data available for some
outcomes from those lost to follow up. Lost
to follow up not included as continuing
smokers in analysis as attrition from each
study group not reported separately.
Free of selective reporting? Unclear Results were difficult to interpret.
Free of detection bias? Yes Biochemical validation by urinary cotinine
levels.
Gielen 1997
Methods Randomised trial of a smoking cessation and relapse prevention intervention in an urban,
prenatal clinic in Baltimore, USA. Nov 1996-June 1997.
Participants Pregnant women currently smoking (even 1 puff in the past 7 days); < 28weeks’ gestation;
African-American or white; 85% of whom were on medical assistance, attending the
Outpatient Department at John Hopkins. No other exclusions specified. 2319 women
assessed, 32%currently smoking by above definition, -1585 non-smokers, -72 (gestation,
ethnicity, not interviewed at their first visit or changing to another care provider) leaving
662 eligible of whom 510 agreed to take part. 25 quit prior to first visit, 18 did not wish
to quit, leaving 467 (232 + 235) reduced by withdrawals, miscarriage, termination and
change of care provider to (193 + 193). Mean cigarettes/day at intake I = 9.7, C = 7.5
(P = 0.01).
Interventions Control: a brief discussion with a nurse/health counsellor about the risks of smoking; a
recommendation to quit and pamphlets from the area’s voluntary agencies.
Intervention: peer health counsellors recruited from local communities, received 2 ses-
sions training from PIs who explained content, rationale and how it was to be provided,
then observed in practice by PIs with feedback to her.
(i) A Pregnant Woman’s Guide to Quit Smoking (RA Windsor), 6th Grade level.
(ii) 15 minutes 1:1 counselling session with peer health counsellor on how to use the
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Guide, showing how it is organised to be used daily, and discussing women’s thoughts
and concerns about quitting, targeting cessation or relapse prevention, as appropriate.
(iii) Educational materials for cessation support persons included with the Guide.
(iv) Reinforcement at each clinic visit from doctors and nurses, written prescription to
stop smoking provided directly from doctor to woman; 2 letters of encouragement (from
the doctor and the counsellor)mailed to the woman 1-2 weeks after her first visit.
Theoretical basis: social learning theory. Intensity rating: I = 4, C = 2.
Outcomes Smoking cessation in third trimester, validated by salivary cotinine. Proportion cotinine
reduction > 50%.
Notes Guide developed through needs assessment with pregnant women, constructs from the
PRECEDE/PROCEED diagnosis and social learning theory, tested with focus groups,
additional section on relapse prevention, and on passive smoking postpartum.
Process evaluation showing good implementation.
Discussion by authors of the extremely disadvantaged population in inner city, with
major neighbourhood level factors of unemployment, poverty, drug use, violence and
crime. Results show high rate of misclassification by self-report (I = 37%, C = 48%)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided.
Allocation concealment? Unclear Described as “randomly assigned”.
Blinding?
Women and clinical staff
No Educational intervention.
Incomplete outcome data addressed?
All outcomes
No Almost 50% attrition for some outcomes.
Attrition: I = 35.2%, C = 35.3%.
Those remaining available to follow up
but failing to provide saliva samples were
treated as continuing smokers but those
lost for other reasons were not included in
the analysis (number excluded not reported
separately to be able to include).
Free of selective reporting? Unclear None apparent.
Free of detection bias? Yes Biochemical validation by salivary coti-
nine.
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Haddow 1991
Methods Randomised trial in physicians offices and clinic sites within Maine, USA, 1984-7,
of providing feedback on cotinine measured in maternal serum screening programme
(for the identification of open neural tube defects) as part of an smoking cessation
intervention.
Participants Pregnant women with a singleton live pregnancy; having maternal serum AFP screening
at 15-20 weeks’ gestation; who smoked >= 10 cigarettes a day. 25,628 screened, 97%
answered question on smoking, about 3,000 met smoking criteria (17%). 1423 inter-
vention and 1425 control with 41 + 39 lost to follow up.
Interventions Control: standard medical care not otherwise specified.
Intervention: report on cotinine generated for her physician with interpretation relating
smoking level to birthweight. Physician explained this to the woman and also gave her a
copy of the report and a pregnancy-specific booklet about how to quit, using the cotinine
information also + repeat measure 1month later, 2 copies to physician, comparison of 1st
and 2nd cotinine, report commenting on the change and its interpretation. Theoretical
basis: feedback. Intensity rating: I = 3, C = 1.
Outcomes No smoking cessation data. Smoking data limited to comparability at first assessment
and serum cotinine levels; mean birthweight; low and very low birthweight; preterm
birth (< 37 weeks); fetal deaths; neonatal deaths; postneonatal deaths. 695/1343 women
provided repeat serum cotinine for comparison.
Notes Physician consent only sought.
Process evaluation showed less than good implementation with differential impact on
perinatal outcome by completeness with second blood samples taken for cotinine mea-
surement.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated random numbers.
Allocation concealment? Unclear Information not provided.
Blinding?
Women and clinical staff
No Caregivers aware of group allocation. Ex-
perimental group given feedback on serum
cotinine levels.
Incomplete outcome data addressed?
All outcomes
No Small loss to follow up for some outcomes
but 48% of the intervention group did not
provide follow-up samples for serum coti-
nine analysis. No ITT analysis.
Free of selective reporting? Unclear Results difficult to interpret. Smoking ces-
sation not recorded.
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Free of detection bias? Unclear Serum cotinine measurement at baseline
for both the experimental and comparison
groups but it was not clear that any follow
up measurements were made for the com-
parison group.
Hajek 2001
Methods Cluster-randomised trial of a brief midwife-delivered smoking cessation intervention
in 9 hospital and community trusts in the UK. 290 midwives randomised to provide
intervention or control care.
Participants Women recruited at first visit (approximately 12 weeks’ gestation)and considered eligible
if they reported current smoking or having stopped within the last 3 months (n = 1287).
189 current smokers not motivated to stop therefore, received no intervention.
Interventions Control group midwives received 1 hour of training to discuss the study and were asked
to provide UC and any usual pamphlets. Intervention midwives received 2 hours training
which included using the COmonitor and providing ’stage of change’ based advice, CO
assessments. Intervention group also received written advice and motivational materials
for current and recent smokers, including designating a ’quit date’, a ’quiz’ and the offer
of ’buddying’ to another pregnant smoker for support. Intensity rating: I = 4, C = 2.
Outcomes Smoking cessation biochemically validated with exhaledCO in the early postnatal period
and at 6 months postpartum.
Birthweight for smokers and ex-smokers recorded.
Participants and midwives views of interventions reviewed.
Notes Good process evaluation showed poor implementation in some areas, with only 61% of
midwives actually recruiting anywomen for the study. Financial incentives paid to service
to improve recruitment. Discussion of barriers includes 65% of midwives reporting
the intervention could not be undertaken in the time they had available. Sample size
justification.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No Consecutive names on a list of midwives.
Allocation concealment? No Midwives randomised.
Blinding?
Women and clinical staff
No Midwives aware of allocation group. Edu-
cational intervention. Blinding women not
feasible.
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Incomplete outcome data addressed?
All outcomes
Unclear Approximately 9% of women were lost to
follow up. Non-respondents were treated
as smokers in the analysis but those lost to
follow up for other reasons were excluded
from the analysis.
Free of selective reporting? Unclear Clustering effect not reported, so sensitiv-
ity analysis conducted using four ICCs and
outcome figures adjusted using conserva-
tive intracluster correlation of 0.1.
Free of detection bias? Yes Biochemical validation by expired CO.
Hartmann 1996
Methods Trial of medical smoking cessation counselling and peer support, in a teaching hospital
(academic) clinic in North Carolina, USA. 1991-1993.
Participants All women receiving prenatal care at the University of North Carolina residents clinic
were surveyed: 842/846 completed survey; 793/846 provided a carbon monoxide breath
sample; 2 were excluded as > 36 weeks’ gestation; 1 for psychiatric diagnosis; leaving 266
eligible smokers (smoked at least once in the prior week) of whom 12 refused, 4 were
missed, 2 were not pregnant and 1 was a private patient; 247 recruited, losses were 40 (-4
miscarriage first trimester, -3 miscarriage second trimester, - 3 terminations, -15 moved
to alternative care, -12 lost to follow up) leaving 107 intervention and 100 control.
Interventions All 1-4 year residents given didactic and role play training for smoking cessation coun-
selling, including self-assessment of current techniques and skills, which they were asked
to continue with for the control group.
Control group: standard care; residents reminded not to alter amount or time of this; help
was provided if woman sought it and prenatal classes included discussion of substance
abuse including cigarettes.
Intervention: (i) residents provided counselling at each visit, and a brief script aimed at
setting a quit date or negotiated an alternative assignment such as a smoking diary at
every contact;
(ii) given Windsor’s self-directed 7 day smoking cessation guide;
(iii) quit date patients given written prescription to quit, letter of support from doctor,
contacted by volunteer smoking cessation counsellor to review the quit plan and encour-
age follow-through
charts flagged, prompts with flow sheet, most recent CO and self-report included for
care provider;
(iv) successful quitters sent an encouraging postcard each week.
Theoretical basis: feedback and reinforcement. Intensity rating: I = 4, C = 2 (not clear).
Outcomes Smoking cessation biochemically validated by exhaled CO at each visit. Proportion >
50% reduction in CO.
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Notes Concerns about residents having to treat similar/consecutive patients differently, and
self-help manuals accidentally given to some controls.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated random numbers.
Allocation concealment? No State that neither the enrolling nurse nor
the patient were aware of allocation, but
experimental group notes were flagged.
Blinding?
Women and clinical staff
No Case notes flagged. States patient not aware
of randomisation status.
Incomplete outcome data addressed?
All outcomes
No Attrition 16%. Drop-outs not reported by
intervention group so not able to be in-
cluded in analysis.
Free of selective reporting? Unclear Not apparent.
Free of detection bias? Yes Expired CO measured at each visit for the
experimental group and at 3 visits for the
comparison group.
Hegaard 2003
Methods Trial of multimodel intervention to promote smoking cessation in pregnancy in a large
midwifery centre in the Netherlands, 1996-1998.
Participants Pregnant women attending first antenatal visit (approximately 16 weeks’ gestation)who
identified as “daily smokers” were invited (n = 905). Exclusion criteria: inability to speak
Danish; age > 18 years; gestation > 22 weeks; verified psychiatric disease, and alcohol or
drug abuse. Participation rate 77% (n = 696). I = 348, C = 347. 87 in the intervention
group accepted intensive smoking program (81 group and 6 individual). 75 opted to
use NRT. Withdrawals = 48 (miscarriage, moving and premature birth) excluded from
the smoking cessation outcomes. Mean cigarettes/day = 11 in both groups. Significant
difference in partner smoking I = 67%, C = 77% (P = 0.03).
Interventions Control group received standard smoking cessation counselling from theirmidwife about
risk of smoking and general advice on cessation or reduction, within the standard 30
minute booking consultation.
The intervention group all received an extended first antenatal visit of 40minutes, which
included a dialogue, and written information on hazards of smoking in pregnancy and
for newborns. This information was reinforced in the following 5-6 antenatal visits,
within the normal 20 minute visit.
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Women were invited to join the intensive smoking program, based on cognitive be-
haviour modification program, with 9 group (90 minutes) or individual sessions (15-30
minutes), conducted over 14 weeks, by specifically trained midwives. Exhaled CO levels
taken at each visit, the first 3 weekly sessions prepared women for quitting, with the final
6 sessions designed to assist women to maintain cessation and provide an NRT regime
tailored to Fagerstrom nicotine dependence assessments.
Intensity rating: I = 4, C= 1.
Outcomes Self-reported smoking cessation at 37 weeks’ gestation.
Meanbirthweight; lowbirthweight (< 2500g); pretermbirths (< 37weeks). A subsequent
paper measures smoking cessation at 1 month and 1 year postpartum.
Notes Sample size justification. Process evaluation shows 86% of intervention group used
patches.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No Quasi-randomised, allocation of even/un-
even birth dates to designated clinic days.
Allocation concealment? No Possible for those recruiting to anticipate al-
location. Educational intervention by usual
caregiver.
Blinding?
Women and clinical staff
No Educational intervention by usual care-
giver, so not blinded.
Incomplete outcome data addressed?
All outcomes
Unclear Uneven randomisation. Approximately
10% lost to follow up and missing data 16-
19%at later data collection points.Women
lost to follow up were excluded from the
analysis but those remaining in part of the
studywithmissingdatawere treated as con-
tinuing smokers.
Free of selective reporting? Unclear Birthweight and low birthweight data pro-
vided. No other adverse outcomes re-
ported.
Free of detection bias? Yes Salivary cotinine measured to verify re-
ported abstinence.
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Heil 2008
Methods Randomised controlled trial in Greater Burlington, Vermont, USA. 2001-2003.
Participants Participants were recruited from 1 of 4 large obstetric practices. Inclusion criteria: self-
reported smoking (even a puff in the last 7 days), gestational age less than 20 weeks, living
within study clinic county and not planning tomove until at least 6months postpartum,
English speaking, not incarcerated and not previously participating in the study or living
with anyone who has previously participated in the study.
182 women were eligible for the study, and 82 (45%) agreed to participate. 5 women
withdrew from the study due to fetal demise or termination of pregnancy and were not
included in the final analysis (I = 3, C = 2).
There was no significant difference in baseline characteristics of the groups, including
pre-pregnancy cigarettes per day (I =18.7, C =18.4), health insurance (I =19, C =13),
and timing of recruitment (I = 8.9, C = 9.5).
Interventions Intervention (contingent voucher): participants chose a quit date, and reported daily to
the clinic for COmonitoring for 5 days, then urine cotinine monitoring twice weekly for
7 weeks, weekly for 4 weeks, and then every 2 weeks for the remainder of the pregnancy.
Vouchers were given dependent on biochemical validation, beginning at US$6.25 and
escalated by US$1.25 to a maximum of US$45.00. Positive test results reset voucher
back to original value, but two consecutive negative tests restored value to pre-reset value.
Control (non-contingent voucher): Participants received voucher independent of smok-
ing status. US$15.00 per antenatal visit and US$20.00 per postpartum visit, to result in
a comparable average earnings to the contingent group.
Both groups received routine advice from the clinic.
It is unclear who delivered the intervention.
The theoretical basis on the intervention is rewards and feedback.
The intensity rating: I = 4, C = 4.
Outcomes Smoking cessation at 28 weeks’ gestation, 12 weeks and 24 weeks’ postpartum.
Reduction in mean cotinine.
Mean birthweight, gestational age, fetal growth measures (US), and proportion of NICU
admissions and low birthweight babies.
Notes Sample size justification. Process evaluation not reported.
Some discussion of cost implications.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as “randomisation stratified to
clinics”. Details of randomisation not de-
scribed.
Allocation concealment? Unclear No information.
Blinding?
Women and clinical staff
No Participants and providers not blinded as
receiving incentives for participation.
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Incomplete outcome data addressed?
All outcomes
Yes Small loss to follow up due to pregnancy
termination or fetal death. Available case
analysis.
Free of selective reporting? Yes Detailed birth outcomes reported.
Free of detection bias? Yes Exhaled CO for 5 days (< 6 ppm) and then
urine cotinine (< 80 ng/ml).
Higgins 2004
Methods Pilot study in Greater Burlington, Vermont, USA during 2001-2003.
Participants Inclusion criteria: currently smoking (even a puff in the last 7 days), living within city
limits of clinic, planning to remain for 6 months postpartum, English-speaking, not
incarcerated and not having previously participated in the study or living with anyone
who has participated in the study.
100 women were eligible to participate, 58 consented (58% participation rate), with 5
excluded from analysis due to fetal demise or termination of pregnancy.
There was no significant difference between the intervention and control groups in
baseline characteristics, including number of pre-pregnancy cigarettes per day (I = 23.3,
C = 22.7); health insurance (I = 10, C = 13). The attendance rate was similar between
groups (I = 63.7%, C = 63.3%)
Interventions Intervention (contingent voucher): participants chose a quit date, and reported daily to
the clinic for COmonitoring for 5 days, then urine cotinine monitoring twice weekly for
7 weeks, weekly for 4 weeks, and then every 2 weeks for the remainder of the pregnancy.
Vouchers were given dependent on biochemical validation, beginning at US$6.25 and
escalated by US$1.25 to a maximum of US$45.00. Positive test results reset voucher
back to original value, but 2 consecutive negative tests restored value to pre-reset value.
Control (non-contingent voucher): participants received voucher independent of smok-
ing status. US$11.50 per antenatal visit and US$20.00 per postpartum visit, to result in
a comparable average earnings to the contingent group.
Both groups received routine advice from the clinic.
It is unclear who delivered the intervention.
The theoretical basis of the intervention is rewards and feedback.
The intensity rating: I = 4, C = 4.
Outcomes Smoking cessation at 36 weeks of pregnancy, 12 weeks’ postpartum and 24 weeks’ post-
partum.
Notes There is no sample size justification for this pilot study and no process evaluation re-
ported. There is some discussion of cost implications.
Risk of bias
Item Authors’ judgement Description
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Adequate sequence generation? No 37/53 were consecutively assigned (quasi-
randomised)as part of pilot study, and
16/53 were randomised.
Allocation concealment? No Group allocation could be anticipated.
Blinding?
Women and clinical staff
No Unable to blind participants or providers
in this trial.
Incomplete outcome data addressed?
All outcomes
Yes Very low loss to follow up (10% at end of
pregnancy). Those lost to follow up were
counted as continuing smokers.
Free of selective reporting? Unclear Only smoking status reported.
Free of detection bias? Yes Biochemically validated with exhaled CO (
abstinence < 6 ppm) for 5 days, then urine
cotinine (abstinence < 80 ng/ml).
Hjalmarson 1991
Methods Quasi-randomised (allocation by birth date) trial of smoking cessation intervention based
onRAWindsor self-helpmanual in 13/14 public healthmaternity clinics inGothenburg,
Sweden 1987-1988.
Participants Women who spoke Swedish, smoking >= 1 cigarette/day, gestational age < 12 weeks at
first antenatal visit, (no other exclusion criteria specified), leaving n = 745 of whom 22
had quit by the second antenatal visit. 15% refused to take part (-75) leaving 417 in the
intervention and 231 in the control group.
Interventions All women were advised to quit by the midwife at the first antenatal clinic; pre-inter-
vention.
Control: basic information sheet given to women by the doctor with basic facts about
smoking and pregnancy and recommendation to quit.
Intervention: self-help manual based on Windsor 1985, revised and with new parts
added, distributed by the obstetrician at the second antenatal visit. Self-help tasks were
based on principles of behavioural therapy. Intensity rating: I = 3, C = 2.
Outcomes Smoking cessation data; biochemically validated (blood thiocyanate < 100 ng/ml) at
first and second antenatal visit and in late pregnancy, and 8 weeks’ postpartum; mean
birthweight; low birthweight; preterm birth (< 36 weeks).
Smoking reduction in mean cigarettes per day (the standard deviation for the mean was
not provided so in the analysis it was calculated from the confidence intervals given in
the paper).
Notes Same data published by Svanberg 1992.
No process evaluation.
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Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No By birthday. Uneven groups.
Allocation concealment? No Possible to predict allocation.
Blinding?
Women and clinical staff
No Neither provider nor women blinded to
this educational intervention.
Incomplete outcome data addressed?
All outcomes
No Attrition in both groups, approximately
15% in the experimental group at the out-
set and 11% later. No ITT analysis. Some
loss to follow up but where data were avail-
able all cases were included.
Free of selective reporting? Unclear Not apparent.
Free of detection bias? Yes Serum thiocyanate analysis at 30-34 weeks’
gestation and postpartum.
Hotham 2005
Methods Randomised controlled trial of use of nicotine patches in Adelaide, South Australia,
1999-2000.
Participants Inclusion criteria: self-reported smokers (greater than 15 cigarettes per day), between 12-
28 weeks’ gestation, and not planning shared antenatal care with a general practitioner.
1462 women were screened and 72 were eligible to participate in the study. 39 (54%)
agreed to participate in the study (I = 20, C = 19).
There was no apparent significant difference in baseline characteristics, including pre-
pregnancy cigarettes per day (I = 19.8, C = 19.6).
Interventions The intervention group received nicotine patches 15 mg for 16 hours, for 12 weeks, with
optional weaning to lower strengths.
Control: no placebo patches were available.
All participants received counselling at the initial and follow-up visits, with CO mea-
surements and salivary samples.
High attrition rate: I = 7/20 (35%), C = 7/19(37%).
Theoretical basis: Nicotine replacement therapy
Intervention intensity: I = 4, C = 3
Outcomes Smoking cessation and smoking reduction (> 50% cotinine levels).
Notes Detailed process evaluation in associated case study reports of participants’ views suggests
significant resistance of women to using NRT in pregnancy. Only 25% of women in the
treatment group (n = 5) complied with treatment protocol.
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Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated sequence.
Allocation concealment? Yes Described as “sealed envelope system”. Un-
clear whether envelopes opaque.
Blinding?
Women and clinical staff
No No placebo patches available.
Incomplete outcome data addressed?
All outcomes
No 14/40 withdrew from the study (35% attri-
tion). All withdrawals included in this anal-
ysis as continuing smokers.
Free of selective reporting? Unclear No birth outcomes reported.
Free of detection bias? Yes Exhaled CO and salivary samples
Kapur 2001
Methods Canadian double-blind, placebo controlled trial of nicotine replacement therapy
(patches) in pregnancy.
Participants Women recruited from the Motherisk Program at 12-24 weeks’ gestation, smoked > 15
cigarettes/day, and who reported they wanted to quit, but could not do so, in the first
trimester.
Interventions Intervention group received a 12 week NRT patch regimen: 18 hour 15 mg patch for 8
weeks; 10 mg patch for 2 weeks, and 5 mg patch for 2 weeks + counselling with a video
presentation at baseline, 1, 4 and 8 weeks.
Control group received as for intervention group,with a placebo patch.Weekly telephone
support was given from 1 investigator to encourage continuation with the program,
enquire about adverse effects and to co-ordinate clinic visits. All women were encouraged
to call the investigative team for advice, reassurance and support.
Intensity rating: I = 4, C = 3.
Outcomes Smoking cessation during second trimester, biochemically validated with serum and
salivary cotinine levels. No neonatal outcomes provided.
Notes Study ceased after only 30/40 women recruited due to severe fetal withdrawal symptoms
in the 30th recruit. The code concealment was broken to reveal the allocation of the
woman to placebo. The trial was discontinued due to concerns of providing placebo
patches.
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Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as “randomised”.
Allocation concealment? Yes Placebo controlled trial.
Blinding?
Women and clinical staff
Yes Placebo controlled trial. Described as dou-
ble-blind. Placebo provided butmost of the
women in the placebo group did not com-
plete the programme.
Incomplete outcome data addressed?
All outcomes
No Biochemical validation data was missing
for approximately a third of the sample.
Not clear if there was ITT analysis.
Free of selective reporting? Unclear No birth outcomes reported.
Free of detection bias? Yes Biochemical validation by serum thio-
cyanate and salivary cotinine, but missing
data for these outcomes.
Kendrick 1995
Methods Cluster-randomised trial of smoking cessation in public prenatal and WIC clinics in
Maryland, Colorado and Missouri, USA, 1987-89.
Participants 5262, 6087 and 4943 pregnant women screened in Colorado, Missouri and Maryland
respectively, with nearly 50% of women in each State smoking. Smoking defined as “even
a puff within the last 7 days before the women knew she was pregnant” (includes recent
quitters). Consent for data collection ranged from 66% to 79%. High proportions were
young, < 12 years education, White, unmarried and poor. Mean gestation at enrolment
= 15.2 - 16.6 weeks. Mean cigarettes/day at enrolment combined for smokers = 12
cigarettes/day.
Interventions Control: UC not otherwise specified by usual clinic staff.
Interventions based on stages of change, but differed by State, locally adapted with some
detailed development.
Colorado: 1-5 minutes counselling; assessing smoking status; quitting tips; supportive
statements by nurse-clinicians; healthcare providers’ Guide; 8 brochures for pregnant
smokers; additional one for women postpartum.
Maryland: brief clinic-based counselling program + self-help material focussing on the
stages of quitting.
Missouri: “becoming a life-long smoker” 6 minutes with clinic patient brochures, flip
charts; 1-2 minutes at WIC clinics training staff, chart documentation and forms.
All included effects of smoking on the fetus; benefits of quitting; quitting techniques;
developing social support; preventing relapse and limiting exposure to environmental
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tobacco smoke. All materials were at 6th Grade reading level. Intensity rating: I = 3, C
= 1 (not clear and varied).
Outcomes Smoking cessation biochemically validated with urine cotinine. The necessary adjust-
ment for clustering means that the data cannot be put into the standard table of com-
parisons. Adjusted data showed no differences in verified quitting, mean birthweight or
low birthweight.
Notes Intracluster correlation of 0.003 reported and used for adjusting outcome figures in
analysis. Substantial misclassification of self-report as non-smoking: 28% at enrolment;
35% at 8th month; 49% of self-reported quitters at intervention clinics; 32% of self-
reported quitters at control clinics. Process evaluation suggested less difference between
I and C clinics than might have been expected.
Project staff felt that the use of existing staff to deliver the new interventions and to
collect data affected the study negatively especially given the time needed to process
questionnaires and urine samples. This led to less than full implementation and variable
motivation to promote smoking cessation counselling among staff.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Clinics stratified by size of clinic and also
by prior low birthweight programme (Col-
orado) or % minority clients (Maryland),
and randomly assigned to deliver either in-
tervention or continue with standard care.
No details of randomisation provided.
Allocation concealment? Unclear Cluster-randomised trial.
Blinding?
Women and clinical staff
Unclear Unclear whether participants and providers
were aware of clinic allocation.
Incomplete outcome data addressed?
All outcomes
Unclear Records used to collect some outcome data
for respondents lost to follow up. Loss to
follow up balanced in experimental and
control groups. Varying enrolment and at-
trition rates in different centres. No ITT
analysis.
Free of selective reporting? Unclear High rates of non-disclosure for smoking
outcomes.
Free of detection bias? Yes Biochemical validationby urinary cotinine.
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Lawrence 2003
Methods Cluster-randomised trial of 2 different interventions, in community midwife clinics in
the West Midlands region of the UK.
Participants Inclusion criteria were all women seen in routine antenatal appointments who were
aged 16 years or over, a current smoker at booking. Women not fluent in English were
excluded. Initial target of 1440 participants was reduced to 900 due to slow recruitment
(particularly in standard care arm). Eligible smokers approached A = 34%, B = 47%,
C = 75%. Refusal rate A = 13.4%, B = 7.2%, C = 22.5%. Mean cigarettes per day at
baseline were similar between groups.
207 women (22.5%) withdrew from the study, 77 due to early end of pregnancy, 38
changed practice, 32 declined further participation and 60 left for other reasons, with
similar rates of withdrawal between groups, except for failure to complete the question-
naire and provide a urine sample, with highest compliance in Group C.
Interventions Control group (A) received standard care. Midwives received a half day training on
research protocol, and asked all midwives to give women theHealth Education Authority
booklet “Thinking about stopping”.GroupBmidwives received 2 and ahalf days training
on theory of transtheoretical model. Participants received a set of 6 stage based self-
help manuals “Pro-Change programme for a healthy pregnancy”. The midwife assessed
each participant’s stage of change and pointed the woman to the appropriate manual.
No more than 15 minutes was spent on the intervention. Group C midwives received
the same training as for Group B, and participants received the same self-help manual
and intervention as group B. Additionally the participants used a computer programme,
which consisted of questions and auto feedback of what stage they were in and what
this meant, and a range of other concepts. It took about 20 minutes for the woman to
complete. Printed information of the feedback was sent to the participant within a week
of the intervention.
Intensity rating: I = 4, C = 2.
Outcomes Biochemically validated smoking cessation at 28-30 weeks’ gestation and 10 days post-
birth. Point prevalence and sustained abstinence of 10 weeks or more were calculated.
Arms B+C combined for intervention figures in this analysis.
Effect of midwife training (attitudes, expectations, confidence, concerns and routine
practice) was assessed by pre-post training questionnaires.
Subsequent papers measure and describe smoking cessation at 18 months postpartum,
movement in stage of change, partner quitting, social support mobilization, and the
stress of receiving the intervention.
Notes Intracluster correlation of 0.003 reported and used for adjusting outcome data included
in this meta-analysis. Sample size calculation given, but unable to recruit sufficient
numbers. 17practices added to armA, 12 to armBand0 to armC to increase recruitment.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes A computerised minimisation programme
was used to stratify 72 eligible practices into
3 equal groups from101 available practices.
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Lawrence 2003 (Continued)
Allocation concealment? No Further practices were added to the sample
because of slow recruitment - these were
not randomly allocated.
Blinding?
Women and clinical staff
No Neither providers nor women blinded to
this educational intervention.
Incomplete outcome data addressed?
All outcomes
No Different rates of recruitment and follow
up in different arms of the trial. 22% with-
drew and data on smoking status were only
available for 67% of women.
Where there was no urine sample available
women were treated as continuing smok-
ers. There was a sensitivity analysis carried
out for those lost to follow up, and these
figures were used in this analysis.
Free of selective reporting? Unclear Not apparent.
Free of detection bias? Yes Urinary cotinine analysis.
Lilley 1986
Methods A randomised trial in Newcastle Hospital antenatal clinic (UK) and with other shared
antenatal care providers of individual counselling to promote smoking cessation over 3
months in 1982.
Participants All pregnant women currently smoking >= 1 cigarette a day at the time of the first
antenatal clinic, and < 28 weeks” gestation. 156 contacted, -5 > 28 weeks leaving 151,
5 exclusions (not pregnant, guilt over previous stillbirth, and 3 miscarriages), leaving 72
(I) + 73 (C).
Interventions Control: usual antenatal care with possible exposure to a concurrent television series (6
x 10 minute programme on stopping smoking in pregnancy).
Intervention: (i) 10 minutes anti-smoking advice from SHO (Resident) based onHealth
Education Council Booklet “So you want to stop smoking.. for you and your baby”,
an additional leaflet from the same source, and copies of the booklet for other family
members;
(ii) woman’s GP sent a letter describing the purpose of the study and a booklet, asked to
reinforce the information at usual contacts;
(iii) 2 weeks later a letter of reinforcement was sent to the woman;
(iv) 4 weeks later there was a preplanned home visit to provide anti-smoking advice with
a letter of the same advice sent if the woman was not at home;
(v) possible exposure to the concurrent TV series.
Intensity rating: I = 4, C=- 2 (not clear).
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Lilley 1986 (Continued)
Outcomes Smoking status and smoking/day assessed 6 weeks later. Reduction in mean cigarettes/
day (the standard deviation used in the analysis in this review was calculated from a P
value of 0.05 given in the paper).
Notes Short interval between intervention and assessment.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as balanced “simple random al-
location” in blocks.
Allocation concealment? Unclear Information not provided.
Blinding?
Women and clinical staff
No Neither women nor providers blinded to
this educational intervention.
Incomplete outcome data addressed?
All outcomes
Unclear Small loss to follow up, some missing data
but balanced across groups. No ITT anal-
ysis.
Free of selective reporting? Yes None apparent.
Free of detection bias? No No biochemical validation of reported
smoking behaviour.
Loeb 1983
Methods Trial of anti-smoking interventions (individual and group) based on the MRFIT trial,
carried out in Oregon (USA) where 95% of pregnant women attending one of the two
hospitals were enrolled in the Kaiser Permanente HMO, 1979-1980.
Participants Pregnant women contacted at first antenatal visit: 3856 asked about smoking; 963 self-
reported current smokers (25%). 21% of them in receipt of public assistance but only
7% of non-smokers. Poor participation in the study: 83.6% contacted; refusal rate 37%.
Interventions Control group - routine care.
Planned intervention: (i) letter of invitation with sae, reminder letter;
(ii) group information meeting on programme for respondents with short information
session by physician;
(iii) individual session with trained smoking counsellor;
(iv) 6 x 1.5 hour group sessions, once a week;
(v) subsequent support groups, individual sessions and phone calls.
Theoretical basis for intervention: behavioural techniques to encourage cessation.
Intensity rating: I = 4, C = not clear.
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Outcomes Smoking cessation by late pregnancy, biochemically validated with cord blood thio-
cyanate in a subsample, but no misclassification of self-reported non-smoking.
Notes Very poor response to group sessions so intervention changed over the course of the
trial to individual counselling, which also had very low participation overall: 18% active;
25.2% dropped out; 38% did not participate; 18% could not be contacted.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No details of randomisation.
Allocation concealment? Unclear Described as “randomly assigned”.
Blinding?
Women and clinical staff
No
Incomplete outcome data addressed?
All outcomes
No Attrition rates high at all stages of this
study. Approximately 45% lost to follow
up.Questionnaire response rate 25%. No
intention to treat analysis and high attri-
tion rates.
Free of selective reporting? Unclear Birth outcomes reported by smoking sta-
tus, not intervention group.
Free of detection bias? Unclear Biochemical validation at delivery on a
small sub-sample.
Lowe 1997
Methods A randomised trial of relapse prevention among women who had stopped smoking
since the beginning of pregnancy, in the public maternity clinics of a large hospital in
Birmingham, Alabama 1987-1989, USA.
Participants Pregnant women recruited at their first prenatal visit reporting as having quit since
conception, no exclusions mentioned, n = 115, 9 refused to participate leaving 106 of
whom 3 had a miscarriage, 4 moved and 2 had babies for adoption, leaving 54 (I) and
45 (C), Follow-up data were available on 80%.
Interventions Control: nurses’ advice to all women not to smoke.
Intervention: 10minute counselling by health educator using smoking relapse prevention
materials on effects of smoking; benefits of maintaining cessation; possible problems;
smoking triggers; solutions to smoking cues; strategies for staying quit, contract, and flip
chart (5th Grade reading material, “stay quit buddy” encouragement = non-smoking
gifts and pamphlets)clinic reinforcement by prenatal staff through reminder form in the
73Interventions for promoting smoking cessation during pregnancy (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lowe 1997 (Continued)
notes and staff training to confirm abstinence, praise, encourage continuing cessation.
Intensity rating: I = 4, C = 2.
Outcomes Continued smoking cessation in late pregnancy, biochemically validated with salivary
thiocyanate. Included in relapse prevention outcome tables only.
Notes Concurrent trial with Windsor 1993.
Process evaluation showed good implementation.
Issues of possible ’contamination’ in clinics with individual randomisation discussed.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as “randomly assigned”.
Allocation concealment? Unclear No information provided.
Blinding?
Women and clinical staff
No Notes flagged.
Incomplete outcome data addressed?
All outcomes
Unclear Approximately 20% attrition. Intention to
treat analysis for main outcome, those lost
to follow up treated as continuing smokers.
Free of selective reporting? Unclear Unclear what data were collected. Only
smoking outcomes reported.
Free of detection bias? Yes Salivary thiocyanate analysis.
Lowe 1998a
Methods Controlled clinical trial in antenatal clinic of a large metropolitan public hospital in
Brisbane (Queensland, Australia)to assess the effectiveness of a self-help booklet devel-
oped by Windsor (for women of low socioeconomic status - mostly black women - in
Alabama), in urban Australian women. This first trial (i) was followed by a second one
(ii) with a modified intervention, but no other change to the methods.
Participants All pregnant women attending for a first antenatal clinic, who identified themselves as
current smokers, had no current pregnancy complications and were not planning to have
the child adopted, were approached at their first antenatal clinic appointment (n = 244
- 27 who declined = 217). (ii) Participation rate of 91%, 108 women recruited, 8 had
a miscarriage or fetal death or discontinued care at the hospital; 2 withdrew from the
study and 19 were lost to follow up (LTFU) by 20 weeks. All those LTFU were counted
as continuing smokers.
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Lowe 1998a (Continued)
Interventions Control: given the self-help booklet and a midwife caution against smoking.
Intervention: as for control plus a 15 minutes 1:1 motivational counselling session pro-
vided by the midwife, focusing on the booklet (based on cognitive behaviour strategies)
, a flip chart which demonstrated the effects of smoking on the fetus, being shown how
to use the manual, two contracts developed (partner and non-smoking friend) and these
people contacted to sign. Aim was to increase self-efficacy and create a social support
structure for women during her attempts to quit and motivating her to use the booklet.
(ii) Booklet modified through focus groups with input from health promotion special-
ists, medical specialists and GPs, to a glossy format with coverage of additional topics
(growth and development of the fetus, enjoyment of certain foods and sex during preg-
nancy, emotional and physical aspects of pregnancy and stopping smoking. (C): only
the midwifery caution against smoking; (I): the midwife provided the booklet without
any additional discussion or counselling.
Intensity rating I = 4, C = 2.
Outcomes Smoking reduction and cessation assessed at the 20 week visit. Biochemical validation
of smoking status in self-reported non-smokers, same for (i) and (ii).
Notes Process evaluation showed poor response to the booklet.
Focus groups with women from I and C identified problems with the material and made
suggestions about changes.
Discussions with staff showed time pressures over counselling component.
Trial stopped and redesigned, see (ii). Second trial (ii) had a positive process evaluation
though staff identified a range of barriers to implementing smoking cessation counselling.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No Quasi randomised trial with alternate
weekly allocation.
Allocation concealment? No Not specified.
Blinding?
Women and clinical staff
No Educational intervention, so providers not
able to be blinded.
Incomplete outcome data addressed?
All outcomes
Unclear Loss to follow up 28%. All women lost to
follow up assumed to be continuing smok-
ers.
Free of selective reporting? Unclear Unclear what data collected.Only smoking
outcomes reported.
Free of detection bias? Yes Urinary cotinine analysis for those report-
ing quitting.
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Lowe 1998b
Methods See Lowe 1998a for setting as this trial followed immediately after the first one.
Participants See Lowe 1998a. The participation rate was 91% with 108 women recruited of whom 8
had a miscarriage, or a fetal death or discontinued care at the hospital. 2 more withdrew
and 19 were lost to follow up by 20 weeks. All those lost to follow up were counted as
continuing smokers.
Interventions Booklet modified from the one used in Lowe 1998a, through focus group discussions
with input from health promotion specialists, medical specialists and GPs to a glossy
format with coverage of other topics (growth and development of the fetus, enjoyment
of certain foods and sex during pregnancy, emotional and physical aspects of pregnancy
and stopping smoking).
Control group: only the midwifery caution against smoking.
Intervention: the midwife provided the booklet without any additional discussion or
counselling. Intensity rating: I = 3, C = 2.
Outcomes Smoking behaviour/reduction (self-report)and smoking cessation at 20 weeks, biochem-
ically validated.
Notes Process evaluation of materials was positive, though staff identified a range of barriers to
implementing smoking cessation counselling.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quasi-randomised trial with alternate
weeks allocated to control and interven-
tion.
Allocation concealment? Unclear Not specified.
Blinding?
Women and clinical staff
No Educational intervention, so providers not
blinders.
Incomplete outcome data addressed?
All outcomes
Yes Loss to follow up 28%. All women lost to
follow up assumed to be continuing smok-
ers.
Free of selective reporting? Unclear Unclear what data collected.Only smoking
outcomes reported.
Free of detection bias? Yes Urinary cotinine analysis for those report-
ing quitting.
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MacArthur 1987
Methods Quasi-randomised trial in a large English city maternity hospital to identify effects on
fetal size at birth mediated by an anti-smoking intervention, 1981-1982.
MacArthur 2001 reported follow up when the children were 9.
Participants Pregnant women smoking at booking: 29% had been pre-pregnancy smokers, 23% were
smoking at booking. 1008/1156 women identified as smokers interviewed, 48 lost (early
discharge, infection/isolation, changed surname); exclusions were multiple births (6 (I)
+ 8 (C); records not linked to hospital data 8 (I) + 4 (C)) leaving 493 (I) and 489 (C).
Mean cigarettes/day at booking I = 14.4, C = 13.7.
Interventions Intervention: advice to stop smoking+ information or discussion of the effects of smoking
on the fetus offered by the obstetrician at the first antenatal (booking) visit, supported
by giving her a leaflet to be shared with the partner, family and friends. If leaflet not
given by obstetrician, the midwife was asked to give it to the woman and advise her to
stop smoking.
Control: routine advice, not specified further.
Intensity rating: I = 2, C = 0 (not clear).
Outcomes Smoking cessation and reduction - biochemical validation commenced, but abandoned
when it became clear it did not distinguish levels of smoking. Birthweight, length and
head circumference;
Height, weight, IQ and neuromaturity at 9.4 years. Experimental results only discussed
in this review (data according to group allocation).
Report includes observational data (according to smoking behaviour)smoking status not
biochemically validated.
Notes Consent not sought from individual women, implementation of the trial across all clinics
routinely. Process evaluation shows poor implementation, with only 10% receiving “full
intervention”.
No details of the content of the leaflet.
Follow-up data not sufficient for tabulation.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No Based on date of booking visit.
Allocation concealment? No Alternation of 4 week blocks to interven-
tion or control. Group allocation could be
anticipated.
Blinding?
Women and clinical staff
No Caregivers not blinded to this educational
intervention.
Incomplete outcome data addressed?
All outcomes
Yes No loss to follow up apparent.
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Free of selective reporting? Yes Detailed smoking and birth outcomes re-
ported up to 9 years post intervention.
Free of detection bias? No No biochemical validation of reported
smoking behaviour.
Malchodi 2003
Methods Trial of effects of peer counselling on smoking cessation and reduction in a large urban
clinic in Hartford Hospital, USA, Jan 1998-Feb 2000.
Participants Low-income, uninsured women, who smoke at least 1 cigarette per day before pregnancy,
less than 20 weeks’ gestation, literate in English or Spanish, and intending to carry to
term. High smoking prevalence in pregnancy (29%). Recruited n = 142 (I = 67, C =
75). Mean cigarettes/day at baseline significantly higher in intervention group. I = 13.3,
C = 11.2.
Interventions The control group received routine care, which included the program of “Ask, Advise,
Arrange and Assist”, based on cognitive behaviour, described byWindsor et al 2000. The
intervention received as for the control group + peer counselling from lay community
health outreach workers (telephone or home visits). Peer counsellors received 2 x 3 hours
of training. Intensity rating: I = 4, C = 3.
Outcomes Smoking cessation and reduction (cigarettes/day) at 36 weeks’ gestation, biochemically
validated with urine cotinine and exhaled CO.
Nicotine addiction assessments (FagerstromToleranceQuestionnaire), and breastfeeding
at 6 months postpartum.
Infant birthweight correlated with cigarettes/day in late pregnancy. Reduction data not
included in review as adjusted data only used and high attrition.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated list.
Allocation concealment? Unclear Information not provided.
Blinding?
Women and clinical staff
Unclear State that caregivers were masked but ed-
ucational/counselling support intervention
that women may have discussed with care-
givers.
Incomplete outcome data addressed?
All outcomes
No High attrition rates (I = 43%, C = 36%).
ITT analyses for whole sample and for
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those remaining at follow up.
Free of selective reporting? Unclear Birth outcomes only reported by smoking
status not intervention group.
Free of detection bias? Yes Urinary cotinine levels at baseline and at
36 weeks’ gestation. Exhaled CO at each
prenatal visit.
Manfredi 1999
Methods Cluster-randomised trial of a smoking cessation program in 33 prenatal, family planning
and paediatric services within 12 public clinics in Chicago, Illinois, USA, 1994-6.
Participants Clinics matched on size, type, location, and racial mix of clientele. Smokers in interven-
tion group more likely to be African-American. Participation rate I = 76% (n = 1025),
C = 86% (n = 784). Mean cigarettes/day at intake.
Interventions Control group received smoking cessation advice and available brochures, dependant
on the clinician. The intervention group received brief advice to quit (from a variety
of clinicians), a written agreement on a quit date, a take home motivational self-help
booklet “Its Time”, a reminder letter, and a 15 minute telephone motivational interview.
High intensity intervention based on stages of change theory and Miller 2003’s brief
motivational interviewing approach. Intensity rating: I = 4, C = 2 (variable).
Outcomes Self-reported smoking cessation and reduction (not biochemically validated)at 2, 6, 12
and 18 months post intervention. Movement in stages of change.
A subsequent paper describes long-term (18month) cessation and stress/anxietymeasures
at baseline and end of pregnancy by intervention group.
Notes Data from this study have not been included in the pooled analysis as it was not possible
to separate out those data relating to pregnant women (as opposed to women recruited
via family planning and well child clinics). Further, data were collected a specific time
points post intervention; women were not recruited at a particular stage in pregnancy,
so it was not clear at what stage of pregnancy or postpartum women had reached at the
various follow up points.
There was good process analysis and outcomes were analysed by exposure to intervention
and there was a discussion of provider views.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Cluster randomisation. Described as “ran-
domly assigned”.
Allocation concealment? Unclear Matched pairs of clinics with one allocated
to experimental condition.
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Manfredi 1999 (Continued)
Blinding?
Women and clinical staff
No Educational intervention.
Incomplete outcome data addressed?
All outcomes
No Very high attrition rates. Attrition rate I =
38%, C = 41%. For example, in the ex-
perimental group less than half of those
recruited completed follow up. Outcomes
only reported on participants who were ex-
posed to the intervention, not on all in the
intervention group. No ITT analysis and
no discussion of reasons for high attrition.
Free of selective reporting? Unclear Data not adjusted for clustering.
Free of detection bias? No No biochemical validation.
Mayer 1990
Methods Trial comparing 3 smoking cessation interventions in WIC clinics in Grand Rapids,
Michigan, USA, 1985-86.
Participants Women currently smoking (>= 1 cigarette/day) comprised 271/641 attending the clinics
(42%), 219 agreed to take part, data on 186. Losses to follow up were that a quarter
refused, and the rest either moved, changed their source of antenatal care or had a
miscarriage (no details of numbers). Mean cigarettes/day prior to pregnancy I = 19.9, C
= 20.3.
Interventions Control: printed information about the risks of smoking in pregnancy.
Intervention (a) risk information: 10 minute discussion with a health educator using a
flip chart and a brochure but with no behaviour change counselling or self-helpmanual.
Intervention (b)multi-component: 20minute 1:1 counselling including risk information
(“Because I Love My Baby” Am Lung Assoc, flip chart and brochure to take away),
and behavioural change manual adapted from RA Windsor and the Am Lung Assoc
“Freedom from Smoking” focusing on contracting and self-monitoring (CBT).
Intensity rating: I = 3, C = 2.
Outcomes Smoking cessation in late pregnancy and postpartum, biochemically validated with sali-
vary thiocyanate in approximately a third of participants, but no adjustment for misclas-
sification.
Notes No process evaluation.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as “randomly assigned”.
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Allocation concealment? Unclear Not stated.
Blinding?
Women and clinical staff
No Caregivers not blinded to this educational
intervention.
Incomplete outcome data addressed?
All outcomes
No 15%attrition at followup, butmissingdata
for many variables. Those lost to follow up
were treated as continuing smokers in the
analysis.
Free of selective reporting? Yes Not apparent.
Free of detection bias? Unclear Saliva samples from a sub-sample of the
participants.
McBride 1999
Methods Randomised trial of relapse prevention at the Group Health Cooperative of Puget Sound
(Seattle, USA) (HMO), and Park-Nicollet of Minnesota (USA), a multispecialty group
practice. Years of data collection not stated.
Participants Women booked for a first prenatal visit were offered, by letter, study participation and
unless they opted out were given a baseline telephone interview. Women who had com-
pleted the baseline survey, were < 20 weeks of pregnancy, were currently smoking or had
smoked in the 30 days before pregnancy but had quit at the time of the baseline survey.
They were stratified by baseline smoking status.
9152 approached, 714 ineligible because of miscarriage, pregnancy termination, inabil-
ity to speak English; 697 refused; 262 could not be reached by telephone after repeated
attempts. 7479 completed survey. 1007 were randomised: 88 miscarried and were ex-
cluded; 22 were sent wrong intervention material; 897 participated (457 from Seattle,
440 from Minnesota). Mean cigarettes/day 4.8 in intervention and control groups.
Interventions There were 3 stages of change based interventions, all delivered by mail or telephone
without involving prenatal care providers.
(1) Self-help booklet “Stop now for your baby”; 5th grade reading level; health effects
of smoking during pregnancy; specific suggestions for quitting (setting date, enlisting
support). For recent quitters: stress reduction techniques; suggestions for handling high-
risk situations; pregnancy-appropriate behavioural alternatives to smoking.
2 and 3. High intensity interventions in pre and postpartum groups also received: (i)
a personalised letter acknowledging baseline readiness for change, personal health con-
cerns, motivation to quit, comparison with other pregnant women who had successfully
quit. (ii) relapse prevention kit within 2 weeks of completing the 28 week follow-up sur-
vey. (iii) a booklet which discussed transition from pregnancy and factors that influence
cessation and relapse; practical tips for high-risk situations, strategies for avoiding self-
defeating reactions to slips, personal anecdotes from women who quit. (iv) 3 antenatal
counselling phone calls: 2 weeks after the booklet and 1 and 2 months later. Calls were
open-ended but with standardised protocol based onmotivational interviewing and with
stage-based objectives average 8.5 min.
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3. The pre-post group received an additional 3 counselling calls in the first four months
after birth reinforcing themes from the Relapse Prevention booklet; 3 newsletters at 2,
6 and 12 months postpartum about health effects of environmental tobacco smoke and
the importance of being a non-smoking parent.
Intensity rating: I = 4, C = 3.
Outcomes Smoking cessation; relapse prevention and patterns of smoking; biochemically validated
with salivary cotinine at 28 weeks’ gestation; 8 weeks’ PP; 6 months PP; and 12 months
PP. Response rates were 92% at 28 weeks; 91% at 8 weeks’ postpartum; 89% at 6months
postpartum; 87% at 12 months postpartum.
Salivary cotinine requested from all who reported abstaining for 7 days (< 20 ng/ml as
cut off ).
A subsequent paper reports partner abstinence.
Notes Process evaluation describes participation in specific intervention components, including
relapse prevention.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not described.
Allocation concealment? Unclear No information provided.
Blinding?
Women and clinical staff
No Caregivers not blinded to this educational
intervention.
Incomplete outcome data addressed?
All outcomes
Unclear Approximately 10-15% but higher levels of
missing data for some variables.
Free of selective reporting? Unclear Smoking outcomes only reported. Not
clear what data were collected. For self-
reported smoking status non-respondents
were treated as continuing smokers.
Free of detection bias? Yes Salivary cotinine analysis.
McLeod 2004
Methods Cluster-randomised trial of smoking and breastfeeding education in the Lower North
Island, New Zealand, recruited from June 1999-September 2000.
Participants The midwifery team was the unit of randomisation, which were stratified by locality
and randomised into 1 of 4 groups. All 121 midwives in selected localities in the lower
north island were invited to take part. Midwives asked all women who had smoked at
the time they conceived to take part in the study. 80 midwives consented to take part
and received training, and 61 midwives recruited women to the study (76%). 46/349
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women approached declined to take part in the study.
Interventions (1) Control group received UC; (2) Smoking education group received midwife training
to implement education and support; (3) breast-feeding group received training and
support to implement education and support for BF; (4) combined group midwives
received training to implement smoking education and BF programmes. Stratified by
breastfeeding group for analysis (2x2) with control and BF only group (n = 120) and
smoke education and combined group (n = 177).
Smoking education included motivational interviewing provided by a midwife (who was
allocated an extra funded visit and given 4 hours training with a counsellor), flip-chart,
video-tape.
Intensity rating: I = 4, C = 3.
Outcomes Smoking cessation and reduction at 28 and 36 weeks’ gestation, and 6 weeks and 4
months postpartum.
Breastfeeding outcomes.
Intervention developed with provider input and detailed discussion of provider views
included.
Notes Refusal rate approximately 20%.Design effect for clustering reported, so outcome figures
used.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Random sequence generation using excel
for each stratum.
Allocation concealment? Yes Group allocation by external statistician.
Blinding?
Women and clinical staff
No Not possible to blind midwives to alloca-
tion group.Women were not aware of mid-
wife group allocation.
Incomplete outcome data addressed?
All outcomes
No Missingdata formost outcomes, 28%attri-
tion for 4month postnatal followup. Avail-
able case analysis, only women who moved
from the area were excluded.
Free of selective reporting? Unclear Smoking status only reported.
Free of detection bias? Yes Cotinine serum assay.
83Interventions for promoting smoking cessation during pregnancy (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Moore 2002
Methods Cluster-randomised trial of provision of self-help in 3 UK NHS hospital trusts, 1998-
2000.
Participants 128 community midwives in 3 trusts were randomly allocated to 6 strata. Inclusion
criteria: women attending first visit; > 16 years; < 17 weeks’ gestation; literate in English.
Smokers counted as those who reported “I smoke now”, “I smoke now but have cut
down since I thought I might be pregnant”, or “I have stopped smoking since I thought
I might be pregnant”. Mean number of cigarettes per day at baseline I = 16, C = 15.1.
Interventions Control group midwives continued to give routine advice according to usual practice.
Intervention midwives gave their UC and spent at least 5 minutes introducing a series of
5 self-help booklets “Stop for Good”, based on stages of change theory, and gave them
a copy of the first booklet. Subsequent booklets were mailed directly to the woman.
Intensity rating: I = 3, C = 2 (not clear).
Outcomes Self-reported smoking cessation validated by urine cotinine (94%).
Perinatal outcomes: birthweight, gestation at birth. Stillbirths, perinatal, neonatal and
childhood deaths not reported but available on request.
Smoking reduction in mean cigs/day.
Notes Reported intracluster correlation of 0.031 used to adjust outcome data for inclusion in
outcome tables. Detailed qualitative and quantitative process analysis of participants’
and midwives’ views of the intervention, which suggested poor implementation in some
areas. Some concerns about contamination of control group. Sample size justification.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Stratified random allocation by computer-
generated random numbers. 118 midwives
stratified according to workload and ran-
domly allocated to provide intervention or
control care.
Allocation concealment? Unclear No information.
Blinding?
Women and clinical staff
No Midwives randomised. Educational inter-
vention.
Incomplete outcome data addressed?
All outcomes
Yes Some attrition: 8%. Drop-outs included in
denominator for ITT analysis.
Free of selective reporting? Unclear No adjustment for clustering.
Free of detection bias? Yes Urinary cotinine levels analysed.
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O’Connor 1992
Methods Quasi-randomised (allocation by alternate days) trial of a new smoking cessation pro-
gramme provided by public health nurses in the antenatal clinic of an Ontario (Canada)
teaching hospital, compared with previous standard care. Dates of data collection not
specified.
Participants 1028 women screened, 267 daily smokers (673 non-smokers, 88 spontaneous quitters).
Ineligible (39) late gestation; miscarriage; missed abortion; termination; malformation;
mental illness; mental retardation. Refusal (4). 224 at baseline; 202 at 1 month follow
up; 174 at 36 weeks; 190 at 4 weeks’ postpartum. Reasons for dropout: miscarriage (17),
no further clinic visit (3), subsequent refusal (2), and preterm birth (16 - all of these seen
postpartum), and 12 lost to follow up. Mean cigarettes/day at intake I = 13, C = 12.8.
Interventions Control: 3-5 minutes explanation of the risks of smoking during pregnancy and a pam-
phlet inviting women to a 2 hour cessation class in the evenings where theWindsor self-
help manual would be taught and provided.
Intervention (provided in English or French): 20minutes 1:1 session with a public health
nurse going through the Windsor self-help manual program + follow-up telephone call
at a mutually agreed time. High intensity intervention. Intervention intensity: I = 4, C
= 2.
Outcomes Smoking cessation biochemically validated by urine cotinine at end of pregnancy and 6
weeks’ postpartum.
Notes No one attended the evening group class which was offered and was free.
Interesting discussion of women’s perceptions of risk based on personal experiences.
Process evaluation showed 93% received the intervention by second visit.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No Alternate according to the day of the week.
Allocation concealment? No Nurse delivering the intervention attended
on alternate days. Authors state the ap-
pointmentsweremade by a personwhowas
unaware of the intervention days.
Blinding?
Women and clinical staff
No Educational intervention by designated
nurse.
Incomplete outcome data addressed?
All outcomes
No Full data available for 76%.
Free of selective reporting? Unclear Unclear what data were collected. Smoking
cessation outcomes only reported.
ITT analysis (with drop-outs treated as
continuing smokers) was not set out in the
paper but authors state that this had been
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O’Connor 1992 (Continued)
performed, and that this did not change the
size of the treatment effect. Women lost to
follow up not included in this review.
Free of detection bias? Yes Reported smoking validated by urinary co-
tinine levels.
Olds 1986
Methods Randomised trial with 4 arms whose aims were to improve the uptake of prenatal care
and pregnancy outcomes, especially low birthweight, in a semi-rural county of New York
State, USA, 1978-1980.
Participants Active recruitment of pregnant women with no prior live births + any of the following: <
19 years; single; low socioeconomic status, and any other women with no prior live births
who wished to participate in the program. Exclusions were > 25 weeks’ gestation (though
some were enrolled at 25-29 weeks). Recruitment was through private obstetricians’
offices, plannedparenthood, public schools health department antenatal clinics andother
health and human service agencies. 10% of target population entered prenatal care too
late, 10% were not referred from private care, 500 interviewed, 400 participated; 47%
< 19, 62% single, 61% low SES. Non-Whites (46) excluded because too few; serious
maternal or fetal conditions (20) excluded. Mean cigarettes per day at intake: C = 6.94,
I = 7.65.
Interventions Control (i) health and developmental screening of the baby at 12 and 24 months;
(ii) (i) + free transport to pregnancy and well-child visits (control);
(iii) (i) + (ii) + nurse home visits during pregnancy (intervention);
(iv) (i) + (ii) + (iii) + nurse home visits in child’s first 2 years.
The focus of the home visiting was individualised from a detailed curriculum dealing
with information on fetal and infant development; improvement of maternal diet; mon-
itoring weight gain; elimination of cigarettes, alcohol and drugs; identifying pregnancy
complications; encouraging rest, exercise and hygiene; preparing for labour birth and
early newborn care. The intervention was also described as enhancement of informal
support systems and linkage of parents to community services.
Intensity rating: I = 4, C = 0.
Outcomes Smoking cessation with biochemical cotinine validation in a subsample (n = 116). Data
not included in high intensity outcome tables, as smoking was not the focus of the
intervention.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided.
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Olds 1986 (Continued)
Allocation concealment? Unclear Not specified.
Blinding?
Women and clinical staff
No Home visitation programme.
Incomplete outcome data addressed?
All outcomes
No Very high attrition. Smoking outcomes
only reported on less than 50% (141/354
recruited). No explanation for reason the
outcome was not reported in the remaining
participants. No ITT analysis.
Free of selective reporting? Yes Detailed range of outcomes reported.
Free of detection bias? Yes Serum cotinine analysis on sub-sample of
116/354.
Panjari 1999
Methods Randomised controlled trial of personalised smoking cessation interventions in a low
socioeconomic population in Melbourne, Victoria, Australia. Data collected from April
1994-June 1996.
Participants Women who identified as “current smokers” at their first antenatal visit at approximately
12 weeks’ gestation (“even a puff in the last 7 days”). Exclusion criteria: > 20 weeks’
gestation; twin pregnancy; not literate in English; drug dependency.
Mean cigarettes per day = 11 in both groups. Participation rate = 52% (n = 1013), with
the majority of eligible non participants refusing to enter the study.
Interventions Control group received UC, which included advice at the discretion of the caregiver,
a group counselling session, and a pamphlet “Smoking & Pregnancy” . The interven-
tion group received as for the control group plus 4 counselling sessions by a midwife
specifically trained and employed to provide smoking cessation counselling, using CBT.
Sessions included video presentation, interactive discussion and strong verbal messages.
These were followed up with a 5 - 10 minute personalised counselling session. High
intensity intervention: I = 4, C = 2.
Outcomes Self-reported smoking cessation biochemically validated with urine cotinine at 36 weeks’
gestation, 6 weeks’ postpartum, and 6 months postpartum. Breastfeeding at 6 weeks’
and 6 months postpartum. General health assessment at first visit and 36 weeks. Preterm
delivery rate, mean birthweight, proportion LBW (< 2500 g).
Reduction in mean cigarettes/day and cotinine levels.
General health questionnaire (including stress and depression measurement)at baseline
and end of pregnancy.
Notes Process evaluation showed 71% women in the intervention group received the full in-
tervention.
Risk of bias
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Panjari 1999 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information.
Allocation concealment? Unclear Described as “randomly allocated”.
Blinding?
Women and clinical staff
No Educational intervention delivered by
clinic midwife.
Incomplete outcome data addressed?
All outcomes
No Only 52% eligible agreed to participate,
and 22% attrition. Only women available
for follow up included in the analysis.
Free of selective reporting? Yes A detailed list of birth outcomes reported.
Free of detection bias? Yes Urinary cotinine levels measured at base-
line and in late pregnancy.
Pbert 2004
Methods Cluster-randomised trial in Massachusetts, USA of implementation of the “Quit To-
gether” study. Data were collected from May 1997 to November 2000.
Participants Unit of randomisation was 6 community health centers. Eligibility: pregnant women,
English or Spanish speaking, less than32weeks’ gestation, current smoker or spontaneous
quitter, planning to remain in area for 6 months after delivery.
Interventions The dissemination intervention consisted of provider training based on national clinical
practice guidelines, an office practice management system for routine screening and fol-
low-up reminders, and establishment of programboards. The intervention towomenwas
based on motivational interviewing and the “4A’s” and the trial conducted by Windsor
2000a.
Intervention intensity: I = 3, C = 3.
Outcomes Biochemically validated smoking cessation at end of pregnancy, and 3 and 6 months
postpartum.
Reduction in mean cigarettes/day.
Notes No estimates of clustering effect reported, so sensitivity analysis conducted and intra-
cluster correlation of 0.10 used to adjust data for inclusion in outcome tables.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided.
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Pbert 2004 (Continued)
Allocation concealment? Unclear No information provided.
Blinding?
Women and clinical staff
No Sites aware of allocation status.
Incomplete outcome data addressed?
All outcomes
No One clinic dropped out due to poor recruit-
ment.
Free of selective reporting? Unclear Trial part of a nutritional program, but only
smoking outcomes in this report. ITT not
conducted in trial report, but all dropouts
included as continuing smokers in this re-
view.
Free of detection bias? Yes Cotinine assay.
Petersen 1992
Methods A randomised trial comparing the impact on smoking cessation of 2 different packages
of material mailed to current smokers and recent quitters at a large Boston HMO, USA,
1986-1988.
Participants English-speaking women enrolling in prenatal care; >= 18 years; < 24 weeks’ gestation
who reported themselves as currently occasional or regular smokers or who had quit
smoking in the previous 3 months. 1439/1442 screened (3 refused), 317 current/ recent
smokers, 93 dropped out because of miscarriage, termination, moved away or left the
HMO; 274 at second assessment and 224 at 8 weeks’ postpartum. 78 control and 71
intervention at baseline.
Interventions UC: routine obstetric care, mailed list of community-based smoking cessation resources
other pregnancy-related health education materials.
Intervention: pregnancy-specific self-help manual (Am Lung Assoc and Harvard Com-
munity Health Plan (HMO)) and audiotape on safe aerobic exercise and pregnancy-
related relaxation, mailed with other health-related education. Smoking component em-
phasised behavioural strategies for quitting, issues and concerns specific to pregnant
women, non-smoking as part of a continuum of care in pregnancy; included a main-
tenance section for the postpartum period. Intervention based on CBT. Brief repeated
counselling by obstetricians and midwives for both groups as part of routine care. Inten-
sity rating: I = 3, C = 2.
Outcomes Smoking cessation for smokers and spontaneous quitters at mid-pregnancy and 6
months, postpartum. Biochemical validation in 50% women.
Mean birthweight, low birthweight (< 2500 g) and very low birthweight (< 1500 g)
outcomes.
Notes Refusal of urine test = coded as smoking.
Substantial misclassification of non-smoking self-report at 6 months gestation 24%
controls 21% intervention (and 30% in clinic where the interventionwasmore intensive)
. Data from two interventions combined in relapse prevention outcomes, so not included
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Petersen 1992 (Continued)
in tables.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Table of randomnumbers. Allocation to in-
tervention arm 2 was not randomised but
offered to all eligible enrollees at one clinic:
data from this intervention arm are not in-
cluded in the review.
Allocation concealment? Unclear No information provided.
Blinding?
Women and clinical staff
Unclear State that caregivers were blind as materials
to the intervention group were mailed. Not
feasible to blind women.
Incomplete outcome data addressed?
All outcomes
No 224 of 317 randomised completed the
study. 30% attrition.
Those refusing urine testing were treated
as continuing smokers but not clear that
analysis included all randomised women.
Free of selective reporting? Unclear None apparent but results were not simple
to interpret.
Free of detection bias? Yes Urinary cotinine validation performed on
a 50% sub-sample of those that reported
not smoking.
Polanska 2004
Methods Cluster-randomised trial in the Lodz district, Poland. Data collected 2000-2001.
Participants 15/33 maternity units were allocated to intervention (10) or control (5) groups.
Eligibility criteria: current smokers or women who quit 1 month before the visit. Exclu-
sions: miscarriage (I = 5.1%, C = 6.2%).
Interventions Control group: received standard written information about health risks of smoking.
Intervention group women received 4midwife home visits, based on a booklet translated
from English (Ottawa) to Polish “How to talk about smoking with high risk pregnant
smokers”.
Intervention intensity rating: I = 4, C = 1.
Outcomes Smoking cessation (spontaneous quitters and smokers), mean birthweight.
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Polanska 2004 (Continued)
Notes No estimates of clustering effect reported, so sensitivity analysis conducted and intraclus-
ter correlation of 0.10 used to adjust data for inclusion in outcome tables. High refusal
rate.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Notes random allocation, but no descrip-
tion of how this occurred. Only 15/33 eli-
gible clinics allocated.
Allocation concealment? Unclear Not specified.
Blinding?
Women and clinical staff
No Caregivers not blinded to this educational
intervention.
Incomplete outcome data addressed?
All outcomes
Yes Refusals and those lost to follow up in-
cluded in analysis of smoking outcomes.
Free of selective reporting? Unclear Birthweight and smoking outcomes re-
ported.
Free of detection bias? No Self-reported smoking status only.
Pollak 2007
Methods Randomised controlled trial of Nicotine Replacement Therapy. Conducted in 3 clinical
sites and 5 sites which provide services for military personnel, in North Carolina, USA.
Trial period May 2003-August 2005.
Participants Inclusion criteria: initial assessment:Pregnant women 13-25 weeks’ gestation, who have
smoked over 100 cigarettes in their lifetime, currently smoking 5 or more cigarettes per
day, enrolled in prenatal care, equal to or greater than 18 years old, English speaking, with
no evidence of cognitive or mental health problems. Secondary assessment: no evidence
of alcohol or drug addiction, no history of placental abruption, hypertension, cardiac
arrhythmia, myocardial infarction, previous pregnancy with congenital abnormality or
family history with congenital abnormalities.
1219 women eligible smokers identified, 926 approached as met inclusion criteria at
initial assessment. 181 randomised as met secondary assessment and did not refuse (79%
refusal rate). A further 102 withdrew from the study or were unable to be contacted
before the end of pregnancy assessment, but were included as continuing smokers in the
analysis (participation rate = 43%).
Control (CBT only) n = 59, Intervention (CBT+NRT) n = 122. (1:2 randomisation).
Care program and baseline characteristics were similar for both groups.
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Pollak 2007 (Continued)
Interventions Control: received a “Quit kit” (which contained a booklet, water bottle, straws, candy,
exercise band, and stress management tape), as well as 3 counselling sessions from a
“support specialist” based onmotivational interviewing, transtheoreticalmodel and social
cognitive theory.
Intervention: as above plus an option of NRT by patch, gum or lozenge. Participants
could change mode of administration if they wished.
Intensity rating: C = 4, I = 4.
Theoretical basis: NRT.
Outcomes Outcomes measured included 7-day point prevalence abstinence after 7 weeks, at 38
weeks’ gestation, and 3 months postpartum.
Birthweight and mean gestation reported.
A range of perinatal outcomes reported, including preterm births, NICU admissions,
small for gestational age, placental abruption, fetal demise.
Notes Sample size calculation justified, but aimed for 300. Only 181 included in final analysis,
with 102 of those having withdrawn before final analysis.
Associated reference discusses challenges to recruitment and the high refusal rate.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computerised-random number genera-
tion.
Allocation concealment? No Described as “open label randomised trial”.
Blinding?
Women and clinical staff
No Caregivers and women not blinded.
Incomplete outcome data addressed?
All outcomes
No Participation rate only 19.5%. Loss to fol-
low up low for perinatal outcomes but
more than 30% attrition for assessment
of smoking status at the postnatal follow
up. No birth outcome data for 10/181
women.Women lost to follow up included
as smokers.
Free of selective reporting? Yes All adverse outcomes reported.
Free of detection bias? Yes Salivary cotinine
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Price 1991
Methods A randomised comparison of two different minimal contact interventions to encourage
smoking cessation and reduction during pregnancy, in women of low SES and low
education, compared with UC in an inner urban setting, Toledo, Ohio, USA, 1987-89.
Participants “Typically low income, single and poor”. 1164 approached, 486 (42%) were current
smokers: 60% not enrolled (exclusion criteria not listed, though includes gestation > 28
weeks and refusal); 193 entered the study.
Interventions Control: UC not specified or assessed but “usual for physicians to address this issue with
participants at least 1 prenatal visit”.
Intervention (i): tailored educational videotape 6.5minutes, potential fetal risks, benefits
if mother quit + pamphlet on how to quit and opportunity to ask questions of the health
educator.
Intervention (ii): American Lung Association self-help booklet (with brief overview and
explanation)emphasising behaviour modification skills, relation techniques and the sup-
port of significant others, + opportunity to ask questions of the health educator. Intensity
rating: I = 3, C = 1.
Outcomes Smoking reduction (mean cigarettes/day) and cessation, validated by exhaled CO mon-
itoring.
Notes Programwas developedwith input from a questionnaire and open-ended questions about
the advantages and disadvantages of smoking when pregnant from local population to
inform Health Belief Model used in program.
Commentary on the contextual factors in the lives of indigent women which lead them
to have different perceptions about the relative importance of smoking.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not reported.
Allocation concealment? No Tossed die (allocation could therefore be
changed). Method resulted in three un-
equal groups, so randomisation to only 2
groups for some of the study period.
Blinding?
Women and clinical staff
No Educational intervention in antenatal clin-
ics.
Incomplete outcome data addressed?
All outcomes
No Relatively low participation and high at-
trition (57% dropout) from enrolment to
completion. Differential drop-out rate in
the three study groups. No ITT.
Free of selective reporting? Unclear Low participation and high attrition.
93Interventions for promoting smoking cessation during pregnancy (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Price 1991 (Continued)
Free of detection bias? Yes Biochemical validation by exhaled CO.
RADIUS 1995
Methods An analysis within a subset of births in the RADIUS trial (births in Missouri, USA) to
see whether ultrasound of the fetus at 18-21 weeks and 31-33 weeks decreased adverse
perinatal outcomes, including smoking in pregnancy. Data were collected from Novem-
ber 1987-May 1991.
Participants 53,367 pregnant women; -32,317 ineligible or excluded; leaving 21,050 -3163 refused;
-2357 had miscarriage or change of provider; leaving 15,530 (7812 intervention + 7718
controls). subsequently - 64 + 63 miscarriage, -131+121 records lost or women moved,
leaving 7617 + 7534; 1768 smoking (I) and 1,803 smoking (C). Smoking defined as
any smoking within the year before their enrolment. Inclusion criteria = last menstrual
period known within 1 week, gestational age < 18 weeks, no plans to change providers.
Exclusion criteria include medical or obstetric complications, planning an ultrasound
for other reasons, twin pregnancy, not intending to continue pregnancy. Intensity rating:
I = 0, C = 0.
Interventions Ultrasound only, at 18-20 and 31-33 weeks, no details about feedback to the mother
or others. The women in the control group only had ultrasounds if ordered by their
physician for medical reasons.
Outcomes Self-reporting smoking cessation, recorded on birth certificate, not biochemically vali-
dated (not included in outcome tables). Mean birthweight, preterm birth (< 36 weeks)
and very preterm birth (< 33 weeks).
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Stratified computer randomisation.
Allocation concealment? Unclear Information not provided.
Blinding?
Women and clinical staff
Unclear Smoking status not revealed to sonog-
rapher. Intervention not explicitly about
smoking cessation.
Incomplete outcome data addressed?
All outcomes
Yes Small loss to follow up (approximately
2%). Available case analysis but smoking
cessation was not a primary outcome.
Free of selective reporting? Yes None apparent.
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RADIUS 1995 (Continued)
Free of detection bias? No No biochemical validation.
Reading 1982
Methods A randomised comparison of the effects on health behaviours (including smoking) of
providing specific verbal and visual feedback to the mother about fetal size, shape and
movement during an ultrasound examination (or having the screen not visible and
providing no specific feedback) at the first antenatal visit, in London, UK.
Participants Pregnant women at 10-14weeks’ gestation; 18 to 32 years; stable relationship; Caucasian;
85% had planned pregnancy, at low risk of complications; 86% nulliparous. Exclusions:
prior miscarriage or extended infertility investigations.
Interventions Control: no/low feedback.
Intervention: high feedback about the fetus, with the fetus visible. No clear smoking
cessation component.
Intensity rating: I = 0, C = 0.
Outcomes Self-reported smoking cessation at 16 weeks’ gestation, without biochemical validation.
Notes Not clear whether quitting was recent or not - no time period specified.
3/62 low feedback group did not attend next visit at 16 weeks.
Cites evidence for the reliability of self-report (Pettiti 1981).
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as “assigned at random”.
Allocation concealment? Unclear No information.
Blinding?
Women and clinical staff
Unclear Intervention with verbal feedback, so not
feasible to blind women. State that those
providing care were not involved in the
study.
Incomplete outcome data addressed?
All outcomes
No Small loss to follow up, but considerable
amounts ofmissing data for some variables.
Those lost to followupnot included in ITT
analysis. Only smoking outcomes for ap-
proximately 50% participants are reported.
Free of selective reporting? Unclear Data collected not specified.
Free of detection bias? No No biochemical validation.
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Rigotti 2006
Methods Randomised controlled trial of a telephone counselling intervention. Trial conducted in
Massachusetts, New England, USA, between September 2001 and July 2004.
Participants Study conducted in a network-managed care organisation and a group of 65 community
based prenatal care practices.
Inclusion criteria: pregnant smoker (at least 1 cigarette in the past 7 days), At least 18 years
of age, 26 weeks or less gestation, willing to consider altering smoking during pregnancy,
reachable by telephone, English speaking and expected to live in New England for the
next year.
1444 pregnant smokers were referred to the study and 665 assessed as eligible. 223
refused to participate (refusal rate 34%). 442 were randomised (I = 220, C = 222).
21 women were excluded from the analysis due to miscarraige. I = 209, C = 212. 113
women did not have final assessment due to refusal (22%), baby born before assessment
or lost to follow up, but were included in the final analysis (ITT analysis).
Baseline characteristics of both groups were similar, though the intervention group had a
significantly higher proportion of women who had made a quit attempt this pregnancy
and had social support to quit from partner.
Interventions In addition to UC, the control group were mailed a validated pregnancy-tailored smok-
ing cessation booklet, and their prenatal care providers were sent the ACOG smoking
cessation practice guideline, with a reminder to address smoking at the subject’s visits.
The enrolment call concluded with a trained counsellor providing brief smoking coun-
selling (less than 5 minutes). Smokers who requested further assistance were referred to
the Massachusetts telephone quitline.
The intervention group received as above, as well as a series of telephone calls accom-
panied by additional mailed written materials. Each subject had a dedicated counsellor
who offered up to 90 minutes of counselling during pregnancy and up to 15 minutes
over the 2 months postpartum. The trained counsellor tailored the call to the subjects
needs, consistent with the 5-step smoking cessation guideline,and drew on social learn-
ing theory and the transtheoretical model of change, the health belief model, and the
principles of motivational interviewing.
Intensity rating: I = 4, C = 3.
Theoretical basis: Motivational interviewing, stages of change, by telephone
Outcomes Self-reported and biochemically validated 7-day point prevalence nonsmoking at end of
pregnancy, and 3 months postpartum. Also measured reduction in smoking (proportion
>50% reduction)and number of quit attempts.
Self-efficacy and social support at baseline and follow up.
Women’s satisfaction with the intervention.
Notes Initial recruitment in a managed care organisation did not yield a sufficient sample size,
so 140 community-based prenatal care practices were invited to participate in the study.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated.
96Interventions for promoting smoking cessation during pregnancy (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rigotti 2006 (Continued)
Allocation concealment? Yes Stated that recruiters were not aware of
group allocation.
Blinding?
Women and clinical staff
No All providers and women sent smoking ces-
sation practice guideline.
Incomplete outcome data addressed?
All outcomes
No Missing data (up to 30%) for outcomes
measured in the postnatal period. Women
lost to follow up were included as continu-
ing smokers in this review.
Free of selective reporting? No
Free of detection bias? Yes Salivary cotinine confirmation in 66%.
Rush 1992
Methods Quasi-randomised study (allocation by alternate weeks) of the effectiveness of a health
education intervention provided by a psychologist from booking to birth, compared
with standard care, at a large maternity hospital in England, 1978-1979.
Participants Pregnant women registering for maternity care: 371/1645 were currently smoking at
least 1 cigarette/day, 25 refused participation and 27 were lost because of miscarriage,
termination or transfer to another care provider, leaving 319. No exclusions were men-
tioned or mean cigarettes/day pre-pregnancy.
Interventions Control: standard care not otherwise specified.
Intervention: counselling begun in antenatal clinic at 1st visit, with follow-up visit 2
weeks after booking at home, then monthly to the birth, each visit 15-20 minutes, (5 on
average). Focus of counselling was help and support to change smoking, focus also on
short and long-term benefits; advice on stopping/cutting down, strategy planned with
woman, follow up planned with clear objectives, involvement of other family members,
friends and partner in support. Counselling by psychologist. Intensity rating: I = 4, C =
0 (not clear - routine care).
Outcomes Smoking cessation, biochemically validated with exhaled CO and serum thiocyanate.
Mean birthweight in subgroup smoking >= 5 cigarettes at booking.
Smoking reduction in mean cigarettes per day.
Maternal weight gain and discussion of participants’ views.
Notes Detailed account of the intervention in King 1981.
Subgroup analysis seems not to have been a pre-specified one.
Apparent problems with the thiocyanate measures and with loss of some data files (see
paper).
Risk of bias
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Item Authors’ judgement Description
Adequate sequence generation? No Alternation (group allocation on alternate
weeks).
Allocation concealment? Unclear Not specified.
Blinding?
Women and clinical staff
No Caregivers not blinded to counselling in-
tervention.
Incomplete outcome data addressed?
All outcomes
Unclear Attrition 8% and missing data for some
variables. Available case analysis.
Those lost to follow up were included in
this review as continuing smokers.
Free of selective reporting? Unclear Those who discontinued counselling were
analysed separately and were different at
baseline from those continuing (drop outs
were heavier smokers and less likely to be
married).
Free of detection bias? Yes Exhaled CO measured at each clinic visit.
Secker-Walker 1994
Methods A randomised trial comparing the effectiveness of individualised, but protocol-based
smoking cessation counselling provided by a specially trained health educator, compared
with UC, at the University of Vermont, Burlington, USA, 1984-1987.
Participants Women receiving prenatal care from obstetricians + nurse-midwives, or residents; private
and public including Maternal, Infant & Child clinic for under-insured or non-insured
women (23%Medicaid in study); < 25 weeks pregnant (mean gestation 13/40), smoking
at least 1 cigarette a day, no exclusions mentioned. 808 interviewed, 33 refused, 175
spontaneous quitters went into separate study of relapse prevention, leaving 300 + 300;
(-49: 27 miscarriage, 7 fetal deaths, 5 infant deaths), further losses were 24 + 24 changed
care provider, 37 (I) + 4 (C)withdrew and 31 + 28were lost to follow up.Mean cigarettes/
day pre-pregnancy I = 24.4, C = 25.1.
Interventions Control: UC, not otherwise specified.
Intervention, from a trained health educator: addressed concerns re smoking and preg-
nancy, health benefits of stopping, perception of the advantages and disadvantages of
stopping, problem solving around those issues and coming to a decision, if yes to quitting
formulating a plan, skills rehearsal + pregnancy-specific booklet. Follow up at second
antenatal clinic, 36 weeks and 6 week check (where infant health and parental role mod-
elling was discussed)and re-encouraged to quit.
Health educators given selected readings, discussion, rehearsal with psychologist + health
educator (both former smokers) about smoking and smoking cessation counselling tech-
niques + American Lung Association training group for class leaders + 4 week pilot.
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Secker-Walker 1994 (Continued)
Intensity rating I = 4, C = 1 (not clear).
Outcomes Smoking cessation at 36 weeks’ gestation (75% biochemically validated with cotinine),
8-15 weeks’ pp, 16-24 pp, and 25-54 pp (self-reported). Mean birthweight, low birth-
weight, other smoking-related complications (PPROM, placental abruption and pla-
centa praevia).
Reduction in mean cotinine at 36 weeks’ gestation.
Separate paper (Secker-Walker 1995) evaluates relapse prevention.
Notes Sample size calculated for 10% increase (from 10% to 20%) in quitting.
Differential withdrawal in I and C groups a concern; good information collected on
drop-outs being different.
Allocation for fetal and infant deaths not reported.
No adjustment for misclassification.
Separate paper (Secker-Walker 1992) evaluates training program for residents.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as “randomly assigned”.
Allocation concealment? Unclear Not stated. Unclear when randomisation
took place.
Blinding?
Women and clinical staff
No Educational intervention in antenatal clin-
ics.
Incomplete outcome data addressed?
All outcomes
No 26% lost to follow up during pregnancy.
39% lost to follow up in the longer term.
Significant difference in pregnancy drop
out rates for I (13% drop out rate ) and C
(1.4% drop out rate). Those lost to follow
up smoked more.
Voluntary drop-outs treated as continuing
smokers for some analyses. Women lost
to follow up were included as continuing
smokers in this review.
Free of selective reporting? Unclear Data collected not specified. Only smoking
outcomes reported.
Free of detection bias? Yes Urinary cotinine levels measured at 36
weeks.
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Secker-Walker 1995
Methods Randomised controlled trial of relapse prevention counselling for spontaneous quitters,
Burlington, Vermont, USA, May 1984-June 1987.
Participants Those from Secker-Walker 1994 who had stopped smoking spontaneously before their
first prenatal clinic visit (n = 175). Attrition: 5 miscarriages, 1 termination, 1 fetal death
and 1 infant death leaving I = 85 and C = 80. 15 were transferred to other care, 9 dropped
out and 8 were lost to follow up.
Interventions Control: UC by provider.
Intervention: See Secker-Walker 1994 for training of health educators and cessation
planning. Concerns dealt with included staying away from smoking, perceptions of ad-
vantages and disadvantages of maintaining cessation, problem-solving and skills practice,
infant risks and benefits. Women were also given a booklet.
Intensity rating: I = 4, C = 0 (not clear - routine care).
Outcomes Smoking cessation, biochemically validated at end of pregnancy.
Mean birthweight, low birthweight, preterm birth.
Notes Exclusion of fetal and infant deaths.
Biochemical validation showed substantial misclassification at 36 weeks in this study,
more so than for the continuing smokers.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as ’randomly assigned’.
Allocation concealment? Unclear Not stated. Unclear when randomisation
took place.
Blinding?
Women and clinical staff
No Educational intervention in antenatal clin-
ics.
Incomplete outcome data addressed?
All outcomes
No Data included on approx 65% of par-
ticipants who had biochemical validation
of smoking status. Voluntary drop-outs
treated as continuing smokers for some
analyses.
Free of selective reporting? Unclear Only smoking outcomes reported.
Free of detection bias? Yes Urinary cotinine levels measured at 36
weeks.
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Secker-Walker 1997
Methods Trial comparing the added effectiveness for smoking cessation during pregnancy of a free
videotape using peer role models, Burlington, Vermont, USA, 1992-1993.
Participants Women in a state supported clinic for underinsured women, currently smoking at least
1 cigarette/day, 7/67 refused leaving 30 (I) + 30 (C), 4 had miscarriage leaving 26 + 30,
3 lost to follow up and 7 moved to another care-provider leaving 17 + 27 seen at 36
weeks. Mean cigarettes per day pre-pregnancy = 22.6.
Interventions Control: advice from obstetrician or nurse-midwife + tip sheet on quitting.
Intervention: as above + 29 minute videotape of 4 women going through the process
of quitting during pregnancy; talking about feelings; coping with weight gain; getting
support, which could be borrowed and taken home. Based on social learning theory.
Intensity rating: I = 3, C = 2.
Outcomes Smoking cessation in late pregnancy (36/40), biochemically validated with exhaled CO
measurements.
Notes Process evaluation included perceptions of the videotape contents and showed 53%
viewed the videotape. 17% had no VCR, and 10% reported having no time.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as “randomly assigned”.
Allocation concealment? Unclear No information provided.
Blinding?
Women and clinical staff
No Educational intervention.
Incomplete outcome data addressed?
All outcomes
No 20% attrition after randomisation. Loss to
follow up not balanced, greater loss from
the intervention group.
Those lost to follow up for reasons other
than miscarriage (4) were included in the
analysis for this review as continuing smok-
ers.
Free of selective reporting? Unclear Not apparent.
Free of detection bias? Yes Exhaled CO measured at 36 weeks’ gesta-
tion.
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Secker-Walker 1998
Methods A trial of structured physician’s advice supported by individual counselling (I) provided
to pregnant women during prenatal care compared with UC, Vermont, USA, 1988-92.
The study included a relapse prevention component, reported separately.
Participants Woman attending the state-supported (Maternal and Infant Care) prenatal clinic for
underserved women or attending the Adolescent clinic for women 12 to 18 years.
544 women smoking at pregnancy onset approached:
21 refused;
124 had quit spontaneously- relapse prevention trial;
399 into cessation trial - 197 (I), 202 (UC);
14 miscarriages, 5 fetal deaths 5 infant deaths (allocation not reported);
34 in each group moved or transferred their care;
12 women withdrew from study (7 (I), 5 (UC));
17 delivered before 36 weeks (9 (I), 8 (UC));
135 (I) and 141 (UC) remained;
114 (I) and 110 (UC) were contacted 1 year after birth, including 16 (I) and 18 (UC)
lost to follow up during pregnancy.
Mean cigarettes/day pre-pregnancy I = 26.1, C = 25.1.
Interventions All participants received:
baseline questionnaire, measurement of exhaled CO, and brief standardised health risk
message from a research nurse about the effects of smoking on the fetus and pregnancy.
UCwas: physician acknowledged women’s smoking , gave a rationale for quitting, strong
recommendation to quit and provided smoking cessation booklet designed for pregnant
women.
I was: smoking cessation protocol provided by physicians trained in its use (Secker-
Walker 1992): acknowledging the woman’s smoking, her exhaled CO level, any progress
towards quitting, rationale for & unambiguous recommendation to quit, asking how she
felt about quitting and acknowledging her response, asking how she could be helped and
telling her about the counsellor, eliciting a commitment to change smoking behaviour
before the next prenatal visit and referring her to the counsellor. The aim was to gain her
agreement to set a quit date, a date when she would quit for 24 hours or a date when she
would cut her consumption by half. Counsellor advised women on ways to accomplish
the behaviour change.
2nd visit same with praise for those who had quit with referral to counsellor for help in
staying quit, 3rd 5th 7 36 week visits a briefer protocol was followed with referral for
those who wanted to change, praise for success and referral. Intensity rating: I = 4, C =
2.
Outcomes Smoking cessation maintained in late pregnancy (36/40) and 1 year postpartum, bio-
chemically validated with exhaled CO and urine cotinine.
Mean birthweight.
Low birthweight.
Notes Methods included a detailed process evaluation of participants’ views and recall of
provider advice. Sample size justification.
Risk of bias
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Secker-Walker 1998 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as “randomly assigned”.
Allocation concealment? Unclear No details provided.
Blinding?
Women and clinical staff
No Intervention by clinic staff. Notes flagged.
Incomplete outcome data addressed?
All outcomes
No High attrition rate. More than 25% lost to
followup in pregnancy andmore than 30%
lost to longer-term follow up. There were
further missing data for some outcomes.
Free of selective reporting? Unclear Only smoking outcomes reported.Women
with adverse outcomes were not included
in the analysis. Women lost to follow up
were not included in an ITT analysis.
Free of detection bias? Yes Validation by exhaled CO and urinary co-
tinine levels.
Sexton 1984
Methods A randomised trial of an intervention to increase birthweight by changing maternal
smoking, carried out in Baltimore, USA. Enrolled during a 2.5 year period (dates not
specified).
Participants Pregnant womenwhowere smoking >= 10 cigarettes/day immediately prior to pregnancy
(71% of whom were spontaneous quitters), < 18 weeks’ gestation, attending 52 private
physicians and the hospital antenatal clinic. Heterogeneous population, including large
inner-city and suburban. 89% of those eligible were recruited n = 935, 463 (I), 472 (C).
Mean cigarettes/day pre-pregnancy I = 20.9, C = 20.7.
Interventions Control: UC, not further specified.
Intervention: at least 1 personal visit, supplemented by frequent mail and telephone
contacts (at least 1 visit and 1 call/month) from 1 of 2 health educators (MEd level,
trained in pregnancy counselling and smoking intervention), providing information,
support, practical guidance and behavioural strategies for quitting.
Information on quitting and health risks of smoking was mailed every 2 weeks with
“homework” linked to telephone calls; group sessions were also available. There was a
monthly lottery and in the last year of the study a monthly newsletter. Intensity Rating:
I = 4, C = 1 (not clear).
Outcomes Smoking in late pregnancy, 97% biochemically validated with salivary thiocyanate. Mis-
carriage; fetal deaths; mean birthweight; low birthweight; very low birthweight; % Apgar
scores < 7 at 1 minute and 5 minutes; length and head circumference.
Reduction in mean cigarettes per day and mean thiocyanate.
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Sexton 1984 (Continued)
Notes Change of criteria for enrolment after the first 185 as 35% of these had smoked < 10/day
and 71% of that group had quit spontaneously with little relapse.
Detailed account of the intervention is in Nowicki 1984.
Group sessions in the intervention were not readily accepted.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not stated.
Allocation concealment? Unclear No information.
Blinding?
Women and clinical staff
No Educational intervention.
Incomplete outcome data addressed?
All outcomes
Unclear 11% attrition overall but missing data for
some outcomes including smoking status.
Women lost to follow up included as con-
tinuing smokers in this review.
Free of selective reporting? Yes Extensive range of outcomes reported.
Free of detection bias? Yes Validated by salivary thiocyanate.
Solomon 1996
Methods A randomised trial of a smoking cessation intervention on women’s “stages of change” (
precontemplation, contemplation, preparation and action) in Vermont, USA. Dates of
study enrolment not specified.
Participants Low-income pregnant women enrolled in a state-supported service for uninsured and
under-insured women, receiving care in a large obstetric group practice. 521 women
smoking >= 1 cigarette/day at the onset of pregnancy enrolled, 349 (67%) completed
assessments at 1st, 2nd and 36 week visits. Mean cigarettes/day pre-pregnancy I = 22.8,
C = 23.6.
Interventions Control: 3minute physician-delivered protocol at first visit, acknowledging her smoking,
concerns re quitting or staying quit; strong recommendation to quit and a cessation
pamphlet designed for pregnant women.
Intervention: as control plus quit date or date to cut down set with on-site counselling,
10-30 minutes at 1st, 2nd, 3rd 5th and 36 week visits from trained obstetric nurse:
encouragement and reinforcement of small changes, problem solving around barriers to
cessation, and prevention of relapse, including dealing with other smokers, coping with
the urge to smoke, withdrawals symptoms, weight gain, eliciting support for quitting.
Intensity rating: I - 4, C - 2.
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Solomon 1996 (Continued)
Outcomes Shifts in ’stage of change’ at 2nd visit and 36 weeks’ gestation.
No smoking cessation data to include in tables.
Notes Comment made that stages of change at the first visit are not sustained.
“Enthusiasm for behaviour change may wane towards the end of the gestational period
when attention may be focused on labour
and delivery”.
Pattern of ’stages’ at first visit different from community-based studies, i.e. more women
were in the later stages than would be expected at the study onset.
No difference in late pregnancy.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as “randomised”.
Allocation concealment? Unclear No information.
Blinding?
Women and clinical staff
No Caregivers not blinded to this educational
intervention.
Incomplete outcome data addressed?
All outcomes
No 33% attrition for questionnaire follow up.
Not clear if loss was balanced across groups.
Smoking outcomes not reported.
Free of selective reporting? Unclear Several outcomes not reported in this pa-
per.
Free of detection bias? Unclear Smoking outcomes not reported.
Solomon 2000
Methods Trial of proactive telephone peer support in a large obstetric practice in Burlington,
Vermont, USA, 1996-7.
Participants Women reporting smoking at least 1 cigarette in the past week at their first antenatal visit,
were approached. Refusal rate = 19%. Women tended to be white, English speaking,
and of lower income and education. No exclusion criteria specified. Control n = 74,
intervention n = 77. Mean cigarettes/day before pregnancy I = 22.6, C = 20.2.
Interventions Control group received brief smoking cessation advice from a MW/Obst at each of the
3 prenatal visits and stage appropriate printed materials. MWs/Obst were provided with
a 45 minute training session. The intervention group received the same as the control
group plus they were offered telephone peer support from a female ex-smoker, who
received 8 hours of training who called the participant within several days to provide
support for positive changes in smoking behaviour. Intensity rating: I = 4, C = 3.
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Solomon 2000 (Continued)
Outcomes Self-reported abstinence at 28-34/40 gestation, defined as no smoking for the past 7
days, biochemically validated with urine cotinine measurement. Movement in stages of
change and proportion of smoking reduction by more than 50%.
Notes Process evaluation showed 53% received the peer intervention.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear States participantswere randomised into ei-
ther experimental or control condition.
Allocation concealment? Unclear No information.
Blinding?
Women and clinical staff
No Educational intervention by care providers.
Incomplete outcome data addressed?
All outcomes
Unclear Approximately 11% attrition at follow up.
Report that all were analysed according to
randomisation and drop-outs were treated
as continuing smokers.
Free of selective reporting? Unclear Only smoking outcomes reported.
Free of detection bias? Yes End of pregnancy urinary cotinine assess-
ment to confirm smoking status.
Stotts 2002
Methods Trial of individualized stage of change, motivational smoking cessation intervention (
“one-to-one”), with personalized feedback for “resistant” pregnant smokers, in 3 large
multispecialty clinics in Texas, USA. Enrolment over a 17 month period, dates not
specified.
Participants Women who continue to smoke at 28 weeks’ gestation, after having counselling and
8 self-help booklets earlier in pregnancy care. Inclusion criteria were women fluent in
English, over 18 years, over 20 weeks’ gestation at first an visit, and smoke more than
5 cigarettes per week prior to pregnancy. All women had group insurance. Eligibility
interview participation rate 97%. All eligible included in randomised sample (n = 269),
as data collection and implementation were adopted as routine procedures, and required
to formal written consent. Women in the intervention group had significantly higher
proportion of women smoking > 61 cigarettes/week before pregnancy (I = 57.9%, C =
43%) and a higher proportion of partners who smoke (I = 69.6%, C = 62.5%).
Interventions All women smoking at intake (< 20 weeks), were provided with MI counselling and
motivational self-help books, based on “stage of change” program shown to be effective
by Ershoff 1995. Women still smoking at 28 weeks were randomised to this study. The
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Stotts 2002 (Continued)
high intensity intervention group (and their partners) then received: a 20-30 min MI
telephone counselling call (conducted by trained counsellors and nurse health educators)
, a personalised, stages of change based feedback letter, and a final MI-base telephone
call conducted 4-5 days after the feedback letter was sent. Intensity rating: I = 4, C = 3.
Outcomes Self-reported smoking cessation at 34 weeks’ gestation, validated by an anonymous urine
cotinine subsample. Postpartum follow up (6 w, 3 m, 6 m) interview response rate 61%
(data collected from a separate survey, with financial incentives). Movement in “stages of
change”. Breastfeeding rates and general health behaviours obtained but not reported.
Notes Only 55% of the experimental group received the full intervention (32% were never
able to be reached). Implementation analysis suggested an effect in women who received
full implementation: 43% vs 34% control group. Discussion of provider views.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated random number list.
Allocation concealment? Unclear No details provided.
Blinding?
Women and clinical staff
Unclear Described as “single blind”. Cotinine
analysis performed blind but other care
providers and womenmay have been aware
of group allocation.
Incomplete outcome data addressed?
All outcomes
No 35% attrition for cotinine testing. 39% at-
trition for 6 weeks’ postpartum follow up.
All women lost to follow up for cotinine
validated smoking status at 36/40 were in-
cluded in this review as continuing smok-
ers.
Free of selective reporting? Unclear Only smoking outcomes reported.
Free of detection bias? Yes Urinary cotinine analysis for a subset of the
sample.
Strecher 2000
Methods Trial of personalised, computer generated, smoking cessation messages, in 2 university
hospitals in North Carolina & Michigan, USA, Dec 1996-97.
Participants Women who have “smoked 100 cigarettes in their lifetime and still smoking” or “had
quit since becoming pregnant”, completed a self-administered computer screening pro-
gram to determine eligibility (no details of inclusion or exclusion criteria). 173 women
participated. Mean cigarettes/day smoked before pregnancy I = 20.3, C = 18.7 (ns).
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Strecher 2000 (Continued)
Interventions Control group received “a pregnant woman’s guide to quit smoking” at the first visit.
The intervention group entered personal data into a hand-held computer at antenatal
visits, which subsequently generated personalized tailored messages, which were posted
to the woman. Intensity rating: I = 3, C = 1.
Outcomes Self-reported smoking cessation validated by urine cotinine at first visit, 24/40 and 6
weeks’ postpartum. Attrition rate 14% in control group, and 15.2% in experimental
group.
Notes Numbers in paper inconsistent: I = 88, C = 85 in methods section, I = 104, C = 87 in
results section. No justification for change of denominators.
Participant evaluation of using hand-held computers and reactions to computerised
materials.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes By computer algorithm.
Allocation concealment? Unclear Not described.
Blinding?
Women and clinical staff
No Caregivers not blinded to intervention.
Incomplete outcome data addressed?
All outcomes
No Figures are inconsistent. More than 30% of
the control group were lost to follow up.
Figures for the intervention group were not
clear.
Figures not consistent. Figures from results
used in analysis in this review.
Free of selective reporting? Unclear Results are conflicting.
Free of detection bias? Yes Urinary cotinine analysis at 24 weeks’ ges-
tation and at 6 weeks’ postpartum.
Tappin 2000
Methods Pilot study of home based motivational interviewing for smoking cessation in a Glasgow
Hospital, Scotland, March-May 1997.
Participants Self-reported women who identified as smokers on a questionnaire at antenatal clinic
booking. Participation rate 75%, 27 refused. (n = 100). Mean cigarettes/day pre-preg-
nancy I = 19.6, C = 18.1.
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Tappin 2000 (Continued)
Interventions The control group received usual advice from their prenatal providers, which should
include information about smoking. The intervention group received 2-5 motivational
interviewing sessions, based on stages of change, in the clients’ home conducted by a
midwife trained in smoking cessation counselling. High intensity intervention. Intensity
rating: I = 4, C = 2.
Outcomes Self-reported smoking cessation, at 27/40ormore, with urine cotinine validation in 93%.
Mean birthweight, preterm births. Ranking interviews measured movement around the
’cycle of change’.Detailed evaluationof participant andmidwifery views of interventions.
Attrition rate 2%.
Notes Good process evaluation of implementation quality according to Miller 2003’s rating
tool, showed 79% of women in the intervention group received at least 2 counselling
sessions, and less than20%of the control group recalled being given smoking information
at the time of booking.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomnumbers stratified by deprivation.
Allocation concealment? Yes Group allocation by telephone.
Blinding?
Women and clinical staff
No Midwife intervention.
Incomplete outcome data addressed?
All outcomes
Yes Low attrition. Some missing data for coti-
nine validation. Smoking outcome results
reported for all of those randomised.
Free of selective reporting? Yes Detailed outcomes reported.
Free of detection bias? Yes Serum cotinine levels measured.
Tappin 2005
Methods Randomised controlled trial of home-basedmotivational interviewing bymidwives. Trial
conducted in Glasgow, Scotland, from March 2001 to May 2003.
Participants Women were recruited from two hospitals.
Inclusion criteria: Pregnant smokers, less than 24 weeks’ gestation.
1684 women eligible, 762 consented to take part (55% refusal rate). I = 351, C = 411.
29 women lost to follow up due to termination, preterm birth, or unable to contact.
Attrition rate 2%.
Baseline characteristics similar in both groups.
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Tappin 2005 (Continued)
Interventions The control group received counselling from a midwife who had received counselling
training.Midwives provided standard health promotion including information on smok-
ing in pregnancy from a book given to all women in pregnancy in Scotland.
The intervention group also were offered 2-5 additional home visits of about 30 minutes
duration from the same study midwife.
Intensity of intervention: C = 3, I = 4
Theoretical basis: motivational interviewing and CBT
Outcomes Biochemically validated and self-reported quitting at end of pregnancy, reduction (mean
cotinine), birthweight. Data collected on adverse events including miscarriage, termi-
nation of pregnancy, preterm delivery, very low birthweight, neonatal death, assisted
delivery and admission to NICU.
Discussion of participant and provider views of intervention and thorough process eval-
uation showed good implementation.
Notes Sample size calculated by recruitment to achieve sufficient power not able to be achieved.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Stratified central randomisation.
Allocation concealment? Yes Group allocation provided by central ad-
ministrator.
Blinding?
Women and clinical staff
No Midwife intervention, with caregivers not
blinded.
Incomplete outcome data addressed?
All outcomes
Yes Low attrition. Some missing data for coti-
nine validation.
Results reported for all of those ran-
domised.
Free of selective reporting? Yes Detailed outcomes reported.
Free of detection bias? Yes Serum cotinine levels measured.
Thornton 1997
Methods Trial of smoking cessation counselling and information packs in a large public antenatal
clinic, in Rotunda Ireland, during 3 months in 1995.
Participants Inclusion criteria: women who currently smoke or had spontaneously quit since becom-
ing pregnant; have a viable pregnancy; and intend to deliver in the hospital. Intervention
group were less likely to have spontaneously quit, or be employed. Mean gestation at
first visit I = 15.5, C = 15.3. Number of daily cigarettes at intake: 1-9 I = 61, C = 54;
10-19 I = 74, C = 73; 20+ I = 68, C = 65.
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Thornton 1997 (Continued)
Interventions The control group completed a questionnaire at first visit, followed by routine prenatal
advice on a range of health issues, from midwives and obstetricians. The intervention
group received as for the control group + structured one to one counselling by a trained
facilitator (based on stages of change theory); partners invited to be involved in the
program; an information pack; and invited to join a stop smoking support group. A
carbon monoxide monitor was available for the intervention group, to quantify smoking
habit and act as a motivational tool. High intensity intervention. Intensity rating: I = 4,
C = 1 (not clear).
Outcomes Smoking cessation at delivery and 3 months postpartum, biochemically validated by
exhaled CO. Reduction in mean cigarettes/day, quit attempts, comparisons of quitters
and non quitters at various stages.
Infant outcomes (singleton births): delivery type, mean gestation, mean birthweight,
proportion LBW (2500 g), preterm births, NICU admissions, infant outcomes at 3
months.
Notes Good process analysis and participant feedback of program implementation. A high
baseline smoking prevalence rate (58.7%). Limited exhaled CO measurement on post-
natal ward.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Random number tables with restricted ran-
domisation in groups of ten.
Allocation concealment? Yes Sealed opaque envelopes.
Blinding?
Women and clinical staff
Yes Intervention provided by trained facilita-
tor, with staff unaware of allocation.
Incomplete outcome data addressed?
All outcomes
Yes Participation rate = 81% (n = 418). Low
attrition at delivery: I = 6.2%, C = 8.6%.
Women lost to follow up included as con-
tinuing smokers in this review.
Free of selective reporting? Yes All outcomes reported.
Free of detection bias? Yes Exhaled CO.
111Interventions for promoting smoking cessation during pregnancy (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Valbo 1991
Methods Quasi-randomised trial of smoking cessation interventions (allocation to 1 of 4 arms,
3 intervention and 1 control, by date of enrolment for care, with the four time blocks
assigned randomly) in women smoking at the time of the 18 week ultrasound scan, at a
regional hospital in Norway, 1988.
Participants 283 women reported current smoking and wanted to quit. (mean 9-11 cigarettes/day)
at the 18 weeks scan: 200 recruited, 50 in each arm. 1/3 receiving private obstetric care.
Interventions Control: not specified.
Intervention (i): information provided by a physician to women in groups of 10 about
the harmful effects of smoking on mother and child;
(ii) 2 page pamphlet mailed 3 weeks after the ultrasound scan, with information on the
harmful effects of smoking plus advice on how to quit;
(iii) smoking cessation group of 12 - 13 people; 5 x 2 hour meetings over 5 weeks,
offered a cognitive behaviour modification program, including self-monitoring, stimulus
control, response control, reinforcement control and maintenance strategies, run by a
clinical psychologist.
Intensity rating: I = 3 (variable), C = 0 (unclear).
Outcomes Smoking cessation and reduction assessed immediately after the intervention, biochem-
ically validated but not reported.
Notes Biochemical validation of smoking status using salivary thiocyanate was carried out but
not reported in the paper.
Doctor information group treated as ’control’ for the other interventions because of
minimal impact at either time.
Smoking assessed 12 months (96% response rate to questionnaire)after the intervention
showed sustained differences by allocation though more than half the quitters had re-
lapsed in the behaviour modification group.
Process evaluation showed 20% women attended only the first of the 6 group meetings,
and 12% of the women in the brochure group did not read them.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No Described as “randomly chosen by draw-
ing lots”. But recruitment to different arms
over 4 separate periods.
Allocation concealment? No Quasi- randomised design. 3 months re-
cruitment for each of 4 arms.
Blinding?
Women and clinical staff
No Group educational intervention.
Incomplete outcome data addressed?
All outcomes
Yes Low attrition. All drop-outs treated as con-
tinuing smokers.
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Valbo 1991 (Continued)
Free of selective reporting? Unclear Smoking outcomes only reported.
Free of detection bias? Unclear Salivary thiocyanate tested but results not
reported.
Valbo 1994
Methods Quasi-randomised trial of cognitive-behavioural modification, (using RAWindsor’s self-
help manual translated into Norwegian)to promote smoking cessation in women smok-
ing heavily at the time of the 18 week ultrasound scan, in Oslo, Norway, 1990-1991.
Participants Pregnant women attending the National University Hospital Oslo at 18 weeks for ultra-
sound, and smoking 10 cigarettes/day. No exclusion criteria mentioned and no refusals.
112 women recruited (1800 births/year, study over 15 months). Pre-pregnancy mean
cigarettes/day: I = 8, C = 11.
Interventions Control: information on the negative effects of smoking and encouragement to quit,
reinforced by a pamphlet, provided at the time of the ultrasound examination.
Intervention: offered the Windsor self-help manual describing a 10 day program, 2
weeks later reminder. Letter and encouragement and appointment for 32 week scan with
reinforcement at the 32 weeks scan and 2 weeks later a further letter.
Both intervention and control information were provided by obstetrician or midwife.
Intervention intensity: I = 4, C = 2.
Outcomes Smoking cessation and reduction in late pregnancy. No biochemical validation.
Notes Evidence is provided for an increase in smoking compared with 18 weeks, especially in
the control group.
Process evaluation suggested that the acceptance of the manual was low (mean score 2.6
on 7 point scale) and that it was staff involvement which had the most impact.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No Described as “consecutively randomised”.
Allocation concealment? No Women consecutively randomised into 2
groups.
Blinding?
Women and clinical staff
No Educational intervention and ultrasound.
Incomplete outcome data addressed?
All outcomes
Unclear Attrition approximately 10%. All drop-
outs included in analysis as continuing
smokers.
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Valbo 1994 (Continued)
Free of selective reporting? Unclear Only smoking outcomes reported.
Free of detection bias? No No biochemical validation and difference
in smoking rates between groups at base-
line.
Valbo 1996
Methods Randomised trial of hypnosis for smoking cessation and reduction among women still
smoking at the time of the 18 week ultrasound scan in a Norwegian hospital, 1990-
1993.
Participants Women were offered participation if still smoking at 18 week ultrasound visit, (after
explanation including potential allocation to control) and then randomised after signing.
Expected numbers of women in the recruitment period were 630, 158 (25%) agreed to
participate. Of 80 allocated to intervention 13 did not receive an appointment in time,
15 did not attend leaving 52. Mean cigarettes/day prior to pregnancy I = 15.6, C = 15.0.
Interventions Control: “routine pregnancy health care”.
Intervention: anaesthesiologist provided 2 x 45 minute sessions at 2 week interval of
a protocol-based script (Handbook of the American Society of Clinical Hypnosis); the
tape played after hypnosis was established emphasised the unpleasant effects of smoking,
affirmed her wish to quit, encouraged her will and capacity to quit, and instructed her
in meeting cravings with relaxation techniques and self-hypnosis, explained during the
session. Second visit tape was different with more weight on her capacity and taking
control. Both tapes avoided “moralizing about her responsibility for pregnancy outcome”.
Intensity rating: I = 4, C = 1 (not clear).
Outcomes Self-reported smoking cessation, reduction (mean cigarettes/day, the standard deviation
used in the analysis in this review was calculated from a P value = 0.2 given in the paper)
and increase at end of pregnancy, not biochemically validated.
Perinatal deaths.
Notes Process evaluation did not rate the intervention highly: mean score of 2.05 on a 7 point
scale.
Norway.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Random numbers.
Allocation concealment? Unclear Women allocated to groups by drawing lots
(it was not clear when this took place).
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Valbo 1996 (Continued)
Blinding?
Women and clinical staff
Unclear Psychological intervention, authors state
that usual caregivers were not aware of
group allocation.
Incomplete outcome data addressed?
All outcomes
No High levels of attrition in the intervention
group. Intention to treat analysis for the
main outcome (smoking cessation).
Free of selective reporting? Unclear Only smoking outcomes reported.
Free of detection bias? No No biochemical validation. Only 25% of
those eligible agreed to participate.
Walsh 1997
Methods Trial of a structured, cognitive-behavioural, smoking cessation program for pregnant
women delivered by UC providers in a public hospital antenatal clinic in Newcastle,
Australia, 1990-1991.
Participants 1909 pregnant women were screened at the first visit (approximately 12 weeks’ gestation)
. Classified as a smoker if they answered yes to the question “Are you a smoker?”: 725
smokers (38%), - 187 ineligible > 26 weeks, - 47 too ill or disturbed, -11 other reasons
left 538. 293 agreed to take part. 7 (I) + 7 (C) withdrew, 10 + 10 had a miscarriage or
termination, 4 + 3 gave birth preterm, leaving 125 + 127. Baseline smoking data not
specified.
Interventions Control: doctor and Midwife both informed women that smoking was an important
cause of pregnancy problems and they should stop; Midwife provided a package (sticker,
pamphlet on risks of smoking and 2 page cessation guide), none of whichwere specifically
tailored to pregnant women.
Intervention based on CBT: (i) 2-3 minute standardised risk information from Doctor
plus 14 minute video on risk information rebuttal of barriers to quitting, cessation tips
and 10 minute standardised information and counselling fromMidwife after the video,
using a flip chart, with negotiation of a quit date whenever possible and self-helpmanual
on risks, barriers and cessation plus 4 packets of confectionary gum and lottery chance
(4 prizes) for biochemically validated abstainers at the next visit, plus social support
from accompanying adult (partner/friend/other) via support tip sheet, contract and form
letter, chart, reminder sticker in the medical record, form-letter and sticker from 1st visit
Midwife mailed within 10 days + 2nd visit and 34 to 36 week visit 5 minute counselling
from Midwife and 1-2 minute risk advice from Doctor. Women still smoking at 34-36
weeks were advised to attend an external cessation course.
Intensity rating: I = 4, C = 2.
Outcomes Smoking status at mid and late pregnancy and 6-12 weeks’ postpartum, biochemically
validated with salivary cotinine (I = 86%, C = 78%).
Discussion of provider views.
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Walsh 1997 (Continued)
Notes Midwives involved in recruitment to the trial had variable ’success’.
Overall participation was quite low (54%).
Cotinine data inconsistent with self-report were 52% in controls and 12% in the inter-
vention group.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated.
Allocation concealment? Yes Described as “precoded questionnaires in
manila envelopes”.
Blinding?
Women and clinical staff
No Educational intervention by UC providers
and notes flagged.
Incomplete outcome data addressed?
All outcomes
No Consent rates for different midwives very
varied (9%-76%). 25% lost to follow up
and further missing data for some vari-
ables including cotinine validation. Those
with missing data were treated as continu-
ing smokers in the analysis.
Free of selective reporting? Unclear Only smoking outcomes reported.
Free of detection bias? Yes Urinary cotinine was measured and
revealed discrepancy with self-reported
smoking status.
Windsor 1985
Methods A randomised trial, comparing the effectiveness of 2 smoking cessation interventions
with standard care, in public health clinics in Birmingham, Alabama, USA 1983-1984.
Participants 1838 pregnant women were screened, 460 current smokers (“>= 1 cigarette in the last 7
days”), -30 antenatal care entry >= 32 weeks, -9 left system or moved, -10 miscarriage or
termination -10 went to group discussions (this intervention abandoned), leaving 102
I1), 103 (I2) and 104 (SC). No baseline data on cigarettes/day.
Interventions Control: 2-3 minutes within a group prenatal education session at the 1st visit, when
maternity clinic staff recommend quitting.
I1: 10 minute standardised counselling session from a health educator (B CommH Ed)
+ Am Lung Assoc “Freedom from smoking” (ALA) manual (17 day self-directed plan for
quitting) + “Because you love your baby” pamphlet on the dangers and risk of smoking
and the benefits of quitting.
I2: as for I1 except that the manual was “A pregnant woman’s self-help guide to quit
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Windsor 1985 (Continued)
smoking” (instead of the ALA manual).
Intensity rating: I = 3, C =1.
Outcomes Smoking cessation or reduction (by 30% cotinine levels), biochemically validated by
salivary thiocyanate, at mid-pregnancy and within 48 hours of birth.
Notes “Multiple attempts were made to bring pregnant smokers together for a peer-led, focused
group discussion: not feasible in this setting”.
Pre-trial assessment showed no nurses (n = 80) had smoking cessation training and less
than 20% felt confident to advise women on how to stop.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated.
Allocation concealment? Unclear No information provided.
Blinding?
Women and clinical staff
No Educational intervention by health educa-
tors in antenatal clinics.
Incomplete outcome data addressed?
All outcomes
Unclear 15% lost to follow up. Women lost to fol-
low up were treated as continuing smokers.
Free of selective reporting? Unclear Only smoking outcomes reported.
Free of detection bias? Yes Salivary cotinine measured.
Windsor 1993
Methods Trial of an enhanced cognitive behaviour therapy intervention, to assist in smoking
cessation and smoking reduction during pregnancy inwomen attending publicmaternity
clinics at a large hospital in Birmingham, Alabama, USA, 1986-91.
Participants 4352 pregnant women screened at approximately 4 weeks’ gestation, 1381 (31.7%)
reported smoking at conception, 1171 current smokers (smoked 1 cigarette even a puff
in the last 7 days), -110 ineligible by entry to care > 32 weeks, did not complete first visit,
did not return, in earlier trial, prisoner reading level too poor, leaving 1061 of whom 67
refused leaving 493 (I) and 501 (C), -93 + 87 miscarriage, termination or withdrawal
from public care, leaving 400 (I) + 414 (C). NS difference in baseline cotinine.
Interventions Control: 2 minute talk in 30 minute group session at first antenatal visit in which women
were urged to quit and given 2 pamphlets: “Smoking and the two of you”’+ “Where to
find help if you want to stop” including the name, contact phone number and cost of
their local program.
Intervention based on cognitive behaviour therapy: 15 minute standardised cessation
skills and risk counselling session from trained female health education counsellor + 7 day
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Windsor 1993 (Continued)
self-directed cessation guide on how to quit written at 6th Grade level + reinforcement
(chart sticker) + letter from Doctor within 7 days + ’buddy’ letter, contract and tip sheet
+ monthly newsletter with testimonials, cessation tips and additional information on
risks.
Intensity rating: I = 4, C = 2.
Outcomes Smoking cessation at 32 weeks’ gestation and postpartum, biochemically validated with
salivary thiocyanate. “Significant” reduction.
Notes Separate paper on spontaneous quitters (Lowe 1997).
All those lost to follow up were counted as continuing smokers.
Data on gestation andbirthweightwere collected but the published analysis is by stopping
smoking and the timingof cessation rather thanby allocation, so not included in outcome
tables.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated.
Allocation concealment? Unclear Not reported.
Blinding?
Women and clinical staff
No Notes flagged. Educational intervention.
Incomplete outcome data addressed?
All outcomes
Unclear 18% attrition due withdrawal from the ser-
vice, miscarriage or abortion not included
in analysis.
15% lost to follow up survey or cotinine
analysis included as continuing smokers in
this review.
Free of selective reporting? Unclear Only smoking outcomes reported.
Free of detection bias? Yes Saliva samples analysed.
Windsor 2000a
Methods Evaluation trial of behavioural impact of new patient education methods (“SCRIPT”)
, provided by trained Medicaid maternity care staff members, in Alabama, USA, 1997-
2001, from 17 eligible counties at 22 urban prenatal care clinics.
Participants Inclusion criteria: smoker (1 puff in last 30 days), less than 27 weeks pregnant, access to
a telephone, English or Spanish speaking.
Both groups smoked approximately 10 cigarettes/d at baseline.
Participation rate = 57%.
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Interventions Women screened at first visit (9 - 12weeks’ gestation)for self-reported smoking, validated
by salivary cotinine (n = 1065), who were randomised to one of 3 treatment groups.
2 separate phases: participation rate phase one (1997) = 95% (n = 93), phase 2 (1998)
participation rate = 60% (n = 172).
Phase one and 20% phase 2 group combined to form control group (n = 126), which
received only self-help materials.
80% phase 2 group (n = 139) formed intervention group 2 who received the quit kit
and were enrolled in a monetary incentive lottery.
Group 3 received the quit kit, the lottery program and up to three motivational in-
terviewing calls. A subsequent paper report 358 persons in this group, which does not
correlate with the original paper trial reports.
Nurses, social workers and WIC administrators received orientation sessions. Trained
motivational interviewing counsellors provided the intervention.
Intervention intensity: I = 4, C = 3.
Outcomes Self-reported smoking status at 60 days after first visit, validated by salivary and urinary
cotinine. Significant (> 50%) reduction in baseline cotinine (harm reduction measures).
Number of quit attempts reported, and aggregated by number of calls received. Attrition
rate 13% (n = 34), counted as smokers.
Subsequent paper assesses cost effectiveness, as “cost per quitter”.
Notes Mixture of RCT/sequential study with main control group being recruited in phase
one of the study to identify representative sample, and small additional control group
recruited in phase 2 with the intervention group. Good process evaluation showed nearly
100% experimental group received the intervention, confirming the feasibility of routine
delivery by regular staff.
An associated reference details formative evaluation of the intervention materials.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No Quasi-randomised design with 80% of the
control group not randomly assigned.
Allocation concealment? No Many of the control group were historical
controls.
Blinding?
Women and clinical staff
No Notes flagged.
Incomplete outcome data addressed?
All outcomes
Unclear 13% not available to follow up. Those lost
to follow up treated as continuing smokers
(but many in control group not randomly
allocated).
Free of selective reporting? Unclear Only smoking outcomes reported.
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Windsor 2000a (Continued)
Free of detection bias? Yes Salivary cotinine measured.
Wisborg 2000
Methods Double-blind, placebo controlled trial of nicotine replacement therapy (patches) in preg-
nant women in a Danish obstetric hospital.
Participants Healthy women less than 22 weeks’ gestation who smoked more than 10 cigarettes per
day after the first trimester, were invited to participate n = 611. Participation rate 41%
(n = 250).Mean cigarettes per day at intake I:n = 13.4, C: n = 14.2.
Interventions Both groups received strong smoking cessation advice and counselling from a midwife,
reinforced with printed materials. The control group received a placebo patch. The
intervention group received 16 hour 15 mg nicotine patches for 8 weeks and 10 mg for
3 weeks.
Intensity rating I - 4 C - 3.
Outcomes Self-reported abstinence of at least 7 days at 2nd, 3rd, and 4th prenatal visits, validated
by salivary cotinine measurement.
Reduction in mean cigarettes per day (the standard deviation used in the analysis in this
review was calculated from a P value = 0.59 given in the paper). Telephone follow up at
3 and 12 months postpartum (self-report).
Mean birthweight, low birthweight (<2500 g), preterm delivery.
Notes Very low recruitment, with non-participants smoking more cigarettes per day. Low com-
pliance with treatment (28% in NRT group and only 7-8% in the placebo group) who
may have guessed allocation. Limited details on 3 months and 1 year follow up.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation list in balanced blocks.
Allocation concealment? Yes Placebo controlled trial with allocation
coded until the end of data collection.
Blinding?
Women and clinical staff
Yes Double blind placebo controlled study.
Incomplete outcome data addressed?
All outcomes
Unclear Small loss to follow up but 13% missing
data for smoking outcomes.
Where data were missing women were
treated as smokers.
Free of selective reporting? Yes Appears that adverse outcomes and birth
outcomes are reported.
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Free of detection bias? Yes Salivary cotinine analysis.
AFP: alpha fetoprotein
ALA: American lung association
AN: antenatal
BP: blood pressure
C: control group
CBT: cognitive behavioral therapy
CO: carbon monoxide
GP: general practitioner
HMO: Health Maintenance Organisation
I: intervention group
ITT:intention to treat
LBW: low birthweight
MI: motivational interviewing
min: minutes
MRFIT: randomised trial of health promotion carried out in the US
MW: midwife
NICU: neonatal intensive care unit
NRT: nicotine replacement therapy
OPD: out-patient department
Pls: principal investigators
ppm: parts per million
PPROM: preterm, prelabour rupture of the membranes
sae: stamped addressed envelope
ses: socioeconomic status
SHO: senior house officer
TFS: teen fresh start
TFSB: teen fresh start + peer support
UC: usual care
WIC: Food program for Women, Infants and Children in the US
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Characteristics of excluded studies [ordered by study ID]
Albrecht 2006 Outcome data not reported in format to include in meta-analysis. No reply from authors to request for
numerical outcome data.
Boshier 2003 Cohort study, not a randomised study design.
Britton 2006 Quasi-experimental design. Control and experimental convenience samples collected consecutively.
Byrd 1993 There are no data provided by trial allocation.
Chan 2005 Controlled observational study of Bupropion for smoking cessation in pregnancy.
Cook 1995 Abstract reports interim findings (outcomes for 43/151 patients at time of publication)of trial of discussion of
smoking risks by physician and nutritionist in Louiseville, USA.No further results published and no response
to letter to author in 2008 requesting final data.
Cope 2001 This paper described an observational study looking at the validity of self-reported smoking measures in
pregnancy and the relationship of reported smoking levels on blood parameters.
Culp 2007 Controlled trial/evaluation of “The Community-Based Family Resource and Support” (CBFRS) Program.
Control group not randomised.
Emmons 2000 Controlled trial/evaluation of the “Healthy Baby Second Hand Smoke Study” uses historical controls. Good
documentation of implementation problems.
Ershoff 1983 The intervention took place in one HMO clinic with historical controls from the same clinic and concurrent
controls from a second clinic. There was no randomisation of clinics and no adjustment of the data for
clustering.
Ferreira-Borges 2005 Pre-test post-test control group design (not randomised).
French 2007 Controlled clinical trial of postpartum relapse prevention. Excluded as not a trial during pregnancy, and not
randomised.
Gebauer 1998 Study of effect of one 15 minute counselling session and a follow-up telephone call, performed 1994-95,
using historical controls from 1993-1994.
Gillies 1987 In this controlled clinical trial the intervention was carried out in 1 hospital with another hospital in the same
city acting as a control, after a prior descriptive study which showed the similarity between the 2 in terms
of social and demographic factors including smoking. There was no randomisation and recruitment differed
substantially across the 2 sites. Data for smoking reduction and smoking cessation are combined in the paper
with no separate data on cessation and no adjustment for clustering.
Graham 1992 Although the multicomponent intervention included a smoking change component there are no smoking
data in the paper.
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Grange 2005 Cohort study design.
Hahn 2005 Controlled trial with a volunteer sample of contest registrants, compared with a randomly selected group of
smokers not exposed to the campaign/contest. Context registrants not randomised and there is evidence of
differences between groups.
Haug 1994 General practitioners, rather than individual women, were randomly allocated to provide the intervention or
not. There was no adjustment for cluster randomisation in the analysis of the study findings.
Haug 2004 Actual outcome smoking cessation figures are not reported. No reply from author to written request for
outcome data.
Heil 2003 Non-pregnant population.
Hiett 2000 Insufficient recruitment data in abstract to include in meta-analysis. No reply to letter sent to author for
andditional information in 2008.
Hughes 2000 Insufficient outcome data reported for meta-analysis
Hymowitz 2006 Postpartum trial only which measures paediatrician implementation of smoking cessation and relapse pre-
vention interventions.
Jaakola 2001 Controlled study, not randomised, of effects of a population-based smoking cessation program and its impact
on smoking in pregnancy. Controls were matched on inclusion criteria from another district.
Kaper 2006 Non-pregnant population.
Kientz 2006 Pretest post test control group design (not randomised).
Langford 1983 Prenatal classes, rather than individual women, were randomly allocated to provide the intervention or not.
The intervention was provided in late pregnancy with no outcome data collected during pregnancy but only
data four months after birth. There was no adjustment for cluster randomisation in the analysis of the study
findings.
Lillington 1995 Four WIC clinics in Los Angeles were matched and randomised within pairs to intervention or control status.
There was no adjustment for clustered data. All those not contacted at postpartum visit (28%) were excluded
even though they should be counted as smokers; their allocation is not stated so adjustment cannot be made
for this. There was significant misclassification of self-reported non-smoking status and 44% did not provide
a sample for cotinine analysis so that verified non-smoking cannot be calculated.
Loke 2005 Intervention aimed at smoking cessation in men (husbands of pregnant women).
Lowe 2002 Data are available onuptake of programs at a hospital level but not at present on smoking cessation effectiveness
or perinatal outcomes.
Messimer 1989 Primary care practices, rather than individual women, were randomly allocated to provide the intervention
or not. There was no adjustment for cluster randomisation in the analysis of the study findings.
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Moore 1998 Not specifically a smoking cessation trial. Data does not include the proportion of smokers which continue
to smoke after the intervention.
Mullen 1990 Data are provided on those who stopped smoking only, not data by trial allocation.
Mullen 1991 This was a study designed to test different ways of eliciting smoking behaviour information. In this randomised
trial a multiple choice format was compared with asking women whether or not they smoked. There was no
intervention to promote smoking cessation.
Mullen 1997 Study designed to promote postpartum smoking cessation (not antepartum).
Olds 1994 Outcome data on child development in this paper have been excluded because the multicomponent inter-
ventions being compared might have had effects on child development other than by a change in maternal
smoking.
Olds 2002 This 3 armed randomised controlled trial of home visiting by paraprofessionals and nurses was excluded as
it did not contain any quitting data, only urine cotinine measurements.
Oncken 2006 No control group without intervention of nicotine gum.
Power 1989 The intervention in this trial was unusual in that the focus was on anticipated benefits of smoking cessation
to women themselves (not on harm to the fetus and infant), and on alternative coping strategies, with
a designated midwife-facilitator to answer queries and provide friendly advice and encouragement. The
intervention was carried out in 1 hospital with another being a comparison setting, after a prior study which
showed the similarity between the 2 in social and demographic factors including smoking rates. There was
no randomisation. Recruitment differed significantly across the 2 hospitals. Data for smoking cessation and
smoking reduction are combined with no separate data on cessation and no adjustment for clustering.
Ratner 1999 Postpartum intervention only. No interventions in pregnancy.
Scott 2000 This controlled clinical trial of the impact of using interactive software to promote smoking cessation, was
excluded as it used historical controls.
Shakespeare 1990 Data on smoking reduction and smoking cessation are combined with no separate data on smoking cessation.
Stanton 2004 Intervention aimed at men (partners of pregnant women).
Stotts 2003 Brief conference abstract reporting on a study looking at stages of change. No separate results were reported
for women in the intervention and control groups.
Stotts 2004 Published data does not specify numbers in each of the control and intervention group, to enable extraction
of outcome data figures presented as a percentage.
Suplee 2004 Randomised trial of relapse prevention counselling in the postpartum period only (not pregnancy).
Thyrian 2006 Randomised trial of postpartum intervention only (not prenatal).
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Valanis 2001 This prospective controlled clinical trial design to test the effect of a low intensity intervention, used historical
controls.
Wadland 2007 Implementation trial to change provider behaviour and increase referrals to quitline. Estimated smoking
cessation outcome data only.
Wiggins 2004 Smoking cessation outcome data not included. Not specifically a smoking cessation trial.
Wisborg 1998 This randomised study of the effect of midwifery training on smoking cessation intervention implementation
and pregnancy outcomes, was excluded due to concerns about allocation concealment (clinic day allocation).
Yilmaz 2006 Postnatal intervention in pediatric setting.
HMO: Health Maintenance Organisation
WIC: Food program for Women, Infants and Children in the US
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Characteristics of studies awaiting assessment [ordered by study ID]
Blasco Oliete 2004
Methods Randomised clinical trial.
Participants Pregnant women smoking at least 1 cigarette each day attending 4 clinics in Madrid, Spain.
Interventions Brief counselling (3 to 5minutes) on smoking cessation compared with a group intervention over 3 half hour sessions.
Outcomes Not clear.
Notes Original article in Spanish.
Study report (2004) describes the study design. No papers including results have yet been identified.
Characteristics of ongoing studies [ordered by study ID]
Coleman 2007
Trial name or title UK Trial of nicotine replacement therapy (NRT) in pregnancy - “SNAP”.
Methods Double-blind, randomised, placebo-controlled trial in 5 east midland hospitals.
Participants Pregnant, nicotine-addicted women are recruited as they attend for antenatal ultrasound scans (12-24 weeks’
gestation). Women report smoking at lest 10 cigarettes before pregnancy and still smoke at least 5 cigarettes
daily. Min exhaled Co of 8 ppm.
Exclusion criteria: severe cardiovascular disease, unstable angina, cardiac arrhythmias, recent cerebrovascular
accident or TIA, chronic generalised skin disorders or known sensitivity to skin patches, chemical dependence/
alcohol addiction problems, major fetal anomalies, or unable to give informed consent.
Interventions Participants receive 8 weeks of treatment with either nicotine or placebo 16 hour transdermal patches,
accompanied by intensive behavioural support delivered by a research midwife, and follow up behavioural
support from NHS stop smoking services (for both intervention and control women).
Outcomes Biochemically validated smoking cessation immediately before childbirth.
Also: cost per smoker; validated smoking status at 1/12 post quit date, self-reported smoking status at 6/12
and 24/12 after birth, fetal loss, fetal and maternal morbidity.
Starting date 1 February 2006
Contact information Dr Tim Coleman, School of Community Services, University Hospital Nottingham.
tim.coleman@nottingham.ac.uk
Notes End date 31 January 2012
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El-Khorazaty 2007
Trial name or title Project DC-HOPE (NICH-DC Initiative)in Columbia, USA.
Methods Randomised controlled trial in 6 urban prenatal care clinics. Research staff were grouped into four teams,
with separation of recruits, intervention providers and assessors. Block randomisation (site and risk-specific)
to intervention and control group
Participants Pregnant women eligible if Washington residents, African American or Latino, at least 18 years of age, at 28
weeks’ gestation or less, and English speaking.
Interventions Multimodal integrated counselling and educational intervention which aims to reduce smoking and envi-
ronmental tobacco exposure. Intervention provided by a trained counsellor after the routine antenatal visit
and at 2 postpartum sessions. Individualised counselling targeting areas of risk identified using an “audio-
computer-assisted self-interview”.
Outcomes Cotinine validated cessation at end of pregnancy (end of pregnancy and 8-10 weeks’ postpartum), depression,
violence, prematurity, birthweight.
Starting date Recruitment 2001-2003. Follow up completed 2004.
Contact information Nabil El-Khorazaty nek@rti.org
Notes Author contacted 2008 - need to await publication of results.
Groff 2005
Trial name or title Ultrasound and motivational enhancement for prenatal smoking cessation.
Methods Randomised clinical trial to test efficacy of motivational enhancement therapy and feedback.
Participants Pregnant women delivering at 2 UT-Houston teaching hospitals, 15-28 weeks’ gestation and over 16 years
of age.
Interventions Participants randomised to 1 of 3 groups (best practice counselling; BP counselling + ultrasound; BP ultra-
sound + motivational enhancement counselling.
Outcomes Cotinine validated cessation at 34 weeks’ gestation and 6 weeks’ postpartum.
Starting date 2001
Contact information Janet Y Groff (Principal Investigator). University of Texas Medical School, Texas, 77030.
Notes National Center for Research Resources reports the study has been completed. No response to letter to
investigator sent in 2008.
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Lasater 2007
Trial name or title Reducing ETS exposure of pregnant women and newborns.
Methods Randomised 2-arm study in 6 prenatal clinics designed to develop and evaluate the efficacy of five tailored
DVDs in reducing exposure to ETS among low-income pregnant/postpartum women.
Participants Pregnant women who attend first prenatal visit by 16 weeks’ gestation who are exposed to tobacco smoke
daily. Exclusion criteria: women expecting complications or multiple births.
Interventions Provision of tailored DVDs to take home.
Outcomes Salivary cotinine concentration of mother and baby.
Starting date Feb 2006
Contact information Thomas M Lasater, Brown University, Rhode Island.
email: thomas˙lasater@brown.edu
Notes
Lopez 2005
Trial name or title Relapse prevention self-help intervention (“Forever Free” booklets) for pregnant and postpartum exsmokers.
Methods Randomised clinical trial.
Participants Pregnant women, 18 years or older, able to read and speak English, 4-8 months pregnant, smoked at least 10
cigarettes per day for at least 1 year prior to pregnancy, quit smoking because of pregnancy and have reported
no tobacco use in the previous 7 days.
Interventions Intervention is provision of mailed “Forever free for baby andme” booklets. The control group receive existing
materials from the National Cancer Institute and the American Cancer Society.
Outcomes 7 day point prevalence abstinence at end of pregnancy.
Starting date 5/1/2004
Contact information thomas.brandon@moffitt.org Tobacco Research and Intervention Program.
Notes No response from author in 2008.
Miller 2003
Trial name or title Bupropion SR for smoking cessation in pregnancy.
Methods Randomised, double-blind, placebo-controlled clinical trial.
Participants Pregnant smokers >13 weeks’ gestation meeting specific criteria.
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Miller 2003 (Continued)
Interventions 8 week intervention of conventional behavioural smoking cessation intervention, combined with either
placebo (control) or SR bupropion (intervention).
Outcomes Point prevalence abstinence and reduction. Intention to treat analysis conducted, but outcome for ITT
abstinence not reported in abstract.
Starting date
Contact information Hugh Miller 2003, University of Arizona, Tucson , AZ
Notes No response to letter to first author of abstract sent in 2008.
Patten 2006
Trial name or title Tobacco cessation treatment for Pregnant Alaska Natives.
Methods Randomised 2 group clinical trial.
Participants Pregnant women 18 years and above, Alaskan native, less than 24 weeks’ pregnant, self-reported use of tobacco
in past 7 days, planning to quit, have access to a telephone, access to a television and VCR.
Interventions Control group (n = 30) receive standard counselling and self-helpwrittenmaterials. Intervention group receive
standard counselling, plus 10-15 mins of culturally tailored counselling and a culturally tailored video.
Outcomes Self-reported cessation at 36 weeks’ gestation.
Starting date Nov 2006. Expected completion Nov 2007.
Contact information Christi Patten, Principal Investigator, Mayo clinic, Rochester, Minnesota, USA.
contact: hughes.christine@mayo.edu
Notes
Zhu 2004
Trial name or title Telephone intervention (California Smokers’ Helpline) or pregnant smokers.
Methods Randomised trial.
Participants Pregnant smokers who called the helpline for services.
Interventions Control group received a self-help quit kit of writtenmaterials, including the AmericanCancer Society booklet
for pregnant smokers. Intervention group received the quit kit plus up to 7 counselling calls.
Outcomes Self-reported smoking cessation in third trimester.
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Zhu 2004 (Continued)
Starting date
Contact information Shu-Hong Zhu 2004, University of California. szhu@ucsd.edu
Notes Author emailed 2008, advised that results would not be available until publication.
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D A T A A N D A N A L Y S E S
Comparison 1. Interventions for smoking cessation in pregnancy versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Continued smoking in late
pregnancy
65 21258 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.93, 0.96]
1.1 Individually randomised
trials
56 15915 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.92, 0.96]
1.2 Cluster-randomised trials 9 5343 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.94, 1.00]
2 Continued smoking in
pregnancy subgrouped by risk
of bias
64 21117 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.93, 0.96]
2.1 Low risk of bias (biochem
val + ITT +ad. rand.)
14 5691 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.94, 0.99]
2.2 Moderate risk of bias
(biochem val only)
35 11638 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.92, 0.97]
2.3 High risk of bias (no
biochem validation)
15 3788 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.87, 0.95]
3 Continued smoking in late
pregnancy by intensity of
intervention
65 21258 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.93, 0.96]
3.1 High intensity 44 14453 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.92, 0.96]
3.2 Medium intensity 18 5670 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.92, 0.98]
3.3 Low intensity 3 1135 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.83, 1.09]
4 Continued smoking in late
pregnancy subgrouped by main
intervention strategy
65 21257 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.93, 0.96]
4.1 Cognitive behaviour
strategies
30 9570 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.93, 0.97]
4.2 Stages of change 11 5073 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.97, 1.00]
4.3 Feedback 4 572 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.84, 1.02]
4.4 Rewards 4 1285 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.71, 0.81]
4.5 Pharmacotherapy (NRT,
Bupropion etc) nicotine
replacement therapy
5 1147 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.92, 0.98]
4.6 Other 11 3610 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.93, 0.98]
5 Continued smoking (relapse) for
spontaneous quitters in late
pregnancy
8 1064 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.75, 1.10]
6 Mean birthweight 21 15119 Mean Difference (IV, Random, 95% CI) 39.26 [15.77, 62.74]
7 Mean birthweight subgrouped
by main intervention strategy
21 15119 Mean Difference (IV, Random, 95% CI) 39.26 [15.77, 62.74]
7.1 Cognitive behavioural
therapy
9 3809 Mean Difference (IV, Random, 95% CI) 47.01 [12.22, 81.80]
7.2 Stages of change 2 1312 Mean Difference (IV, Random, 95% CI) -5.84 [-66.40,
54.72]
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7.3 Feedback 3 6611 Mean Difference (IV, Random, 95% CI) 47.80 [-14.67,
110.28]
7.4 Rewards 2 1008 Mean Difference (IV, Random, 95% CI) 123.98 [-1.92,
249.89]
7.5 Pharmacotherapy 3 1078 Mean Difference (IV, Random, 95% CI) 34.40 [-125.77,
194.58]
7.6 Other 2 1301 Mean Difference (IV, Random, 95% CI) 36.27 [-18.71,
91.25]
8 Low birthweight (under 2500 g) 16 9916 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.73, 0.95]
9 Very low birthweight (under
1500 g)
4 5496 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.69, 1.96]
10 Perinatal deaths 3 4335 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.72, 1.77]
11 Preterm birth (under 37 or
under 36 weeks)
14 11930 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.74, 0.98]
12 Stillbirths 6 4706 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.69, 1.76]
13 Neonatal deaths 3 4143 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.34, 4.01]
14 NICU admissions 4 1394 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.61, 1.18]
15 Smoking reduction: numbers
of women reducing smoking in
late pregnancy
13 Risk Ratio (M-H, Random, 95% CI) Subtotals only
15.1 Self-reported some
reduction in smoking (various
definitions)
5 1487 Risk Ratio (M-H, Random, 95% CI) 1.52 [1.29, 1.78]
15.2 Self-reported > 50%
reduction in smoking
3 779 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.91, 1.67]
15.3 Biochemically validated
reduction
5 1549 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.84, 1.91]
16 Smoking reduction:
biochemical measures in late
pregnancy
4 2511 Std. Mean Difference (IV, Random, 95% CI) -0.11 [-0.24, 0.02]
16.1 Mean cotinine levels 3 1742 Std. Mean Difference (IV, Random, 95% CI) -0.05 [-0.14, 0.05]
16.2 Mean thiocynate level 1 769 Std. Mean Difference (IV, Random, 95% CI) -0.29 [-0.44, -0.15]
17 Smoking reduction: self-
reported mean cigarettes per
day measured in late pregnancy
or at delivery
9 3372 Mean Difference (IV, Random, 95% CI) -0.67 [-1.49, 0.16]
18 Maintained smoking cessation
at 1-5 months postpartum
20 6097 Risk Ratio (M-H, Random, 95% CI) 1.65 [1.22, 2.24]
18.1 Individually randomised
trials
15 4726 Risk Ratio (M-H, Random, 95% CI) 1.43 [1.08, 1.91]
18.2 Cluster-randomised trials 5 1371 Risk Ratio (M-H, Random, 95% CI) 2.08 [0.78, 5.56]
19 Maintained smoking cessation
at 6 to 12 months postpartum
8 2624 Risk Ratio (M-H, Random, 95% CI) 1.39 [0.82, 2.38]
19.1 Individually randomised
trials
8 2624 Risk Ratio (M-H, Random, 95% CI) 1.39 [0.82, 2.38]
19.2 Cluster-randomised trials 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
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Analysis 1.1. Comparison 1 Interventions for smoking cessation in pregnancy versus control, Outcome 1
Continued smoking in late pregnancy.
Review: Interventions for promoting smoking cessation during pregnancy
Comparison: 1 Interventions for smoking cessation in pregnancy versus control
Outcome: 1 Continued smoking in late pregnancy
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Individually randomised trials
Albrecht 1998 23/26 53/58 0.97 [ 0.83, 1.14 ]
Baric 1976 54/63 45/47 0.90 [ 0.80, 1.01 ]
Bauman 1983 36/39 43/49 1.05 [ 0.92, 1.21 ]
Belizan 1995 196/255 207/237 0.88 [ 0.81, 0.96 ]
Bullock 1995 36/65 36/66 1.02 [ 0.74, 1.38 ]
Burling 1991 61/70 65/69 0.93 [ 0.83, 1.03 ]
Cinciripini 2000 39/42 35/40 1.06 [ 0.92, 1.23 ]
Cope 2003 142/164 112/116 0.90 [ 0.84, 0.96 ]
Donatelle 2000 78/112 99/108 0.76 [ 0.66, 0.87 ]
Dornelas 2006 38/53 47/52 0.79 [ 0.66, 0.96 ]
Dunkley 1997 46/50 50/50 0.92 [ 0.84, 1.01 ]
Ershoff 1989 93/126 96/116 0.89 [ 0.78, 1.02 ]
Ershoff 1999 106/131 105/126 0.97 [ 0.87, 1.09 ]
Gielen 1997 181/193 187/198 0.99 [ 0.94, 1.04 ]
Hartmann 1996 86/113 90/106 0.90 [ 0.79, 1.02 ]
Hegaard 2003 304/327 313/320 0.95 [ 0.92, 0.98 ]
Heil 2008 22/37 36/40 0.66 [ 0.50, 0.88 ]
Higgins 2004 19/30 21/23 0.69 [ 0.51, 0.94 ]
Hjalmarson 1991 398/444 198/209 0.95 [ 0.90, 0.99 ]
Hotham 2005 17/20 20/20 0.85 [ 0.70, 1.05 ]
Kapur 2001 13/17 13/13 0.78 [ 0.58, 1.03 ]
Lilley 1986 68/72 72/73 0.96 [ 0.90, 1.02 ]
Loeb 1983 435/477 447/486 0.99 [ 0.95, 1.03 ]
Lowe 1998a 108/111 113/116 1.00 [ 0.96, 1.04 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Lowe 1998b 40/44 34/34 0.91 [ 0.82, 1.01 ]
MacArthur 1987 449/493 464/489 0.96 [ 0.93, 0.99 ]
Malchodi 2003 51/67 59/75 0.97 [ 0.81, 1.16 ]
Mayer 1990 64/72 75/77 0.91 [ 0.83, 1.00 ]
McBride 1999 269/341 130/160 0.97 [ 0.89, 1.06 ]
O’Connor 1992 78/90 79/84 0.92 [ 0.84, 1.02 ]
Olds 1986 77/77 64/64 0.0 [ 0.0, 0.0 ]
Panjari 1999 443/476 506/537 0.99 [ 0.96, 1.02 ]
Petersen 1992 37/43 39/47 1.04 [ 0.87, 1.24 ]
Pollak 2007 105/122 58/59 0.88 [ 0.81, 0.95 ]
Price 1991 67/71 69/70 0.96 [ 0.90, 1.02 ]
Reading 1982 20/39 20/26 0.67 [ 0.46, 0.97 ]
Rigotti 2006 188/209 196/212 0.97 [ 0.92, 1.03 ]
Rush 1992 153/175 131/144 0.96 [ 0.89, 1.04 ]
Secker-Walker 1994 196/225 204/230 0.98 [ 0.92, 1.05 ]
Secker-Walker 1997 21/26 30/30 0.81 [ 0.67, 0.98 ]
Secker-Walker 1998 116/135 130/144 0.95 [ 0.87, 1.04 ]
Sexton 1984 296/463 393/472 0.77 [ 0.71, 0.83 ]
Solomon 2000 63/77 63/74 0.96 [ 0.83, 1.11 ]
Stotts 2002 91/134 89/135 1.03 [ 0.87, 1.22 ]
Strecher 2000 94/104 79/87 1.00 [ 0.91, 1.09 ]
Tappin 2000 46/48 47/49 1.00 [ 0.92, 1.09 ]
Tappin 2005 334/351 392/411 1.00 [ 0.97, 1.03 ]
Thornton 1997 186/209 185/209 1.01 [ 0.94, 1.08 ]
Valbo 1991 31/50 47/50 0.66 [ 0.53, 0.83 ]
Valbo 1994 45/56 54/56 0.83 [ 0.73, 0.96 ]
Valbo 1996 47/52 70/78 1.01 [ 0.90, 1.13 ]
Walsh 1997 110/127 118/125 0.92 [ 0.85, 0.99 ]
Windsor 1985 88/102 102/104 0.88 [ 0.81, 0.95 ]
Windsor 1993 343/400 379/414 0.94 [ 0.89, 0.98 ]
Windsor 2000a 115/139 116/127 0.91 [ 0.83, 0.99 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Wisborg 2000 103/124 108/126 0.97 [ 0.87, 1.08 ]
Subtotal (95% CI) 8178 7737 0.94 [ 0.92, 0.96 ]
Total events: 6965 (Treatment), 7033 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 150.92, df = 54 (P<0.00001); I2 =64%
Test for overall effect: Z = 6.73 (P < 0.00001)
2 Cluster-randomised trials
Campbell 2006 87/98 90/96 0.95 [ 0.87, 1.03 ]
DeVries 2006 47/58 68/73 0.87 [ 0.76, 1.00 ]
Hajek 2001 285/365 293/367 0.98 [ 0.91, 1.05 ]
Kendrick 1995 774/822 998/1063 1.00 [ 0.98, 1.03 ]
Lawrence 2003 572/611 274/284 0.97 [ 0.94, 1.00 ]
McLeod 2004 133/163 96/109 0.93 [ 0.84, 1.02 ]
Moore 2002 435/523 459/567 1.03 [ 0.97, 1.09 ]
Pbert 2004 21/26 16/18 0.91 [ 0.71, 1.17 ]
Polanska 2004 35/62 32/38 0.67 [ 0.52, 0.87 ]
Subtotal (95% CI) 2728 2615 0.97 [ 0.94, 1.00 ]
Total events: 2389 (Treatment), 2326 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 19.91, df = 8 (P = 0.01); I2 =60%
Test for overall effect: Z = 1.78 (P = 0.075)
Total (95% CI) 10906 10352 0.94 [ 0.93, 0.96 ]
Total events: 9354 (Treatment), 9359 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 180.06, df = 63 (P<0.00001); I2 =65%
Test for overall effect: Z = 7.02 (P < 0.00001)
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Analysis 1.2. Comparison 1 Interventions for smoking cessation in pregnancy versus control, Outcome 2
Continued smoking in pregnancy subgrouped by risk of bias.
Review: Interventions for promoting smoking cessation during pregnancy
Comparison: 1 Interventions for smoking cessation in pregnancy versus control
Outcome: 2 Continued smoking in pregnancy subgrouped by risk of bias
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Low risk of bias (biochem val + ITT +ad. rand.)
Hotham 2005 17/20 20/20 0.6 % 0.85 [ 0.70, 1.05 ]
Lawrence 2003 572/611 274/284 3.0 % 0.97 [ 0.94, 1.00 ]
Malchodi 2003 51/67 59/75 0.7 % 0.97 [ 0.81, 1.16 ]
McLeod 2004 133/163 96/109 1.5 % 0.93 [ 0.84, 1.02 ]
Moore 2002 435/523 459/567 2.4 % 1.03 [ 0.97, 1.09 ]
Pollak 2007 99/122 52/59 1.1 % 0.92 [ 0.81, 1.05 ]
Rigotti 2006 188/209 196/212 2.3 % 0.97 [ 0.92, 1.03 ]
Stotts 2002 91/134 89/135 0.8 % 1.03 [ 0.87, 1.22 ]
Tappin 2000 46/48 47/49 1.8 % 1.00 [ 0.92, 1.09 ]
Tappin 2005 334/351 392/411 3.0 % 1.00 [ 0.97, 1.03 ]
Walsh 1997 110/127 118/125 1.9 % 0.92 [ 0.85, 0.99 ]
Windsor 1985 88/102 102/104 1.8 % 0.88 [ 0.81, 0.95 ]
Windsor 1993 343/400 379/414 2.6 % 0.94 [ 0.89, 0.98 ]
Wisborg 2000 103/124 108/126 1.4 % 0.97 [ 0.87, 1.08 ]
Subtotal (95% CI) 3001 2690 25.0 % 0.97 [ 0.94, 0.99 ]
Total events: 2610 (Treatment), 2391 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 20.29, df = 13 (P = 0.09); I2 =36%
Test for overall effect: Z = 2.96 (P = 0.0031)
2 Moderate risk of bias (biochem val only)
Albrecht 1998 23/26 53/58 0.8 % 0.97 [ 0.83, 1.14 ]
Bauman 1983 36/39 43/49 1.0 % 1.05 [ 0.92, 1.21 ]
Burling 1991 61/70 65/69 1.4 % 0.93 [ 0.83, 1.03 ]
Campbell 2006 87/98 90/96 1.7 % 0.95 [ 0.87, 1.03 ]
Cinciripini 2000 39/42 35/40 1.0 % 1.06 [ 0.92, 1.23 ]
Cope 2003 142/164 112/116 2.1 % 0.90 [ 0.84, 0.96 ]
Donatelle 2000 78/112 99/108 1.0 % 0.76 [ 0.66, 0.87 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Dornelas 2006 38/53 47/52 0.6 % 0.79 [ 0.66, 0.96 ]
Ershoff 1989 93/126 96/116 1.1 % 0.89 [ 0.78, 1.02 ]
Ershoff 1999 106/131 105/126 1.3 % 0.97 [ 0.87, 1.09 ]
Gielen 1997 181/193 187/198 2.6 % 0.99 [ 0.94, 1.04 ]
Hajek 2001 285/365 293/367 2.0 % 0.98 [ 0.91, 1.05 ]
Hartmann 1996 86/113 90/106 1.1 % 0.90 [ 0.79, 1.02 ]
Hegaard 2003 304/327 313/320 2.9 % 0.95 [ 0.92, 0.98 ]
Heil 2008 22/37 36/40 0.3 % 0.66 [ 0.50, 0.88 ]
Higgins 2004 19/30 21/23 0.3 % 0.69 [ 0.51, 0.94 ]
Hjalmarson 1991 398/444 198/209 2.7 % 0.95 [ 0.90, 0.99 ]
Kapur 2001 13/17 13/13 0.3 % 0.78 [ 0.58, 1.03 ]
Kendrick 1995 774/822 998/1063 3.2 % 1.00 [ 0.98, 1.03 ]
Lowe 1998a 108/111 113/116 2.7 % 1.00 [ 0.96, 1.04 ]
McBride 1999 269/341 130/160 1.6 % 0.97 [ 0.89, 1.06 ]
O’Connor 1992 78/90 79/84 1.6 % 0.92 [ 0.84, 1.02 ]
Panjari 1999 443/476 506/537 3.0 % 0.99 [ 0.96, 1.02 ]
Pbert 2004 21/26 16/18 0.4 % 0.91 [ 0.71, 1.17 ]
Petersen 1992 37/43 39/47 0.7 % 1.04 [ 0.87, 1.24 ]
Price 1991 67/71 69/70 2.3 % 0.96 [ 0.90, 1.02 ]
Rush 1992 153/175 131/144 2.0 % 0.96 [ 0.89, 1.04 ]
Secker-Walker 1994 196/225 204/230 2.1 % 0.98 [ 0.92, 1.05 ]
Secker-Walker 1997 21/26 30/30 0.6 % 0.81 [ 0.67, 0.98 ]
Secker-Walker 1998 116/135 130/144 1.8 % 0.95 [ 0.87, 1.04 ]
Sexton 1984 296/463 393/472 1.9 % 0.77 [ 0.71, 0.83 ]
Solomon 2000 63/77 63/74 1.0 % 0.96 [ 0.83, 1.11 ]
Strecher 2000 94/104 79/87 1.7 % 1.00 [ 0.91, 1.09 ]
Thornton 1997 186/209 185/209 2.1 % 1.01 [ 0.94, 1.08 ]
Windsor 2000a 115/139 116/127 1.6 % 0.91 [ 0.83, 0.99 ]
Subtotal (95% CI) 5920 5718 54.5 % 0.94 [ 0.92, 0.97 ]
Total events: 5048 (Treatment), 5177 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 114.51, df = 34 (P<0.00001); I2 =70%
Test for overall effect: Z = 4.65 (P < 0.00001)
3 High risk of bias (no biochem validation)
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Baric 1976 54/63 45/47 1.3 % 0.90 [ 0.80, 1.01 ]
Belizan 1995 196/255 207/237 1.8 % 0.88 [ 0.81, 0.96 ]
Bullock 1995 36/65 36/66 0.3 % 1.02 [ 0.74, 1.38 ]
DeVries 2006 47/58 68/73 1.0 % 0.87 [ 0.76, 1.00 ]
Dunkley 1997 46/50 50/50 1.7 % 0.92 [ 0.84, 1.01 ]
Lilley 1986 68/72 72/73 2.3 % 0.96 [ 0.90, 1.02 ]
Loeb 1983 435/477 447/486 2.8 % 0.99 [ 0.95, 1.03 ]
Lowe 1998b 40/44 34/34 1.4 % 0.91 [ 0.82, 1.01 ]
MacArthur 1987 449/493 464/489 2.9 % 0.96 [ 0.93, 0.99 ]
Mayer 1990 64/72 75/77 1.7 % 0.91 [ 0.83, 1.00 ]
Polanska 2004 35/62 32/38 0.4 % 0.67 [ 0.52, 0.87 ]
Reading 1982 20/39 20/26 0.2 % 0.67 [ 0.46, 0.97 ]
Valbo 1991 31/50 47/50 0.5 % 0.66 [ 0.53, 0.83 ]
Valbo 1994 45/56 54/56 1.0 % 0.83 [ 0.73, 0.96 ]
Valbo 1996 47/52 70/78 1.3 % 1.01 [ 0.90, 1.13 ]
Subtotal (95% CI) 1908 1880 20.5 % 0.91 [ 0.87, 0.95 ]
Total events: 1613 (Treatment), 1721 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 41.22, df = 14 (P = 0.00016); I2 =66%
Test for overall effect: Z = 4.30 (P = 0.000017)
Total (95% CI) 10829 10288 100.0 % 0.94 [ 0.93, 0.96 ]
Total events: 9271 (Treatment), 9289 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 175.52, df = 63 (P<0.00001); I2 =64%
Test for overall effect: Z = 6.90 (P < 0.00001)
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Analysis 1.3. Comparison 1 Interventions for smoking cessation in pregnancy versus control, Outcome 3
Continued smoking in late pregnancy by intensity of intervention.
Review: Interventions for promoting smoking cessation during pregnancy
Comparison: 1 Interventions for smoking cessation in pregnancy versus control
Outcome: 3 Continued smoking in late pregnancy by intensity of intervention
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 High intensity
Albrecht 1998 23/26 53/58 0.97 [ 0.83, 1.14 ]
Belizan 1995 196/255 207/237 0.88 [ 0.81, 0.96 ]
Bullock 1995 36/65 36/66 1.02 [ 0.74, 1.38 ]
Campbell 2006 87/98 90/96 0.95 [ 0.87, 1.03 ]
Cope 2003 142/164 112/116 0.90 [ 0.84, 0.96 ]
Donatelle 2000 78/112 99/108 0.76 [ 0.66, 0.87 ]
Dornelas 2006 38/53 47/52 0.79 [ 0.66, 0.96 ]
Ershoff 1999 106/131 105/126 0.97 [ 0.87, 1.09 ]
Gielen 1997 181/193 187/198 0.99 [ 0.94, 1.04 ]
Hajek 2001 285/365 293/367 0.98 [ 0.91, 1.05 ]
Hartmann 1996 86/113 90/106 0.90 [ 0.79, 1.02 ]
Hegaard 2003 304/327 313/320 0.95 [ 0.92, 0.98 ]
Heil 2008 22/37 36/40 0.66 [ 0.50, 0.88 ]
Higgins 2004 19/30 21/23 0.69 [ 0.51, 0.94 ]
Hotham 2005 17/20 20/20 0.85 [ 0.70, 1.05 ]
Kapur 2001 13/17 13/13 0.78 [ 0.58, 1.03 ]
Lawrence 2003 572/611 274/284 0.97 [ 0.94, 1.00 ]
Lilley 1986 68/72 72/73 0.96 [ 0.90, 1.02 ]
Loeb 1983 435/477 447/486 0.99 [ 0.95, 1.03 ]
Malchodi 2003 51/67 59/75 0.97 [ 0.81, 1.16 ]
McBride 1999 269/341 130/160 0.97 [ 0.89, 1.06 ]
McLeod 2004 133/163 96/109 0.93 [ 0.84, 1.02 ]
O’Connor 1992 78/90 79/84 0.92 [ 0.84, 1.02 ]
Olds 1986 77/77 64/64 0.0 [ 0.0, 0.0 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Panjari 1999 443/476 506/537 0.99 [ 0.96, 1.02 ]
Pbert 2004 21/26 16/18 0.91 [ 0.71, 1.17 ]
Polanska 2004 35/62 32/38 0.67 [ 0.52, 0.87 ]
Pollak 2007 99/122 52/59 0.92 [ 0.81, 1.05 ]
Rigotti 2006 188/209 196/212 0.97 [ 0.92, 1.03 ]
Rush 1992 153/175 131/144 0.96 [ 0.89, 1.04 ]
Secker-Walker 1994 196/225 204/230 0.98 [ 0.92, 1.05 ]
Secker-Walker 1998 116/135 130/144 0.95 [ 0.87, 1.04 ]
Sexton 1984 296/463 393/472 0.77 [ 0.71, 0.83 ]
Solomon 2000 63/77 63/74 0.96 [ 0.83, 1.11 ]
Stotts 2002 91/134 89/135 1.03 [ 0.87, 1.22 ]
Tappin 2000 46/48 47/49 1.00 [ 0.92, 1.09 ]
Tappin 2005 334/351 392/411 1.00 [ 0.97, 1.03 ]
Thornton 1997 186/209 185/209 1.01 [ 0.94, 1.08 ]
Valbo 1994 45/56 54/56 0.83 [ 0.73, 0.96 ]
Valbo 1996 47/52 70/78 1.01 [ 0.90, 1.13 ]
Walsh 1997 110/127 118/125 0.92 [ 0.85, 0.99 ]
Windsor 1993 343/400 379/414 0.94 [ 0.89, 0.98 ]
Windsor 2000a 115/139 116/127 0.91 [ 0.83, 0.99 ]
Wisborg 2000 103/124 108/126 0.97 [ 0.87, 1.08 ]
Subtotal (95% CI) 7514 6939 0.94 [ 0.92, 0.96 ]
Total events: 6346 (Treatment), 6224 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 118.47, df = 42 (P<0.00001); I2 =65%
Test for overall effect: Z = 5.83 (P < 0.00001)
2 Medium intensity
Baric 1976 54/63 45/47 0.90 [ 0.80, 1.01 ]
Burling 1991 61/70 65/69 0.93 [ 0.83, 1.03 ]
Cinciripini 2000 39/42 35/40 1.06 [ 0.92, 1.23 ]
DeVries 2006 47/58 68/73 0.87 [ 0.76, 1.00 ]
Dunkley 1997 46/50 50/50 0.92 [ 0.84, 1.01 ]
Ershoff 1989 93/126 96/116 0.89 [ 0.78, 1.02 ]
Hjalmarson 1991 398/444 198/209 0.95 [ 0.90, 0.99 ]
Kendrick 1995 774/822 998/1063 1.00 [ 0.98, 1.03 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Lowe 1998a 108/111 113/116 1.00 [ 0.96, 1.04 ]
Lowe 1998b 40/44 34/34 0.91 [ 0.82, 1.01 ]
Mayer 1990 64/72 75/77 0.91 [ 0.83, 1.00 ]
Moore 2002 435/523 459/567 1.03 [ 0.97, 1.09 ]
Petersen 1992 37/43 39/47 1.04 [ 0.87, 1.24 ]
Price 1991 67/71 69/70 0.96 [ 0.90, 1.02 ]
Secker-Walker 1997 21/26 30/30 0.81 [ 0.67, 0.98 ]
Strecher 2000 94/104 79/87 1.00 [ 0.91, 1.09 ]
Valbo 1991 31/50 47/50 0.66 [ 0.53, 0.83 ]
Windsor 1985 88/102 102/104 0.88 [ 0.81, 0.95 ]
Subtotal (95% CI) 2821 2849 0.95 [ 0.92, 0.98 ]
Total events: 2497 (Treatment), 2602 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 48.26, df = 17 (P = 0.00008); I2 =65%
Test for overall effect: Z = 3.44 (P = 0.00058)
3 Low intensity
Bauman 1983 36/39 43/49 1.05 [ 0.92, 1.21 ]
MacArthur 1987 449/493 464/489 0.96 [ 0.93, 0.99 ]
Reading 1982 20/39 20/26 0.67 [ 0.46, 0.97 ]
Subtotal (95% CI) 571 564 0.95 [ 0.83, 1.09 ]
Total events: 505 (Treatment), 527 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 5.67, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 0.69 (P = 0.49)
Total (95% CI) 10906 10352 0.94 [ 0.93, 0.96 ]
Total events: 9348 (Treatment), 9353 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 175.52, df = 63 (P<0.00001); I2 =64%
Test for overall effect: Z = 6.90 (P < 0.00001)
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Analysis 1.4. Comparison 1 Interventions for smoking cessation in pregnancy versus control, Outcome 4
Continued smoking in late pregnancy subgrouped by main intervention strategy.
Review: Interventions for promoting smoking cessation during pregnancy
Comparison: 1 Interventions for smoking cessation in pregnancy versus control
Outcome: 4 Continued smoking in late pregnancy subgrouped by main intervention strategy
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Cognitive behaviour strategies
Albrecht 1998 23/26 53/58 0.97 [ 0.83, 1.14 ]
Campbell 2006 87/98 90/96 0.95 [ 0.87, 1.03 ]
Cinciripini 2000 39/42 35/40 1.06 [ 0.92, 1.23 ]
Dornelas 2006 38/53 47/52 0.79 [ 0.66, 0.96 ]
Ershoff 1989 93/126 96/116 0.89 [ 0.78, 1.02 ]
Gielen 1997 181/193 187/198 0.99 [ 0.94, 1.04 ]
Hartmann 1996 89/113 90/106 0.93 [ 0.82, 1.05 ]
Hjalmarson 1991 398/444 198/209 0.95 [ 0.90, 0.99 ]
Lowe 1998a 108/111 113/116 1.00 [ 0.96, 1.04 ]
Lowe 1998b 40/44 34/34 0.91 [ 0.82, 1.01 ]
Malchodi 2003 51/67 59/75 0.97 [ 0.81, 1.16 ]
Mayer 1990 64/72 75/77 0.91 [ 0.83, 1.00 ]
McBride 1999 269/341 130/160 0.97 [ 0.89, 1.06 ]
McLeod 2004 133/163 96/109 0.93 [ 0.84, 1.02 ]
Moore 2002 435/523 459/567 1.03 [ 0.97, 1.09 ]
O’Connor 1992 78/90 79/84 0.92 [ 0.84, 1.02 ]
Panjari 1999 443/476 506/537 0.99 [ 0.96, 1.02 ]
Petersen 1992 37/43 39/47 1.04 [ 0.87, 1.24 ]
Polanska 2004 35/62 32/38 0.67 [ 0.52, 0.87 ]
Rigotti 2006 188/209 196/212 0.97 [ 0.92, 1.03 ]
Secker-Walker 1994 196/225 204/230 0.98 [ 0.92, 1.05 ]
Secker-Walker 1998 116/135 130/144 0.95 [ 0.87, 1.04 ]
Tappin 2000 46/48 47/49 1.00 [ 0.92, 1.09 ]
Tappin 2005 334/351 392/411 1.00 [ 0.97, 1.03 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Valbo 1991 31/50 47/50 0.66 [ 0.53, 0.83 ]
Valbo 1994 45/56 54/56 0.83 [ 0.73, 0.96 ]
Walsh 1997 110/127 118/125 0.92 [ 0.85, 0.99 ]
Windsor 1985 88/102 102/104 0.88 [ 0.81, 0.95 ]
Windsor 1993 343/400 379/414 0.94 [ 0.89, 0.98 ]
Windsor 2000a 115/139 116/127 0.91 [ 0.83, 0.99 ]
Subtotal (95% CI) 4929 4641 0.95 [ 0.93, 0.97 ]
Total events: 4253 (Treatment), 4203 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 63.90, df = 29 (P = 0.00020); I2 =55%
Test for overall effect: Z = 4.51 (P < 0.00001)
2 Stages of change
DeVries 2006 47/58 68/73 0.87 [ 0.76, 1.00 ]
Dunkley 1997 46/50 50/50 0.92 [ 0.84, 1.01 ]
Ershoff 1999 106/131 105/126 0.97 [ 0.87, 1.09 ]
Hajek 2001 285/365 293/367 0.98 [ 0.91, 1.05 ]
Kendrick 1995 774/822 998/1063 1.00 [ 0.98, 1.03 ]
Lawrence 2003 572/611 274/284 0.97 [ 0.94, 1.00 ]
Pbert 2004 21/26 16/18 0.91 [ 0.71, 1.17 ]
Solomon 2000 63/77 63/74 0.96 [ 0.83, 1.11 ]
Stotts 2002 91/134 89/135 1.03 [ 0.87, 1.22 ]
Strecher 2000 94/104 79/87 1.00 [ 0.91, 1.09 ]
Thornton 1997 186/209 185/209 1.01 [ 0.94, 1.08 ]
Subtotal (95% CI) 2587 2486 0.99 [ 0.97, 1.00 ]
Total events: 2285 (Treatment), 2220 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 9.81, df = 10 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.66 (P = 0.097)
3 Feedback
Bauman 1983 36/39 43/49 1.05 [ 0.92, 1.21 ]
Burling 1991 61/70 65/69 0.93 [ 0.83, 1.03 ]
Cope 2003 142/164 112/116 0.90 [ 0.84, 0.96 ]
Reading 1982 20/39 20/26 0.67 [ 0.46, 0.97 ]
Subtotal (95% CI) 312 260 0.92 [ 0.84, 1.02 ]
Total events: 259 (Treatment), 240 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 7.35, df = 3 (P = 0.06); I2 =59%
Test for overall effect: Z = 1.54 (P = 0.12)
4 Rewards
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Donatelle 2000 78/112 99/108 0.76 [ 0.66, 0.87 ]
Heil 2008 22/37 36/40 0.66 [ 0.50, 0.88 ]
Higgins 2004 19/30 21/23 0.69 [ 0.51, 0.94 ]
Sexton 1984 296/463 393/472 0.77 [ 0.71, 0.83 ]
Subtotal (95% CI) 642 643 0.76 [ 0.71, 0.81 ]
Total events: 415 (Treatment), 549 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.32, df = 3 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 8.42 (P < 0.00001)
5 Pharmacotherapy (NRT, Bupropion etc) nicotine replacement therapy
Hegaard 2003 304/327 313/320 0.95 [ 0.92, 0.98 ]
Hotham 2005 17/20 19/19 0.85 [ 0.70, 1.05 ]
Kapur 2001 13/17 13/13 0.78 [ 0.58, 1.03 ]
Pollak 2007 99/122 52/59 0.92 [ 0.81, 1.05 ]
Wisborg 2000 103/124 108/126 0.97 [ 0.87, 1.08 ]
Subtotal (95% CI) 610 537 0.95 [ 0.92, 0.98 ]
Total events: 536 (Treatment), 505 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.28, df = 4 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 3.55 (P = 0.00039)
6 Other
Baric 1976 54/63 45/47 0.90 [ 0.80, 1.01 ]
Belizan 1995 196/255 207/237 0.88 [ 0.81, 0.96 ]
Bullock 1995 36/65 36/66 1.02 [ 0.74, 1.38 ]
Lilley 1986 68/72 72/73 0.96 [ 0.90, 1.02 ]
Loeb 1983 435/477 447/486 0.99 [ 0.95, 1.03 ]
MacArthur 1987 449/493 464/489 0.96 [ 0.93, 0.99 ]
Olds 1986 77/77 64/64 0.0 [ 0.0, 0.0 ]
Price 1991 67/71 69/70 0.96 [ 0.90, 1.02 ]
Rush 1992 153/175 131/144 0.96 [ 0.89, 1.04 ]
Secker-Walker 1997 21/26 30/30 0.81 [ 0.67, 0.98 ]
Valbo 1996 47/52 70/78 1.01 [ 0.90, 1.13 ]
Subtotal (95% CI) 1826 1784 0.96 [ 0.93, 0.98 ]
Total events: 1603 (Treatment), 1635 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 12.29, df = 9 (P = 0.20); I2 =27%
Test for overall effect: Z = 3.34 (P = 0.00084)
Total (95% CI) 10906 10351 0.94 [ 0.93, 0.96 ]
Total events: 9351 (Treatment), 9352 (Control)
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Heterogeneity: Tau2 = 0.00; Chi2 = 174.29, df = 63 (P<0.00001); I2 =64%
Test for overall effect: Z = 6.87 (P < 0.00001)
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Analysis 1.5. Comparison 1 Interventions for smoking cessation in pregnancy versus control, Outcome 5
Continued smoking (relapse) for spontaneous quitters in late pregnancy.
Review: Interventions for promoting smoking cessation during pregnancy
Comparison: 1 Interventions for smoking cessation in pregnancy versus control
Outcome: 5 Continued smoking (relapse) for spontaneous quitters in late pregnancy
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Dornelas 2006 4/14 3/19 2.2 % 1.81 [ 0.48, 6.83 ]
Ershoff 1995 14/87 17/84 9.4 % 0.80 [ 0.42, 1.51 ]
Lowe 1997 15/52 20/45 13.3 % 0.65 [ 0.38, 1.11 ]
McBride 1999 34/259 27/137 18.1 % 0.67 [ 0.42, 1.06 ]
Pbert 2004 7/23 4/16 3.5 % 1.22 [ 0.43, 3.48 ]
Petersen 1992 34/71 36/78 33.1 % 1.04 [ 0.74, 1.46 ]
Secker-Walker 1995 13/44 12/43 8.8 % 1.06 [ 0.55, 2.05 ]
Secker-Walker 1998 16/44 15/48 11.7 % 1.16 [ 0.66, 2.06 ]
Total (95% CI) 594 470 100.0 % 0.91 [ 0.75, 1.10 ]
Total events: 137 (Treatment), 134 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.28, df = 7 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
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Analysis 1.6. Comparison 1 Interventions for smoking cessation in pregnancy versus control, Outcome 6
Mean birthweight.
Review: Interventions for promoting smoking cessation during pregnancy
Comparison: 1 Interventions for smoking cessation in pregnancy versus control
Outcome: 6 Mean birthweight
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heil 2008 34 3355 (560) 39 3102 (556) 0.8 % 253.00 [ -3.67, 509.67 ]
Polanska 2004 149 3104 (745) 144 3138 (1090) 1.1 % -34.00 [ -248.49, 180.49 ]
Pollak 2007 122 3061 (661) 59 3132 (688) 1.2 % -71.00 [ -282.13, 140.13 ]
Tappin 2000 48 3205 (500) 49 3271 (500) 1.3 % -66.00 [ -265.01, 133.01 ]
Malchodi 2003 67 3100 (481) 75 3072 (614) 1.5 % 28.00 [ -152.48, 208.48 ]
Ershoff 1989 118 3366 (500) 109 3309 (500) 2.8 % 57.00 [ -73.19, 187.19 ]
Wisborg 2000 124 3457 (500) 126 3271 (500) 3.0 % 186.00 [ 62.04, 309.96 ]
Rush 1992 175 3163 (606) 144 3119 (443) 3.4 % 44.00 [ -71.31, 159.31 ]
Cope 2003 109 3260 (430) 83 3080 (380) 3.4 % 180.00 [ 65.11, 294.89 ]
Secker-Walker 1998 135 3256 (452) 141 3221 (506) 3.5 % 35.00 [ -78.09, 148.09 ]
Tappin 2005 351 3078 (602) 411 3048 (642) 5.1 % 30.00 [ -58.42, 118.42 ]
Thornton 1997 380 3267 (624) 380 3266 (613) 5.1 % 1.00 [ -86.95, 88.95 ]
Donovan 1977 263 3172 (500) 289 3184 (500) 5.5 % -12.00 [ -95.51, 71.51 ]
Panjari 1999 337 3250 (526) 391 3166 (589) 5.7 % 84.00 [ 2.99, 165.01 ]
Hjalmarson 1991 492 3430 (500) 231 3359 (500) 6.0 % 71.00 [ -7.16, 149.16 ]
Secker-Walker 1994 279 3291 (468) 282 3255 (466) 6.1 % 36.00 [ -41.29, 113.29 ]
Hegaard 2003 327 3401 (500) 320 3433 (500) 6.1 % -32.00 [ -109.06, 45.06 ]
Sexton 1984 463 3278 (627) 472 3186 (566) 6.2 % 92.00 [ 15.39, 168.61 ]
MacArthur 1987 493 3164 (500) 489 3130 (500) 7.9 % 34.00 [ -28.55, 96.55 ]
Haddow 1991 1423 3263 (542) 1425 3229 (537) 11.8 % 34.00 [ -5.63, 73.63 ]
RADIUS 1995 1768 3352 (528) 1803 3349 (544) 12.7 % 3.00 [ -32.16, 38.16 ]
Total (95% CI) 7657 7462 100.0 % 39.26 [ 15.77, 62.74 ]
Heterogeneity: Tau2 = 804.85; Chi2 = 29.27, df = 20 (P = 0.08); I2 =32%
Test for overall effect: Z = 3.28 (P = 0.0011)
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Analysis 1.7. Comparison 1 Interventions for smoking cessation in pregnancy versus control, Outcome 7
Mean birthweight subgrouped by main intervention strategy.
Review: Interventions for promoting smoking cessation during pregnancy
Comparison: 1 Interventions for smoking cessation in pregnancy versus control
Outcome: 7 Mean birthweight subgrouped by main intervention strategy
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Cognitive behavioural therapy
Ershoff 1989 118 3366 (500) 109 3309 (500) 2.8 % 57.00 [ -73.19, 187.19 ]
Hjalmarson 1991 492 3430 (500) 231 3359 (500) 6.0 % 71.00 [ -7.16, 149.16 ]
Malchodi 2003 67 3100 (481) 75 3072 (614) 1.5 % 28.00 [ -152.48, 208.48 ]
Panjari 1999 337 3250 (526) 391 3166 (589) 5.7 % 84.00 [ 2.99, 165.01 ]
Polanska 2004 149 3104 (745) 144 3138 (1090) 1.1 % -34.00 [ -248.49, 180.49 ]
Secker-Walker 1994 135 3256 (452) 141 3221 (506) 3.5 % 35.00 [ -78.09, 148.09 ]
Secker-Walker 1998 279 3291 (468) 282 3255 (466) 6.1 % 36.00 [ -41.29, 113.29 ]
Tappin 2000 48 3205 (500) 49 3271 (500) 1.3 % -66.00 [ -265.01, 133.01 ]
Tappin 2005 351 3078 (602) 411 3048 (642) 5.1 % 30.00 [ -58.42, 118.42 ]
Subtotal (95% CI) 1976 1833 33.0 % 47.01 [ 12.22, 81.80 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.28, df = 8 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 2.65 (P = 0.0081)
2 Stages of change
Donovan 1977 263 3172 (500) 289 3184 (500) 5.5 % -12.00 [ -95.51, 71.51 ]
Thornton 1997 380 3267 (624) 380 3266 (613) 5.1 % 1.00 [ -86.95, 88.95 ]
Subtotal (95% CI) 643 669 10.6 % -5.84 [ -66.40, 54.72 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
3 Feedback
Cope 2003 109 3260 (430) 83 3080 (380) 3.4 % 180.00 [ 65.11, 294.89 ]
Haddow 1991 1423 3263 (542) 1425 3229 (537) 11.8 % 34.00 [ -5.63, 73.63 ]
RADIUS 1995 1768 3352 (528) 1803 3349 (544) 12.7 % 3.00 [ -32.16, 38.16 ]
Subtotal (95% CI) 3300 3311 28.0 % 47.80 [ -14.67, 110.28 ]
Heterogeneity: Tau2 = 2122.21; Chi2 = 8.69, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 1.50 (P = 0.13)
4 Rewards
Heil 2008 34 3355 (560) 39 3102 (556) 0.8 % 253.00 [ -3.67, 509.67 ]
Sexton 1984 463 3278 (627) 472 3186 (566) 6.2 % 92.00 [ 15.39, 168.61 ]
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(. . . Continued)
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 497 511 7.0 % 123.98 [ -1.92, 249.89 ]
Heterogeneity: Tau2 = 3621.55; Chi2 = 1.39, df = 1 (P = 0.24); I2 =28%
Test for overall effect: Z = 1.93 (P = 0.054)
5 Pharmacotherapy
Hegaard 2003 327 3401 (500) 320 3433 (500) 6.1 % -32.00 [ -109.06, 45.06 ]
Pollak 2007 122 3061 (661) 59 3132 (688) 1.2 % -71.00 [ -282.13, 140.13 ]
Wisborg 2000 124 3457 (500) 126 3271 (500) 3.0 % 186.00 [ 62.04, 309.96 ]
Subtotal (95% CI) 573 505 10.3 % 34.40 [ -125.77, 194.58 ]
Heterogeneity: Tau2 = 15118.66; Chi2 = 9.35, df = 2 (P = 0.01); I2 =79%
Test for overall effect: Z = 0.42 (P = 0.67)
6 Other
MacArthur 1987 493 3164 (500) 489 3130 (500) 7.9 % 34.00 [ -28.55, 96.55 ]
Rush 1992 175 3163 (606) 144 3119 (443) 3.4 % 44.00 [ -71.31, 159.31 ]
Subtotal (95% CI) 668 633 11.2 % 36.27 [ -18.71, 91.25 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
Total (95% CI) 7657 7462 100.0 % 39.26 [ 15.77, 62.74 ]
Heterogeneity: Tau2 = 804.85; Chi2 = 29.27, df = 20 (P = 0.08); I2 =32%
Test for overall effect: Z = 3.28 (P = 0.0011)
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Analysis 1.8. Comparison 1 Interventions for smoking cessation in pregnancy versus control, Outcome 8
Low birthweight (under 2500 g).
Review: Interventions for promoting smoking cessation during pregnancy
Comparison: 1 Interventions for smoking cessation in pregnancy versus control
Outcome: 8 Low birthweight (under 2500 g)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Donovan 1977 26/263 26/289 6.8 % 1.10 [ 0.66, 1.84 ]
Ershoff 1989 9/118 15/109 3.0 % 0.55 [ 0.25, 1.21 ]
Haddow 1991 99/1423 121/1425 28.1 % 0.82 [ 0.63, 1.06 ]
Hegaard 2003 12/327 10/320 2.7 % 1.17 [ 0.51, 2.68 ]
Heil 2008 3/34 8/39 1.2 % 0.43 [ 0.12, 1.49 ]
Hjalmarson 1991 14/422 11/198 3.1 % 0.60 [ 0.28, 1.29 ]
MacArthur 1987 40/493 47/489 11.3 % 0.84 [ 0.56, 1.26 ]
Malchodi 2003 5/36 6/43 1.5 % 1.00 [ 0.33, 2.99 ]
Panjari 1999 20/337 37/391 6.7 % 0.63 [ 0.37, 1.06 ]
Pollak 2007 17/122 5/59 2.0 % 1.64 [ 0.64, 4.24 ]
Secker-Walker 1994 9/188 10/226 2.4 % 1.08 [ 0.45, 2.61 ]
Secker-Walker 1998 7/135 12/141 2.3 % 0.61 [ 0.25, 1.50 ]
Sexton 1984 31/463 42/472 9.2 % 0.75 [ 0.48, 1.18 ]
Tappin 2005 44/332 59/400 14.0 % 0.90 [ 0.63, 1.29 ]
Thornton 1997 19/190 15/190 4.4 % 1.27 [ 0.66, 2.42 ]
Wisborg 2000 4/120 11/122 1.5 % 0.37 [ 0.12, 1.13 ]
Total (95% CI) 5003 4913 100.0 % 0.83 [ 0.73, 0.95 ]
Total events: 359 (Treatment), 435 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 12.65, df = 15 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.66 (P = 0.0079)
0.1 0.2 0.5 1 2 5 10
Favours Treatment Favours Control
149Interventions for promoting smoking cessation during pregnancy (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.9. Comparison 1 Interventions for smoking cessation in pregnancy versus control, Outcome 9
Very low birthweight (under 1500 g).
Review: Interventions for promoting smoking cessation during pregnancy
Comparison: 1 Interventions for smoking cessation in pregnancy versus control
Outcome: 9 Very low birthweight (under 1500 g)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Hjalmarson 1991 8/1423 9/1425 30.5 % 0.89 [ 0.34, 2.30 ]
MacArthur 1987 7/493 5/489 21.1 % 1.39 [ 0.44, 4.35 ]
Sexton 1984 9/463 5/472 23.3 % 1.83 [ 0.62, 5.43 ]
Tappin 2005 6/331 8/400 25.0 % 0.91 [ 0.32, 2.59 ]
Total (95% CI) 2710 2786 100.0 % 1.16 [ 0.69, 1.96 ]
Total events: 30 (Treatment), 27 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.29, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.57)
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Analysis 1.10. Comparison 1 Interventions for smoking cessation in pregnancy versus control, Outcome 10
Perinatal deaths.
Review: Interventions for promoting smoking cessation during pregnancy
Comparison: 1 Interventions for smoking cessation in pregnancy versus control
Outcome: 10 Perinatal deaths
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Donovan 1977 4/263 1/289 4.2 % 4.40 [ 0.49, 39.08 ]
Haddow 1991 23/1423 22/1425 59.6 % 1.05 [ 0.59, 1.87 ]
Sexton 1984 14/463 13/472 36.2 % 1.10 [ 0.52, 2.31 ]
Total (95% CI) 2149 2186 100.0 % 1.13 [ 0.72, 1.77 ]
Total events: 41 (Treatment), 36 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.56, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
150Interventions for promoting smoking cessation during pregnancy (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.11. Comparison 1 Interventions for smoking cessation in pregnancy versus control, Outcome 11
Preterm birth (under 37 or under 36 weeks).
Review: Interventions for promoting smoking cessation during pregnancy
Comparison: 1 Interventions for smoking cessation in pregnancy versus control
Outcome: 11 Preterm birth (under 37 or under 36 weeks)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Donovan 1977 16/263 17/289 4.5 % 1.03 [ 0.53, 2.00 ]
Ershoff 1989 7/118 7/109 1.9 % 0.92 [ 0.33, 2.55 ]
Haddow 1991 109/1423 137/1425 33.7 % 0.80 [ 0.63, 1.01 ]
Hegaard 2003 7/327 10/320 2.1 % 0.69 [ 0.26, 1.78 ]
Heil 2008 3/34 9/39 1.3 % 0.38 [ 0.11, 1.30 ]
Hjalmarson 1991 13/421 8/197 2.6 % 0.76 [ 0.32, 1.80 ]
MacArthur 1987 32/493 37/489 9.4 % 0.86 [ 0.54, 1.35 ]
Panjari 1999 18/339 34/391 6.4 % 0.61 [ 0.35, 1.06 ]
Pollak 2007 24/122 9/59 4.0 % 1.29 [ 0.64, 2.60 ]
RADIUS 1995 57/1768 67/1803 16.2 % 0.87 [ 0.61, 1.23 ]
Tappin 2000 5/48 4/49 1.2 % 1.28 [ 0.36, 4.47 ]
Tappin 2005 35/342 43/402 10.9 % 0.96 [ 0.63, 1.46 ]
Thornton 1997 14/209 8/209 2.7 % 1.75 [ 0.75, 4.08 ]
Wisborg 2000 10/120 12/122 3.0 % 0.85 [ 0.38, 1.89 ]
Total (95% CI) 6027 5903 100.0 % 0.86 [ 0.74, 0.98 ]
Total events: 350 (Treatment), 402 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.78, df = 13 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 2.17 (P = 0.030)
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Analysis 1.12. Comparison 1 Interventions for smoking cessation in pregnancy versus control, Outcome 12
Stillbirths.
Review: Interventions for promoting smoking cessation during pregnancy
Comparison: 1 Interventions for smoking cessation in pregnancy versus control
Outcome: 12 Stillbirths
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Ershoff 1995 2/118 1/109 3.9 % 1.85 [ 0.17, 20.09 ]
Haddow 1991 21/1423 17/1425 54.9 % 1.24 [ 0.66, 2.33 ]
Pollak 2007 2/122 2/59 5.9 % 0.48 [ 0.07, 3.35 ]
Sexton 1984 9/463 11/472 29.2 % 0.83 [ 0.35, 1.99 ]
Tappin 2000 1/48 0/49 2.2 % 3.06 [ 0.13, 73.34 ]
Thornton 1997 2/209 1/209 3.9 % 2.00 [ 0.18, 21.89 ]
Total (95% CI) 2383 2323 100.0 % 1.10 [ 0.69, 1.76 ]
Total events: 37 (Treatment), 32 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.03, df = 5 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
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Analysis 1.13. Comparison 1 Interventions for smoking cessation in pregnancy versus control, Outcome 13
Neonatal deaths.
Review: Interventions for promoting smoking cessation during pregnancy
Comparison: 1 Interventions for smoking cessation in pregnancy versus control
Outcome: 13 Neonatal deaths
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Haddow 1991 2/1402 5/1408 39.0 % 0.40 [ 0.08, 2.07 ]
Sexton 1984 5/454 2/461 39.1 % 2.54 [ 0.50, 13.02 ]
Thornton 1997 2/209 1/209 21.8 % 2.00 [ 0.18, 21.89 ]
Total (95% CI) 2065 2078 100.0 % 1.17 [ 0.34, 4.01 ]
Total events: 9 (Treatment), 8 (Control)
Heterogeneity: Tau2 = 0.31; Chi2 = 2.69, df = 2 (P = 0.26); I2 =26%
Test for overall effect: Z = 0.26 (P = 0.80)
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Analysis 1.14. Comparison 1 Interventions for smoking cessation in pregnancy versus control, Outcome 14
NICU admissions.
Review: Interventions for promoting smoking cessation during pregnancy
Comparison: 1 Interventions for smoking cessation in pregnancy versus control
Outcome: 14 NICU admissions
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Heil 2008 4/34 6/39 7.8 % 0.76 [ 0.24, 2.49 ]
Pollak 2007 13/122 4/59 9.4 % 1.57 [ 0.54, 4.61 ]
Tappin 2005 32/351 53/411 63.1 % 0.71 [ 0.47, 1.07 ]
Thornton 1997 14/189 12/189 19.6 % 1.17 [ 0.55, 2.46 ]
Total (95% CI) 696 698 100.0 % 0.85 [ 0.61, 1.18 ]
Total events: 63 (Treatment), 75 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.74, df = 3 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
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Analysis 1.15. Comparison 1 Interventions for smoking cessation in pregnancy versus control, Outcome 15
Smoking reduction: numbers of women reducing smoking in late pregnancy.
Review: Interventions for promoting smoking cessation during pregnancy
Comparison: 1 Interventions for smoking cessation in pregnancy versus control
Outcome: 15 Smoking reduction: numbers of women reducing smoking in late pregnancy
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Self-reported some reduction in smoking (various definitions)
Lowe 1998a 32/44 18/34 21.3 % 1.37 [ 0.95, 1.98 ]
MacArthur 1987 138/493 92/489 36.6 % 1.49 [ 1.18, 1.88 ]
Price 1991 37/123 10/70 8.8 % 2.11 [ 1.12, 3.97 ]
Valbo 1994 35/54 19/50 18.3 % 1.71 [ 1.14, 2.56 ]
Valbo 1996 22/52 24/78 15.0 % 1.38 [ 0.87, 2.18 ]
Subtotal (95% CI) 766 721 100.0 % 1.52 [ 1.29, 1.78 ]
Total events: 264 (Treatment), 163 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.86, df = 4 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 5.11 (P < 0.00001)
2 Self-reported > 50% reduction in smoking
Hartmann 1996 34/107 20/100 23.6 % 1.59 [ 0.98, 2.57 ]
Rigotti 2006 61/209 46/212 40.8 % 1.35 [ 0.97, 1.87 ]
Solomon 2000 32/77 33/74 35.5 % 0.93 [ 0.65, 1.35 ]
Subtotal (95% CI) 393 386 100.0 % 1.23 [ 0.91, 1.67 ]
Total events: 127 (Treatment), 99 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 3.63, df = 2 (P = 0.16); I2 =45%
Test for overall effect: Z = 1.37 (P = 0.17)
3 Biochemically validated reduction
Cope 2003 42/109 20/83 37.2 % 1.60 [ 1.02, 2.51 ]
Gielen 1997 14/125 13/121 17.0 % 1.04 [ 0.51, 2.13 ]
Hotham 2005 7/20 5/20 9.7 % 1.40 [ 0.53, 3.68 ]
Tappin 2005 15/351 26/411 21.8 % 0.68 [ 0.36, 1.25 ]
Windsor 1985 31/205 7/104 14.2 % 2.25 [ 1.02, 4.93 ]
Subtotal (95% CI) 810 739 100.0 % 1.27 [ 0.84, 1.91 ]
Total events: 109 (Treatment), 71 (Control)
Heterogeneity: Tau2 = 0.10; Chi2 = 7.36, df = 4 (P = 0.12); I2 =46%
Test for overall effect: Z = 1.14 (P = 0.25)
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Analysis 1.16. Comparison 1 Interventions for smoking cessation in pregnancy versus control, Outcome 16
Smoking reduction: biochemical measures in late pregnancy.
Review: Interventions for promoting smoking cessation during pregnancy
Comparison: 1 Interventions for smoking cessation in pregnancy versus control
Outcome: 16 Smoking reduction: biochemical measures in late pregnancy
Study or subgroup Treatment Control Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Mean cotinine levels
Panjari 1999 318 720 (688) 356 769 (735) 26.0 % -0.07 [ -0.22, 0.08 ]
Secker-Walker 1994 188 1208 (1384) 226 1228 (1612) 21.3 % -0.01 [ -0.21, 0.18 ]
Tappin 2005 290 113 (70) 364 117 (83) 25.6 % -0.05 [ -0.21, 0.10 ]
Subtotal (95% CI) 796 946 72.9 % -0.05 [ -0.14, 0.05 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 2 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
2 Mean thiocynate level
Sexton 1984 380 2094 (1209) 389 2452 (1228) 27.1 % -0.29 [ -0.44, -0.15 ]
Subtotal (95% CI) 380 389 27.1 % -0.29 [ -0.44, -0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.05 (P = 0.000052)
Total (95% CI) 1176 1335 100.0 % -0.11 [ -0.24, 0.02 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 8.08, df = 3 (P = 0.04); I2 =63%
Test for overall effect: Z = 1.71 (P = 0.088)
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Analysis 1.17. Comparison 1 Interventions for smoking cessation in pregnancy versus control, Outcome 17
Smoking reduction: self-reported mean cigarettes per day measured in late pregnancy or at delivery.
Review: Interventions for promoting smoking cessation during pregnancy
Comparison: 1 Interventions for smoking cessation in pregnancy versus control
Outcome: 17 Smoking reduction: self-reported mean cigarettes per day measured in late pregnancy or at delivery
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ershoff 1999 60 8.1 (8) 61 8 (8) 5.8 % 0.10 [ -2.75, 2.95 ]
Hjalmarson 1991 444 9.3 (6.4) 209 9.6 (2.95) 16.6 % -0.30 [ -1.02, 0.42 ]
Lilley 1986 66 13.1 (9.1) 69 16 (9.1) 5.2 % -2.90 [ -5.97, 0.17 ]
Moore 2002 353 10.3 (5.6) 403 10.1 (5.4) 16.1 % 0.20 [ -0.59, 0.99 ]
Panjari 1999 284 8.7 (7.6) 326 11.5 (9.7) 12.4 % -2.80 [ -4.17, -1.43 ]
Price 1991 71 4.3 (8.1) 70 2.3 (5.6) 7.7 % 2.00 [ -0.30, 4.30 ]
Rush 1992 175 10.5 (7.7) 144 11.9 (7.8) 10.4 % -1.40 [ -3.11, 0.31 ]
Thornton 1997 196 10.4 (8.3) 191 12.5 (10.7) 9.4 % -2.10 [ -4.01, -0.19 ]
Wisborg 2000 124 7.2 (2.93) 126 7 (2.93) 16.5 % 0.20 [ -0.53, 0.93 ]
Total (95% CI) 1773 1599 100.0 % -0.67 [ -1.49, 0.16 ]
Heterogeneity: Tau2 = 0.93; Chi2 = 27.73, df = 8 (P = 0.00053); I2 =71%
Test for overall effect: Z = 1.59 (P = 0.11)
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Analysis 1.18. Comparison 1 Interventions for smoking cessation in pregnancy versus control, Outcome 18
Maintained smoking cessation at 1-5 months postpartum.
Review: Interventions for promoting smoking cessation during pregnancy
Comparison: 1 Interventions for smoking cessation in pregnancy versus control
Outcome: 18 Maintained smoking cessation at 1-5 months postpartum
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Individually randomised trials
Cinciripini 2000 2/42 3/40 2.2 % 0.63 [ 0.11, 3.60 ]
Donatelle 2000 22/103 6/102 4.8 % 3.63 [ 1.54, 8.58 ]
Heil 2008 9/37 1/40 1.8 % 9.73 [ 1.29, 73.13 ]
Higgins 2004 10/30 0/23 1.0 % 16.26 [ 1.00, 263.78 ]
Hjalmarson 1991 70/444 19/209 6.5 % 1.73 [ 1.07, 2.80 ]
McBride 1999 16/600 6/297 4.5 % 1.32 [ 0.52, 3.34 ]
O’Connor 1992 13/94 5/96 4.3 % 2.66 [ 0.99, 7.16 ]
Panjari 1999 54/339 47/393 7.0 % 1.33 [ 0.93, 1.91 ]
Petersen 1992 38/71 41/78 7.2 % 1.02 [ 0.75, 1.38 ]
Pollak 2007 24/122 8/59 5.3 % 1.45 [ 0.69, 3.03 ]
Rigotti 2006 14/209 15/212 5.5 % 0.95 [ 0.47, 1.91 ]
Stotts 2002 14/84 14/82 5.6 % 0.98 [ 0.50, 1.92 ]
Thornton 1997 148/209 159/209 7.7 % 0.93 [ 0.83, 1.04 ]
Walsh 1997 13/127 1/125 1.8 % 12.80 [ 1.70, 96.35 ]
Wisborg 2000 21/124 18/126 6.1 % 1.19 [ 0.66, 2.11 ]
Subtotal (95% CI) 2635 2091 71.4 % 1.43 [ 1.08, 1.91 ]
Total events: 468 (Treatment), 343 (Control)
Heterogeneity: Tau2 = 0.16; Chi2 = 50.04, df = 14 (P<0.00001); I2 =72%
Test for overall effect: Z = 2.46 (P = 0.014)
2 Cluster-randomised trials
DeVries 2006 14/65 10/84 5.3 % 1.81 [ 0.86, 3.81 ]
Lawrence 2003 135/611 10/284 5.9 % 6.27 [ 3.35, 11.74 ]
McLeod 2004 17/106 9/82 5.3 % 1.46 [ 0.69, 3.11 ]
Pbert 2004 16/23 13/16 7.0 % 0.86 [ 0.60, 1.23 ]
Polanska 2004 28/62 6/38 5.1 % 2.86 [ 1.31, 6.26 ]
Subtotal (95% CI) 867 504 28.6 % 2.08 [ 0.78, 5.56 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Total events: 210 (Treatment), 48 (Control)
Heterogeneity: Tau2 = 1.14; Chi2 = 50.68, df = 4 (P<0.00001); I2 =92%
Test for overall effect: Z = 1.46 (P = 0.15)
Total (95% CI) 3502 2595 100.0 % 1.65 [ 1.22, 2.24 ]
Total events: 678 (Treatment), 391 (Control)
Heterogeneity: Tau2 = 0.31; Chi2 = 114.65, df = 19 (P<0.00001); I2 =83%
Test for overall effect: Z = 3.22 (P = 0.0013)
0.01 0.1 1 10 100
Favours control Favours experimental
Analysis 1.19. Comparison 1 Interventions for smoking cessation in pregnancy versus control, Outcome 19
Maintained smoking cessation at 6 to 12 months postpartum.
Review: Interventions for promoting smoking cessation during pregnancy
Comparison: 1 Interventions for smoking cessation in pregnancy versus control
Outcome: 19 Maintained smoking cessation at 6 to 12 months postpartum
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Individually randomised trials
Dornelas 2006 5/53 2/52 8.3 % 2.45 [ 0.50, 12.08 ]
Heil 2008 3/37 1/40 4.9 % 3.24 [ 0.35, 29.82 ]
Higgins 2004 8/30 0/23 3.3 % 13.16 [ 0.80, 216.85 ]
McBride 1999 13/600 8/297 17.4 % 0.80 [ 0.34, 1.92 ]
Panjari 1999 54/339 47/393 28.1 % 1.33 [ 0.93, 1.91 ]
Secker-Walker 1994 5/157 6/185 12.7 % 0.98 [ 0.31, 3.16 ]
Stotts 2002 10/84 14/82 19.7 % 0.70 [ 0.33, 1.48 ]
Walsh 1997 13/127 1/125 5.7 % 12.80 [ 1.70, 96.35 ]
Subtotal (95% CI) 1427 1197 100.0 % 1.39 [ 0.82, 2.38 ]
Total events: 111 (Treatment), 79 (Control)
Heterogeneity: Tau2 = 0.23; Chi2 = 13.42, df = 7 (P = 0.06); I2 =48%
Test for overall effect: Z = 1.22 (P = 0.22)
2 Cluster-randomised trials
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1427 1197 100.0 % 1.39 [ 0.82, 2.38 ]
Total events: 111 (Treatment), 79 (Control)
Heterogeneity: Tau2 = 0.23; Chi2 = 13.42, df = 7 (P = 0.06); I2 =48%
Test for overall effect: Z = 1.22 (P = 0.22)
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A P P E N D I C E S
Appendix 1. Reviews of interventions for smoking cessation in a general population
Population-wide measures
Healthcare financing systems for increasing the use of tobacco dependence treatment (Kaper 2005)
Interventions for preventing tobacco sales to minors (Stead 2005b)
Interventions for preventing tobacco smoking in public places (Serra 2008)
Smoking bans for reducing smoking prevalence and tobacco consumption (Callinan 2006)
Mass media interventions for preventing smoking in young people (Sowden 1998)
Mass media interventions for smoking cessation in adults (Bala 2008)
Organisational interventions
School-based programmes for preventing smoking (Thomas 2006)
Workplace interventions for smoking cessation (Cahill 2008d)
Community interventions
Community interventions for preventing smoking in young people (Sowden 2003)
Community interventions for reducing smoking among adults (Secker-Walker 2002b)
Community pharmacy personnel interventions for smoking cessation (Sinclair 2004)
Family and carer smoking control programmes for reducing children’s exposure to environmental tobacco smoke (Priest 2008)
Family-based programmes for preventing smoking by children and adolescents (Thomas 2007)
Group behaviour therapy programmes for smoking cessation (Stead 2005a)
Individual strategies
Acupuncture and related interventions for smoking cessation (White 2006)
Aversive smoking for smoking cessation (Hajek 2001)
Biomedical risk assessment as an aid for smoking cessation (Bize 2005)
Competitions and incentives for smoking cessation (Cahill 2008a)
Enhancing partner support to improve smoking cessation (Park 2004)
Exercise interventions for smoking cessation (Ussher 2008)
Hypnotherapy for smoking cessation (Abbot 1998)
Individual behavioural counselling for smoking cessation (Lancaster 2005a)
Internet-based interventions for smoking cessation (Koshy 2008)
Interventions for preventing weight gain after smoking cessation (Parsons 2009)
Interventions for smokeless tobacco use cessation (Ebbert 2007)
Interventions for waterpipe smoking cessation (Maziak 2007)
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Mobile phone-based interventions for smoking cessation (Whittaker 2007)
Motivational interviewing for smoking cessation (Lai 2008)
Nursing interventions for smoking cessation (Rice 2008)
Physician advice for smoking cessation (Stead 2008b)
Quit and Win contests for smoking cessation (Cahill 2008c)
Self-help interventions for smoking cessation (Lancaster 2005b)
Stage-based interventions for smoking cessation (Cahill 2007b)
Telephone counselling for smoking cessation (Stead 2006c)
Training health professionals in smoking cessation (Lancaster 2000)
Pharmacotherapies
Antidepressants for smoking cessation (Hughes 2007a)
Anxiolytics for smoking cessation (Hughes 2000)
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation (Cahill 2007a)
Clonidine for smoking cessation (Gourlay 2004)
Lobeline for smoking cessation (Stead 1997)
Mecamylamine (a nicotine antagonist) for smoking cessation (Lancaster 1998)
Nicobrevin for smoking cessation (Stead 2006b)
Nicotine receptor partial agonists for smoking cessation (Cahill 2008b)
Nicotine replacement therapy for smoking cessation (Stead 2008a)
Nicotine vaccines for smoking cessation (Hatsukami 2008)
Opioid antagonists for smoking cessation (David 2006)
Silver acetate for smoking cessation (Lancaster 1997)
Relapse prevention
Relapse prevention interventions for smoking cessation (Hajek 2009)
Specific population group interventions
Interventions for preoperative smoking cessation (Møller 2005)
Interventions for smoking cessation and reduction in individuals with schizophrenia (Tsoi 2008)
Interventions for smoking cessation in hospitalised patients (Rigotti 2007)
Interventions for tobacco cessation in the dental setting (Carr 2006)
Smoking cessation interventions for smokers with current or past depression (van der Meer 2006)
Tobacco cessation interventions for young people (Grimshaw 2006)
Appendix 2. Search strategy for EMBASE, PsycLIT and CINAHL
A qualified librarian searched these databases using the Cochrane search strategy and free text terms “pregnancy” or “antenatal” or
prenatal“ and ”smoking“ or ”tobacco“ (January 2003 to June 2008).
WH A T ’ S N E W
Last assessed as up-to-date: 3 December 2008.
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17 November 2008 New citation required but conclusions have not
changed
Two new authors have joined the review team for this
substantive update, which includes the addition of risk
of bias assessments for all trials; additional outcomes
tables for smoking reduction, continued cessation in
the postnatal period, neonatal intensive care unit ad-
missions, psychological impacts of smoking, views of
participants and providers; inclusion of additional data
from previously included cluster-randomised trials;
and risk of bias sensitivity analysis.
17 November 2008 New search has been performed Search updated: 7 new randomised controlled tri-
als (Cope 2003; Dornelas 2006; Heil 2008; Higgins
2004;Hotham2005; Pollak 2007;Rigotti 2006) and4
cluster randomised controlled trials (Campbell 2006;
McLeod 2004; Pbert 2004; Polanska 2004) included.
Mullen 1991 and Hughes 2000 previously included
have now been excluded.
H I S T O R Y
Protocol first published: Issue 2, 1998
Review first published: Issue 3, 1998
3 November 2008 Amended Converted to new review format.
31 July 2003 New search has been performed We have updated the Background and Results sections (comment on the dif-
ferences between the interventions when trials are grouped by intervention)
.
Twenty new trials reporting smoking cessation were included with five ad-
ditional cluster-randomised trials. Nine additional trials were excluded. Six
trials provided new data on fetal and perinatal outcomes.
The overall conclusions about the effectiveness of smoking cessation inter-
ventions did not change. New analyses grouping interventions by strate-
gies showed that the pooled cognitive-behavioural interventions were effec-
tive, nicotine replacement therapy was borderline, and trials using ’stages of
change’ approaches or feedbackwere not effective. The two trials using a com-
bination of rewards and social support were significantly more effective than
other strategies. The increased information on perinatal outcomes strength-
ened the findings of a reduction in preterm birth and low birthweight. One
trial reported method of delivery and one reported breastfeeding: neither
showed an effect of the intervention.
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C O N T R I B U T I O N S O F A U T H O R S
Original review (1999)
Judith Lumley (JL) and Sandy Oliver (SO) conceived and designed the original review, and together with Elizabeth Waters (EW) and
Laura Oakley (LO) completed data extraction and wrote the original review. JL carried out the analyses. EW was unable to contribute
after 2002.
All contributed to the final text.
Update (2004)
JL coordinated the review update, extracted data, conducted the analyses and interpretation of data and wrote the review.
Catherine Chamberlain (CC) searched and screened search results, retrieved papers, extracted data, wrote to authors for additional
information and entered data.
SO and LO provided general advice and contributed to the final text.
Update (2009)
JL screened retrieved papers against eligibility criteria, provided general advice on the review and contributed to the final text.
CC coordinated and secured funding for the review, undertook searches, retrieved papers, extracted data, wrote to authors for additional
information, entered and analysed data, and wrote the review.
Therese Dowswell (TD) completed risk of bias assessments for trials included prior to the 2009 update and revised data abstraction
records into an electronic format. TD revised the risk of bias assessments for RevMan 5 format, extracted, entered and analysed data
on reduction and postpartum outcomes, and provided general advice and a methodological perspective on the review.
SO and LO extracted and analysed data on participant and provider views, provided general advice and contributed to the text of the
review.
Lyn Watson (LW) provided expert statistical advice on including cluster trials, extracted data for cluster trials and adjusted the data.
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reducing tobacco use in the State of Victoria.
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Medical Subject Headings (MeSH)
∗Pregnancy; Infant, Low Birth Weight; Infant, Newborn; Obstetric Labor, Premature [prevention & control]; Patient Education as
Topic; Pregnancy Outcome; Randomized Controlled Trials as Topic; Smoking Cessation [∗methods]
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Female; Humans
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